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La malaltia de Huntington és un trastorn neurodegeneratiu progressiu causat per 
una expansió de repeticions del triplet CAG (més de 37) en l’exó 1 del gen de la 
huntingtina que genera una proteïna aberrant. Aquest canvi en la proteïna provoca una 
pèrdua selectiva de neurones GABAèrgiques de projecció en el nucli estriat, tot i que 
també s’han detectat alteracions i degeneració en altres àrees de l’encèfal, generant 
una simptomatologia complexa que engloba alteracions motores, cognitives i 
emocionals. Un marcador de la patologia és la formació d’agregats que tenen una 
ultraestructura fibril·lar. Aquestes estructures estan principalment formades per 
fragments N-terminals de la huntingtina mutada, que són generats per l’acció de 
proteases. 
Un dels processos que condueix a la mort selectiva de les neurones és l’activació 
de l’apoptosi. L’equilibri entre vies pro-apoptòtiques i vies de supervivència és el que 
regula el destí de la cèl·lula.  D’aquesta manera, la via de supervivència més important 
en la cèl·lula, la via de PI3K/AKT, es troba sobre-activada en el nucli estriat de 
diferents models cel·lulars i animals de la malaltia de Huntington. A més, els nivells de 
PHLPP1, una fosfatasa que defosforila AKT, es troben disminuïts en la malaltia de 
Huntington, contribuint en la sobre-activació de la via d’AKT al llarg de la patologia. 
Una proteïna que es troba en la via de l’AKT i que juga un paper central en la 
supervivència cel·lular, la transcripció, la traducció proteica i l’autofàgia, és mTOR. 
mTOR és a la vegada un substrat indirecte d’AKT i quinasa que fosforila directament 
AKT, segons si forma part del complex mTORC1 o mTORC2 i amb quines proteïnes 
s’associï. El fet que la via d’AKT es trobi alterada en la malaltia de Huntington ens 
suggereix que l’activitat de mTOR també podria estar afectada. Per tant, ens va 
interessar estudiar per una banda la via de mTOR, i per l’altra, un dels processos que 
aquesta via regula, la macroautofàgia (a partir d’ara serà anomenat simplement com a 
autofàgia). A més a més, l’autofàgia participa en l’eliminació d’agregats proteics i, la 
seva activació, s’ha proposat com a mecanisme terapèutic per a la malaltia de 
Huntington. 
La fosfatasa PHLPP1 s’ha descrit que també regula les PKCs. En el moment en 
què PKC es defosforila, es degrada. Aquests experiments juntament amb evidències 
de que una isoforma de les PKC presenta una expressió gènica reduïda, suggereixen 
que hi podrien haver alteracions en la via de les PKC en la malaltia de Huntington. En 
mamífers s’han descrit 12 isoformes diferents de les PKC, que estan distribuïdes en 
categories segons la seva activació. Alhora, les PKCs regulen tant processos de 
proliferació cel·lular i diferenciació, com d’apoptosis. 
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Per tant, en aquesta tesi doctoral hem estudiat possibles alteracions en l’autofàgia 
selectiva i les vies de senyalització de mTOR i de PKC, per tal d’analitzar la seva 
participació en la degeneració que es produeix en la malaltia de Huntington.  
 
Totes aquestes vies s’han estudiat, principalment, en un model animal de la 
malaltia de Huntington, el ratolí R6/1, que sobre-expressa un fragment de la 
huntingtina mutada humana, l’exó-1, amb 145 repeticions CAG. S’ha descrit que en 
aquests animals els símptomes motors apareixen entre les 15 i les 21 setmanes 
d’edat, tot i que ja s’observen agregats de huntingtina mutada a partir de les 8 
setmanes d’edat. Els símptomes cognitius tenen una aparició anterior que els 
símptomes motors, cap a les 12 setmanes d’edat. 
 
Per tal d’estudiar el procés d’autofàgia selectiva al llarg de la malaltia de 
Huntington, es van analitzar els nivells i la localització intracel·lular de dues proteïnes, 
p62/SQSTM1 (p62) i NBR1, que reconeixen específicament components cel·lulars que 
s’han de degradar per autofàgia. Aquestes dues proteïnes tenen un domini d’interacció 
amb els autofagosomes i es degraden en el moment en què els autofagosomes es 
fusionen amb els lisosomes. Per això, alteracions en els nivells de p62 i NBR1 s’han 
associat a canvis en l’activitat autofàgica. Els nivells de p62 i NBR1 van ser estudiats 
en el model de ratolí R6/1 en diferents àrees cerebrals (nucli estriat, hipocamp i 
escorça cerebral) al llarg de la progressió de la malaltia. En comparació amb els 
animals control, els nivells proteics de p62 i NBR1 es van trobar alterats en els animals 
R6/1. Els nivells de p62 i NBR1 disminuïen a un estadi inicial de la malaltia, les 12 
setmanes d’edat dels ratolins R6/1, en totes les zones cerebrals estudiades, suggerint 
una major degradació d’aquestes proteïnes degut a una major activitat autofàgica. A 
les 30 setmanes d’edat, un estadi avançat de la patologia, els nivells de p62 i NBR1 
incrementaven tant en el nucli estriat com en l’hipocamp. Els nivells de les dues 
proteïnes en l’escorça cerebral es mantenien reduïts des de les 12 setmanes d’edat 
fins a etapes avançades de la patologia. Per tal d’entendre la causa d’aquesta 
desregulació es va analitzar la seva expressió gènica en el nucli estriat i en l’escorça 
cerebral als mateixos estadis de la patologia. En les dues zones cerebrals es van 
observar canvis en l’expressió de p62, amb un increment a partir de les 8 setmanes 
d’edat, però no es van trobar canvis en l’expressió de NBR1. Com que el patró 
d’expressió no era suficient per entendre les alteracions dels nivells de proteics, vam 
pensar que altres mecanismes hi podien estar implicats, com per exemple la interacció 
d’aquestes proteïnes amb els agregats de huntingtina mutada. Es van realitzar 
immunoprecipitacions d’extractes proteics del nucli estriat i de l’escorça cerebral 
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d’animals de 30 setmanes. Es va observar que tant p62 com NBR1 co-
immunoprecipitaven amb la huntingtina mutada. Mitjançant immunohistoquímica es va 
detectar que p62 no només interaccionava amb els agregats de huntingtina mutada, 
sinó que ho feia principalment amb els agregats nuclears. Aquest resultat suggeria un 
canvi en la distribució nucli-citoplasma de p62, que es va confirmar mitjançant western 
blot de fraccions citoplasmàtiques i nuclears. En el nucli estriat dels animals R6/1 a les 
12 setmanes d’edat, quan observàvem disminució dels nivells totals de les dues 
proteïnes, p62 era principalment citoplasmàtica, mentre que a les 30 setmanes, 
s’acumulava en les fraccions nuclears d’animals R6/1 en comparació amb els control. 
p62 també s’acumulava en fraccions nuclears d’extractes d’hipocamp, i en menor grau 
en l’escorça cerebral a les 30 setmanes d’edat. Es van realitzar tincions 
immunohistoquímiques en mostres de malalts de Huntington i es va detectar que, 
mentre que p62 es trobava principalment en agregats nuclears, NBR1 tenia una 
localització principalment citoplasmàtica i molt lligada al marcatge de lipofucsina, 
confirmant els resultats que observàvem en el model animal. p62 viatja del nucli al 
citoplasma mitjançant l’exportina-1. S’ha descrit que els nivells proteics d’exportina-1 
disminueixen amb l’edat en mostres d’animals R6/2, un altre model de la malaltia de 
Huntington. Per tal de saber si la reducció dels nivells d’exportina-1 amb l’edat podien 
tenir algun paper en l’acumulació de p62, es van analitzar els nivells d’exportina-1 en 
les diferents àrees cerebrals a les 12 i a les 30 setmanes d’edat en l’animal R6/1. 
Mentre que els nivells d’exportina-1 disminuïen des de l’edat presimptomàtica fins a un 
estadi avançat de la patologia en el nucli estriat i en l’hipocamp, es trobaven inalterats 
en l'escorça cerebral. 
Per tal de determinar si aquesta disminució amb l’edat de l’exportina-1 podia 
tenir algun efecte sobre l’autofàgia, mitjançant l’acumulació nuclear de proteïnes 
importants per aquest procés, es va tractar una línia cel·lular estable d’origen estriatal 
(STHdh7Q/7Q) amb Leptomicina B (LMB), inhibidor irreversible de l’exportina-1. Després 
del tractament es van analitzar els nivells d’autofagosomes totals utilitzant el marcador 
LC3II, que és una proteïna associada específicament a la membrana dels 
autofagosomes. Es va observar un increment significatiu dels nivells de LC3II en les 
cèl·lules tractades amb LMB respecte les cèl·lules control. Per tal de saber si aquest 
increment era resultat d’una major síntesi d’autofagosomes, es va bloquejar la 
degradació d’aquests co-tractant durant 6h amb Bafilomicina A1 (BafA1). No 
s’observava cap increment addicional quan es co-tractava amb els dos fàrmacs, fet 
que suggeria que els increments de LC3II no eren deguts a una major síntesi 
d’autofagosomes. Per tal de saber si la degradació dels autofagosomes, pas essencial 
per la finalització del procés d’autofàgia, podia estar alterada, es van transfectar les 
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cèl·lules amb un plàsmid que expressa mRFP-GFP-LC3 en tàndem. Els 
autofagosomes són positius pels dos fluoròfors. Quan els autofagosomes es fusionen 
amb un lisosoma, s’acidifiquen i el GFP queda atenuat i es degrada ràpidament per 
l’acció de les hidrolases lisosomals. Aleshores, aquestes estructures només són 
positives per mRFP. Es va calcular el percentatge d’autofagosomes no acidificats 
(percentatge de col·localització) respecte el total d’estructures autofàgiques 
(estructures positives per mRFP). En presència de LMB, el percentatge 
d’autofagosomes respecte el total d’estructures autofàgiques incrementava, indicant 
una degradació ineficient dels autofagosomes i per tant un defecte en el procés 
d’autofàgia. Finalment, per saber si aquest defecte en l’autofàgia podia alterar la 
degradació de proteïnes de vida mitja llarga, es van fer estudis de proteòlisi mitjançant 
un marcador radioactiu. L’experiment va ser realitzat en una condició control i també 
sota diferents condicions per portar el sistema a l’extrem, en deprivació de sèrum per 
incrementar l’autofàgia o amb un tractament de NH4Cl i leupeptina per inhibir-la. En 
cap de les condicions el tractament amb LMB retardava la degradació de proteïnes de 
vida mitja llarga. 
Els resultats obtinguts durant el desenvolupament d’aquest primer objectiu 
suggereixen que en fases inicials de la malaltia de Huntington l’autofàgia selectiva es 
troba incrementada, ja que els nivells proteics de p62 i NBR1 disminueixen de forma 
similar en totes les àrees cerebrals del model R6/1. En un estadi avançat de la 
malaltia, p62 es va acumulant al nucli degut a la interacció amb els agregats de 
huntingtina mutada i a la reducció amb l’edat dels nivells d’exportina-1. El fet que 
NBR1 no es localitzi als agregats nuclears de huntingtina mutada, fa pensar que podria 
ser una proteïna essencial en mantenir el procés d’autofàgia en la malaltia de 
Huntington. 
 
Les alteracions detectades en el flux de l’autofàgia selectiva, podrien ser induïdes 
per canvis en l’activitat de la quinasa mTOR. És per això que ens vam plantejar 
estudiar la via de senyalització de mTOR al llarg de la progressió de la malaltia per 
entendre la seva contribució en la desregulació de l’autofàgia, i per la sobre-activació 
específicament estriatal de la quinasa de supervivència AKT. Per això, es va estudiar 
la via de mTOR en l’estriat del model R6/1 en unes edats semblants a les que s’havia 
analitzat la fosforilació d’AKT. S’han descrit sis fosforilacions diferents per mTOR, de 
les quals la fosforilació en la serina 2448 és la que està regulada per AKT, mentre que 
la fosforilació en la serina 2481 està més relacionada amb la seva activació. Es van 
detectar increments significatius d’aquests dos residus fosforilats a partir de les 12 
setmanes d’edat en el nucli estriat dels ratolins mutants en comparació amb els 
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control, mentre que els nivells totals de mTOR es mantenien invariables. En altres 
models de la malaltia de Huntington s’ha trobat mTOR segrestada als agregats 
nuclears de huntingtina mutada. Ens vam preguntar si pmTOR hi podia quedar també 
segrestada i així acumular-s’hi. Es van analitzar les formes fosforilades de mTOR en 
fraccions enriquides en nucli i citoplasma del nucli estriat de ratolins R6/1 de 30 
setmanes d’edat, i no es van detectar canvis en la seva localització respecte els 
animals control. Per immunohistoquímica, tampoc es va observar colocalització de 
pmTOR, ni mTOR, amb els agregats de huntingtina mutada. Aquests resultats ens van 
suggerir que la via de mTOR es trobava alterada i incrementada en la malaltia de 
Huntington. mTOR, però, no treballa sola sinó en associació amb altres proteïnes, 
formant els complexes mTORC1 i mTORC2. Raptor i Rictor s’associen a mTOR per 
definir, respectivament, aquests dos complexes, i són les dues proteïnes que 
determinen l’especificitat de substrat. D’aquesta manera, mTORC1 regula la traducció i 
l’autofàgia, mentre que mTORC2 regula la supervivència cel·lular i el citoesquelet. Per 
tal de conèixer quins dels dos complexes es troba més afectat en la patologia, ens 
vam plantejar d’estudiar els nivells per western blot de les proteïnes Rictor i Raptor. Els 
nivells proteics de Rictor, però no de Raptor es van trobar incrementats al nucli estriat 
dels ratolins R6/1 a totes les edats estudiades, i el mateix efecte es va observar en 
mostres de putamen d’humans afectats de la malaltia de Huntington. Aquest resultat 
ens va suggerir que el complex mTORC2, però no mTORC1 es trobava sobre-activat 
en la malaltia. Per demostrar aquesta hipòtesi, es van analitzar diferents substrats 
específics dels dos complexes. Es van analitzar ULK1, S6K i 4EBP1, que són 
regulades pel complex mTORC1, i per altra banda es van analitzar SGK i PKCα, que 
estan, conjuntament amb AKT, regulades pel complex mTORC2. No es van trobar 
alteracions en cap de les fosforilacions dels substrats de mTORC1 i de mTORC2, a 
part de 4EBP1 i AKT. Els nivells de la forma fosforilada de 4EBP1 incrementaven des 
de les 8 setmanes d’edat, molt abans de que pAKT i pmTOR incrementessin. Els 
resultats que s’han obtingut fins al moment suggereixen que la sobre-activació de la 
via d’AKT podria ser induïda per increments en l’activitat mTORC2, en part deguda a 
l’augment dels nivells proteics de Rictor i de pmTOR, i que podrien tenir un paper 
compensatori en la malaltia de Huntington davant de la toxicitat induïda per la 
huntingtina mutada. Tot i això, mTOR, no sembla tenir cap efecte sobre el procés 
d’autofàgia, ja que no es van trobar canvis en la fosforilació de ULK1, proteïna 
essencial per la formació dels autofagosomes en l’autofàgia. Per tant, els canvis en 
activitat autofàgica, detectats mitjançant l’anàlisi dels nivells de p62 i NBR1, semblen 
ser deguts a una regulació mitjançant un mecanisme independent de mTOR. 
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Finalment, vam analitzar al llarg de la patologia els nivells totals de dues 
isoformes de les PKC convencionals, la PKCα i la PKCβII, i una isoforma de les PKC 
novedoses, la PKCδ, en el nucli estriat, escorça cerebral i hipocamp del model R6/1. 
Vam detectar un lleuger descens dels nivells de les dues isoformes convencionals en 
totes les àrees cerebrals a partir de les 12 setmanes d’edat. En canvi, els nivells de 
PKCδ estaven molt reduïts a totes les àrees cerebrals examinades ja a partir de les 8 
setmanes d’edat, i seguien disminuint fins a arribar a ser molt reduïts a etapes 
avançades de la patologia. Addicionalment es va detectar una disminució dels nivells 
de PKCδ en mostres humanes de putamen afectats de la malaltia de Huntington. A 
partir d’aquest punt vam decidir focalitzar l’estudi en la PKCδ, ja que aquesta era la 
isoforma que presentava unes alteracions majors i que, a més, és pro-apoptòtica. No 
vam trobar diferències en els nivells d’un fragment catalíticament actiu de PKCδ 
generat per la caspasa-3 que es transloca al nucli de les cèl·lules generant 
fragmentació del DNA i apoptosis. A més, vam observar que els nivells estaven reduïts 
en tota la cèl·lula sense haver-hi diferències de reducció dels seus nivells proteics 
entre el nucli i el citoplasma, essent PKCδ una proteïna principalment citoplasmàtica. 
Finalment, vam analitzar si aquesta disminució de PKCδ podia ser deguda a un 
increment en la seva degradació, per un mecanisme independent a PHLPP, ja que 
aquesta es troba reduïda en els mateixos models animals de la malaltia. S’ha descrit 
que un increment en la fosforilació de la treonina 505 incrementa la degradació de la 
proteïna. Els nivells d’aquesta fosforilació es van trobar incrementats a les 30, però no 
a les 8, setmanes d’edat en el model animal R6/1 en el nucli estriat, l’hipocamp i 
l’escorça cerebral. Aquests resultats ens suggerien que la disminució de la proteïna 
pro-apoptòtica PKCδ, mediada per processos de degradació, podrien ser un 
mecanisme compensatori activat per les cèl·lules en resposta a l’expressió de 
huntingtina mutada par tal d’intentar sobreviure. Per demostrar aquesta hipòtesi vam 
transfectar cèl·lules estriatals amb un plàsmid per sobre-expressar PKCδ, juntament 
amb un plàsmid per sobre-expressar l’exó 1 de la huntingtina normal i mutada. Fent un 
recompte de nuclis apoptòtics, vam observar que la sobre-expressió de PKCδ en 
cèl·lules que expressen l’exó 1 de la huntingtina mutada, però no la normal, induïa més 
mort cel·lular que la que s’induïa per l’única sobre-expressió de la huntingtina mutada. 
Aquest últim resultat indica que una reducció de PKCδ des de fases inicials de la 
patologia podria ser un mecanisme de supervivència generat per les cèl·lules per tal de 
contrarestar la toxicitat de la huntingtina mutada. 
 
Tots aquests resultats indiquen que en la malaltia de Huntington hi ha un equilibri 
entre senyals apoptòtiques i mecanismes de supervivència. La huntingtina mutada 
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genera toxicitat que pot ser contrarestada per diferents mecanismes, com la 
degradació de la mateixa huntingtina induint l’autofàgia selectiva, o l’activació de 
senyals de supervivència com la inducció de la via de l’AKT-mTOR i la inhibició de la 
proteïna pro-apoptòtica PKCδ. Per tant, la regulació d’aquestes vies de supervivència 
seria una bona teràpia per evitar la degeneració neuronal en la malaltia de Huntington. 
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Neurodegenerative diseases are characterized by neuronal loss and synaptic 
abnormalities, which are chronic and progressive. Intriguingly, these abnormalities 
most commonly appear later in adulthood and less likely in youth. Mature neurons have 
the ability to activate survival mechanisms in response to harmful stimuli that would act 
as brakes of neurodegeneration. Therefore, whether a neuron lives or dies in 
pathological conditions is the result of a complex balance between anti- and pro-
apoptotic signals, respectively. This balance might strongly regulate the onset of the 
disease. Here, we have characterized some putative compensatory pro-survival 
processes that could be involved in delaying Huntington’s disease pathology. 
 
 
1. - HUNTINGTON’S DISEASE 
 
Huntington’s disease is an autosomal hereditary progressive neuropathological 
disorder characterized by a mutation on the chromosome 4p16.3 (Gilliam et al., 1987; 
Wexler et al., 1987) of the It15 gene, which encodes for the protein huntingtin 
(HDCRG, 1993). The mutant gene contains an expanded number of CAG repeats in 
the N-terminal of the sequence, more precisely at the exon 1 (which is about 88 amino 
acids long) of the gene. This mutation leads to lengthening of the polyglutamine 
(polyQ) chain of huntingtin, and thus to alter its biological functions if the mutation is 
long enough (HDCRG, 1993). The disease occurs when the threshold of about 36 
polyQ is exceeded (Kremer et al., 1994). The mutation generates a mutant protein with 
altered folding and high propensity to generate intracellular aggregates (DiFiglia et al., 
1997). The onset of symptoms has been inversely correlated with the lengthening of 
the mutation. Juvenile or early-onset Huntington’s disease, which is the most severe 
outcome, is associated with CAG repeat lengths greater than 50, whereas adult-onset 
of the disease is associated with CAG repeats from 40 to 50 (Rubinsztein et al., 1996). 
Individuals with CAG repeats in the range of 35 to 40 show incomplete penetrance of 
the mutant allele. Finally, normal CAG repeat length is usually about 17-20. Intervals of 
20-35 CAG repeats are considered rare, and not pathological, but are meiotically 
unstable and can expand into the disease range in some cases (Imarisio et al., 2008). 
 
The disease was first described in 1872 by George Huntington (1850-1916), who 
named the disease Chorea (from the Greek choreia that means dance) due to the 
marked and characteristic feature of involuntary movements in those who are affected 
(Huntington, 1872). The incidence is about 5-7 individuals within 100,000, although in 
some areas such as Tasmania and the area around Lake Maracaibo in Venezuela the 
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incidence increases significantly. In contrast, in most African and Asian populations the 
prevalence of the disease is very low (Walker, 2007). 
 
Huntington’s disease is manifested with a triad of motor, cognitive and also 
psychiatric symptomatologies. Movement disorder for most patients follows a biphasic 
pattern, while initially dyskinetic movements predominate, later on, they decrease to 
bradykinetic movements characterized by rigidity (Young et al., 1986). Chorea, which is 
common at early Huntington’s disease and wanes with disease progression, 
characterizes the dyskinetic movements and refers to the rapid, irregular, and jerky 
movement of the limbs, trunk, and face. Patients with an early-onset Huntington’s 
disease might not develop chorea (Sturrock & Leavitt, 2010). Cognitive dysfunction in 
Huntington’s disease, often spares long-term memory, but is characterized by a loss of 
executive functions, such as organising, planning, checking, or adapting alternatives, 
and delays the acquisition of new motor skills. Speech deteriorates faster than 
comprehension. Psychiatric symptoms, however, arise with some frequency but do not 
progress with disease severity. Depression, anxiety and irritability are typical, and 
suicide happens with more frequency than in general population. Manic and psychotic 
symptoms can also develop (Walker, 2007). Besides the triad, other symptoms do 
appear such as significant weight loss and, occasionally and with more frequency in 
juvenile Huntington’s disease, epileptic seizures (Gonzalez-Alegre & Afifi, 2006; 
Morales et al., 1989). Before all these symptoms start to emerge gradually, individuals 
are healthy and have no detectable clinical abnormalities. Death occurs normally 12-15 
years from the time of symptomatic onset (Vonsattel, 2008). The cause of death is 
infection in about 45% of cases, being pneumonia responsible for around 25% of 
deaths in Huntington’s disease (Sturrock & Leavitt, 2010). 
 
 
1.1 - NEUROPATHOLOGY 
 
Although huntingtin is expressed in all the tissues, some areas of the brain present 
enhanced susceptibility to the mutated protein compared to other areas and tissues in 
the body. Atrophy of the striatum (caudate nucleus and putamen) and thinning of the 
cortex are the most significant neuropathological abnormalities, although atrophy also 
occurs in other brain areas (Vonsattel et al., 1985) (Fig. 1).  It has been suggested that 
this brain atrophy may start before the onset of clinical symptoms (Aylward et al., 2004; 
Kipps et al., 2005). The neuropathologist Jean Paul Vonsattel developed in 1985 a 
scale to grade the striatal neuropathology in Huntington’s disease, which consists of 5 
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grades from 0 (no gross pathological abnormality) to 4 (severe pathology) (Vonsattel et 
al., 1985) (Fig. 1). Grade 0 appears indistinguishable from normal brains after gross 
examination. However, 30–40% neuronal loss can be detected only in the head of the 
caudate nucleus upon histological examination. Grade 1 shows atrophy, neuronal loss, 
and astrogliosis in the tail and, in some cases, the body of the caudate nucleus. 
Grades 2 and 3 are characterized by progressive and severe striatal atrophy, and 
grade 4 includes the most severe Huntington’s disease cases with atrophy of the 
striatum and up to 95% neuronal loss (Vonsattel et al., 1985). 
 
 
Figure 1.- Huntington’s disease pathology. (A) Human brain coronal sections that show the degeneration that occurs 
in the caudate nucleus and putamen as well as the cortical atrophy in Huntington’s disease. Image adapted from 
http://hdroster.iu.edu. (B) Scheme that represents the degrees of the striatal neuropathology in the Vonsattel grade 
scale. A brain in grade 0 appears macroscopically indistinguishable from normal brains, but there is already a 30–40% 
neuronal loss in the striatum. The neuropathology progresses from grade 1 until grade 4, with progressive atrophy, 
increasing astrogliosis and neuronal loss. At grade 4 there is up to 95% neuronal loss in the striatum. Figure adapted 
from Ellison & Love, 2004. 
 
The striatum is a member of the interconnected subcortical nuclei group named 
basal ganglia, together with the globus pallidus pars externa (GPe) and interna (GPi), 
the subthalamic nucleus (STN) and the substantia nigra pars compacta (SNc), and 
INTRODUCTION 
6 
pars reticulata (SNr). The striatum is a convergence point for glutamatergic inputs from 
cortex and thalamus, as well as dopaminergic afferents from the midbrain. It is also the 
source of basal ganglia circuits that are critical for motor function and procedural 
learning (Bolam et al., 2000). Two main types of neurons compose the striatum, the 
medium-sized spiny projection neurons and interneurons. Medium-sized spiny neurons 
represent the 90-95% of neuronal population within the striatum, and their excitability is 
modulated by interneurons (Kreitzer, 2009). Medium-sized spiny neurons are 
GABAergic striatal efferent neurons that connect with the GPe and GPi by two different 
pathways, the ‘direct’ and ‘indirect’ (Fig. 2). Neurons in the ‘direct pathway’ project 
directly from putamen to the GPi/SNr, and express GABA and substance P. Neurons in 
the ‘indirect pathway’, express GABA and enkephalin, and project to the GPe, which in 
turn project to the GPi/SNr (Gerfen & Surmeier, 2011; Obeso et al., 2008) (Fig. 2). 
 
Figure 2.- Basal ganglia circuits. The striatum receives glutamatergic (green arrows) inputs from the cortex and the 
thalamus and projects to the GPe and GPi/SNr by two different GABAergic (blue and red arrows) pathways, the 
‘indirect’ and ‘direct’, respectively. In Huntington’s disease the ‘indirect’ pathway is affected earlier than the ‘direct’ 
pathway. Figure adapted from Gerfen & Surmeier, 2011. 
 
Robert Ferrante and colleagues revealed that not the whole striatal neuronal 
population is prone to degenerate. While medium-sized spiny neurons were found to 
preferentially degenerate in Huntington’s disease, interneurons were relatively spared 
(Ferrante et al., 1985). Further immunohistochemical studies performed by Anne 
Young's group, revealed different degrees of degeneration of distinct medium-sized 
spiny neuron populations in Huntington’s disease. In early and middle stages of 
Huntington’s disease, the ‘indirect pathway’ was much more affected than the ‘direct 
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pathway’. At a stage 4 of the disease, striatal efferent projections were almost all 
depleted, with the exception of some striatal projections to the GPi/SNc (Reiner et al., 
1988). Degeneration of these two neuronal populations severely impairs both basal 
ganglia circuits and gives rise to the motor abnormalities that occur in Huntington’s 
disease (Graybiel, 2000). 
 
Although the striatum is highly affected in Huntington’s disease, the disease is far 
from being only characterized by motor symptoms. Nowadays, it is well established 
that the degeneration that occurs in Huntington’s disease is a more widespread 
phenomenon within the brain, which could explain the clinical heterogeneity and 
complexity of Huntington’s disease. By means of magnetic resonance imaging (MRI)-
based morphometric analysis, almost all brain structures, including cerebral cortex, 
globus pallidus, amygdala, hippocampus, brainstem, and cerebellum, volumes were 
found reduced at mid-stages of Huntington’s disease (Jeste et al., 1984; Rosas et al., 
2003). In grades 3 and 4, the cerebral cortex, particularly the efferent layers III, V, and 
VI, are markedly affected (Hedreen et al., 1991; Heinsen et al., 1994; Rosas et al., 
2008). 
 
 
1.2 - HUNTINGTIN PROTEIN 
 
Huntingtin is encoded by a single gene, which is 200 Kb long and possesses 67 
exons, being the first of them the one containing the mutation (HDCRG, 1993). The 
translated huntingtin is a 348 KDa protein with 3144 amino acids (aa) (HDCRG, 1993), 
which shows ubiquitous expression, being brain and testis the organs that express 
huntingtin at highest levels, and neocortex, cerebellar cortex, striatum and 
hippocampus the main expression sites within the brain (Borrell-Pages et al., 2006). 
Although a small proportion is also found in the nucleus (Kegel et al., 2002), huntingtin 
is a primarily cytoplasmic protein that is known to be associated with the plasma 
membrane, endocytic and autophagic vesicles, endosomal compartments, the 
endoplasmic reticulum, the Golgi apparatus, mitochondria and microtubules (Imarisio et 
al., 2008).  
 
Huntingtin is a multi-domain protein and thus has several interacting partners and 
functions (Fig. 3). A considerable fraction of huntingtin contains tandem arrays of 
Huntingtin, Elongation fator3, PR65/A subunit of protein phosphatase 2A and mTOR 
(HEAT) repeats that are important for protein interactions and protein complex 
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formation (Andrade & Bork, 1995). Moreover, it is predicted that huntingtin contains 
from 28 to 36 HEAT repeats that could stack together generating an elongated 
superhelical solenoid with diameter of 200Å (Li et al., 2006; Takano & Gusella, 2002). 
Both a cluster of the first three HEAT repeats flanked by positively charged regions 
(amino acids residues 172–372), and the huntingtin N-terminal stretch of about 17 aa 
do play an important role in targeting huntingtin to the various intracellular membrane-
bound organelles (Atwal et al., 2007; Kegel et al., 2005; Rockabrand et al., 2007). It is 
unknown whether huntingtin contains nuclear localization signal (NLS), although a 
conserved nuclear export signal (NES) is found near its C-terminus (Xia et al., 2003), 
which would account for the small proportion of huntingtin present in the nucleus. Its 
nuclear entrance could be triggered by other non-described means of transport. 
Another important region within huntingtin sequence is the poly-proline stretch, which is 
localized just after the polyQ chain. This domain also triggers an important structural 
role in the mutant huntingtin (Darnell et al., 2007). 
 
Figure 3.- Schematic diagram of the huntingtin protein. The diagram represents the huntingtin amino acid sequence 
with the polyglutamnie (PolyQ) and poly-proline (PolyP) tracts, the HEAT repeat domains and the nuclear exporting 
signal (NES). The following post-translational modifications are indicated: Phosphorylation at Ser13, Ser421 and Ser434 
(blue), palmytoilation at Cys214 (purple), and acetylation at Lys444 (green). Figure adapted from Zuccato et al., 2010. 
 
Huntingtin and mutant huntingtin undergo posttranslational modifications with 
different preferences. The competition of both SUMOylation and ubiquitination events 
that normally occur at lysines localized at the first 17 aa from the N-terminal huntingtin 
just before the polyQ stretch, regulate huntingtin fate, localization and function. It has 
been proposed that mutant huntingtin would be less ubiquitinated since it would have 
higher preference for SUMOylation events than the wild-type protein. This would permit 
mutant huntingtin escape from degradation fate (Steffan et al., 2004). Huntingtin-
interacting protein 14 (HIP14) induces huntingtin palmitoylation at cystein 214 (Huang 
et al., 2004; Yanai et al., 2006). A mutant huntingtin palmitoylation-resistant form 
induces increased cell toxicity, and HIP14 interacts less with mutant huntingtin than 
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with the wild-type. Thus, mutant huntingtin would potentially be less palmitoylated and 
consequently play a role in the pathology (Yanai et al., 2006). Mutant, but not the wild-
type, huntingtin is also acetylated at lysine 444, which targets the protein to the 
macroautophagy pathway (Jeong et al., 2009). Both huntingtin and mutant huntingtin 
can undergo proteolytic cleavage, generating small N-terminal fragments that, only in 
the case of mutant huntingtin, have been described to be highly toxic and with high 
tendency to aggregate (Hodgson et al., 1999; Wellington et al., 2002). Interestingly, 
phosphorylation reduces caspase-mediated mutant huntingtin cleavage and attenuate 
toxicity (Luo et al., 2005; Warby et al., 2009). Several reports show that huntingtin and 
mutant huntingtin can be phosphorylated on serine (Ser) 421 by protein kinase B (also 
named AKT) (Humbert et al., 2002; Warby et al., 2005) and at Ser434 by the cyclin-
dependent kinase 5 (CDK5) (Luo et al., 2005). Also IkappaB kinase (IKKβ) complex 
phosphorylates huntingtin and mutant huntingtin at Ser13, which promote modification 
of the adjacent lysine residues and target huntingtin clearance by the proteasome and 
the lysosome. In contrast, mutant huntingtin is less efficiently phosphorylated, which 
would ultimately contribute to disease (Thompson et al., 2009). 
 
The large size of the protein that makes isolation and analysis difficult, the lack of 
obvious homology with other proteins, its ubiquitous localization within the cell and 
promiscuous interactions with more than 200 partners identified to date, make difficult 
to understand all the cellular roles of huntingtin (Imarisio et al., 2008) (Fig. 4). 
Huntingtin has been associated with embryonic development due to the fact that 
knockout of the gene encoding for huntingtin in the mouse results in lethality early in 
embryogenesis (Embryonic day 8.5), prior to organogenesis (Duyao et al., 1995; Nasir 
et al., 1995; Zeitlin et al., 1995). Huntingtin is also involved in cell viability with an anti-
apoptotic role (Dragatsis et al., 2000; Zeitlin et al., 1995), in transcription regulation by 
interacting with an array of proteins involved in the regulation of mRNA productions 
such as REST/NRSF (Zuccato et al., 2003), in facilitating transport along microtubules 
by directly interacting with the dynein/dynactin microtubule-based motor complex (Colin 
et al., 2008), in negatively regulating the activity of glutamate receptors (Sun et al., 
2001), in metabotropic glutamate receptor 1 (mGluR1) signalling via its interaction with 
optineurin (Anborgh et al., 2005), and in several other reported processes. 
 
Although the polyQ stretch has received much attention for its pathogenic 
properties when expanded, it is possibly not essential for normal huntingtin function, 
since mice with deletion of the short CAG triplet repeat exhibit no gross phenotypic 
differences in comparison to control littermates (Clabough & Zeitlin, 2006). Thus, 
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mutation and lengthening of this stretch probably confers different posttranslational 
modifications and different structure that would all lead to interact distinctly with its 
partners or with new ones and, thus, acquisition of new toxic functions (Fig. 4). 
 
 
1.3 - MOUSE MODELS OF HUNTINGTON’S DISEASE 
 
Since Huntington’s disease is caused by a single mutation, the introduction of the 
mutant gene into non-human primate, mouse, fly, fish, worm and even sheep has 
permitted the generation of disease models that have helped to advance in the 
mechanistic insights of neurodegeneration.  
However, genetic knowledge of the disease is very recent, and the first transgenic 
mouse model of the disease was not developed until 1996 (Mangiarini et al., 1996). 
Before that, models of the disease were induced by either excitotoxic lesioning or 
mitochondrial dysfunction. The first toxic model of Huntington’s disease was developed 
in 1976 and consisted on intrastriatal administration of kainic acid (a kainate receptor 
agonist) (Coyle & Schwarcz, 1976). It was followed by other models such as 
intrastriatal injection of quinolinic acid (an NMDA receptor agonist) or systemic 
administration of 3-nitropropionic acid (inhibitor of the complex II of the mitochondrial 
respiratory chain) (Beal et al., 1993; Beal et al., 1986). These insults induced in rats a 
selective degeneration of medium-sized spiny neurons, while sparing interneurons. 
Although these approaches could lead to the selective degeneration observed in 
Huntington’s disease, in these models mutant huntingtin was lacking. Thus, the 
generation of several transgenic models has permitted to better understand the 
progression of the pathogenesis that underlies Huntington’s disease and to evaluate 
the potential of new therapeutic approaches. 
 
The wide array of animals that have been generated since the first transgenic 
mouse, provide a broad phenotype variety. While some models do hardly express 
visible phenotype until getting very old, others display neuropathology early from birth. 
This broad phenotype variety does not only exist between species but also in between 
distinct models generated in the same species. The species that has been most 
extensively used for the study of Huntington’s disease is the mouse, and many different 
mouse models have been generated (Table 1).  
 
 
INTRODUCTION 
11 
Mouse 
model Promoter 
CAG 
repeats Aggregates 
Motor 
symptoms  
Cognitive 
deficits  Lifespan References 
R6/1 Human 
Huntingtin 
116 9 W 18 W  
(rota-rod) 
12 weeks 32-40 W Canals et al., 2004; 
Giralt et al., 2011b; 
Mangiarini et al., 
1996; Naver et al., 
2003 
R6/2 Human 
Huntingtin 
144 3-4.5 W 6-8 W 
(rota-rod) 
4-8 weeks 13-16 W Carter et al., 1999; 
Davies et al., 1997; 
Lione et al., 1999; 
Mangiarini et al., 
1996 
N171-
82Q 
Mouse 
prion 
protein 
82 6.5 M 12 W  
(rota-rod) 
Not 
reported 
16-22 W Schilling et al., 1999 
HD94-
tet off 
CAMKIIa-
tTA 
94 12 W 4 W 
(clasping) 
Not 
reported 
Normal Martin-Aparicio et al., 
2001; Yamamoto et 
al., 2000 
YAC72 Human 
Huntingtin 
72 No 16 M  
(rota-rod) 
Not 
reported 
Normal Hodgson et al., 1999; 
Seo et al., 2008 
YAC128 Human 
Huntingtin 
120 18 M 6 M  
(rota-rod) 
8.5 M Normal Slow et al., 2003; 
Van Raamsdonk et 
al., 2005 
Hdh 
94Q 
Mouse 
Huntingtin 
94 18 M 4 M 
(decreased 
locomotion) 
4 M Normal Menalled et al., 2003; 
Trueman et al., 2007 
Hdh 
111Q 
Mouse 
Huntingtin 
109 10 M 24 M  
(gait deficits) 
8 M in 
HdhQ7/Q111 
Normal Giralt et al., 2012; 
Wheeler et al., 2000 
Hdh 
140Q 
Mouse 
Huntingtin 
140 4 M 4 M 
(decreased 
locomotion) 
Not 
reported 
Normal Menalled et al., 2003 
Hdh 
150Q 
Mouse 
Huntingtin 
150 10-14 M 15-40 W 
(gait and 
rota-rod) 
No Normal Heng et al. 2007; Lin 
et al., 2001 
 
Table 1. Genetically modified mouse models of Huntington’s disease. The table includes information about the 
promoter under which the mutation is expressed, the CAG repeat number, the onset of mutant huntingtin aggregation, 
motor and cognitive symptoms, and lifespan. Weeks (W); months (M). 
 
All these mouse models differ from each other with regard to the type of mutation 
expressed, portion of the protein included in the transgene, promoter employed, 
expression levels of mutant protein and even background strain, making each of them 
unique (Alberch et al., 2008). While some strains display early neuropathology and 
mortality, others progress so slowly that visible phenotype is not appreciated until mice 
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get very old. This permits the study of different progression degrees of the human 
pathology. Importantly, none of these models do recapitulate with total reliability the 
phenotypic aspects of human pathology. 
 
Mice models can be classified into categories based on the genetic introduction of 
the mutation, (1) mice that express only a N-terminal fragment of the mutant huntingtin 
gene, and (2) mice that express the full-length mutant huntingtin gene, being the first 
group the one that usually expresses a more severe phenotype of the disease. 
 
 
1.3.1 - N-terminal mutant huntingtin models 
 
R6/1 and R6/2 mice were the first transgenic models to be developed by Gillian 
Bates’ group and collaborators in 1996, and, from all the mouse models generated, 
they present the most aggressive phenotype. They carry a human genomic fragment 
containing huntingtin promoter, mutant huntingtin exon 1 with CAG repeats and the first 
262 base pair (bp) of human huntingtin intron 1 sequence (Mangiarini et al., 1996). The 
differences between both lines are the copies of the transgene that have been 
integrated in the genome and the expression level of the transgene. R6/1 mice 
integrated in their genome one single copy of the transgenic fragment while R6/2 
integrated three copies of it. Moreover, R6/1 transgene expression is 31% while R6/2 is 
75% relative to the endogenous huntingtin expression level (Mangiarini et al., 1996). 
R6/1 mouse model exhibits weight loss at 22 weeks of age, and R6/2 mice, which 
develop a more aggressive phenotype than R6/1 mice, show weight loss at 8 weeks of 
age (Mangiarini et al., 1996). Neuronal atrophy is a general event within the brain in 
both mice strains that curses together with ventricular enlargement but minimal 
neuronal loss (Canals et al., 2004; Mangiarini et al., 1996; Turmaine et al., 2000). R6/2 
mice also develop astrogliosis (Giralt et al., 2011a). 
 
N171-82Q mice carry a N-terminal fragment from the human mutant huntingtin 
gene, which is longer than the exon 1 in R6 models. In these mice, a slight number of 
cortical (4%) and striatal (1.8%) apoptotic neurons have been detected at 5 months of 
age, as well as reactive gliosis at 4 months of age (Yu et al., 2003). 
 
Finally, the generation of a conditional mouse model expressing in the forebrain an 
N-terminal fragment of the mutant huntingtin under an inducible promoter (HD94) has 
favoured the study of Huntington’s disease phenotype reversibility. Silencing the 
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expression of mutant huntingtin, even relatively late in pathology, resulted in not only 
halting the disease progression but also reversal of aggregate formation and motor 
decline (Yamamoto et al., 2000). Interestingly, these mice show a significant 
progressive striatal neuronal loss from 17 to 22 months of age, which can be partially 
reverted by silencing the expression of mutant huntingtin during these months (Diaz-
Hernandez et al., 2005). 
 
 
1.3.2 - Full-length mutant huntingtin models 
 
Mice that express the full-length mutant huntingtin gene can be grouped in those 
in which mutant huntingtin is delivered in a yeast artificial chromosome (YAC) and 
those in which a knock-in mutation has been performed to modify the endogenous 
murine huntingtin. 
 
Several YAC models that express different repeat length have been generated. 
Although all the YAC lines suffer from brain atrophy, the one with 128 CAG repeats 
presents the most severe pathology (Slow et al., 2003). It is the only model that, 
besides striatal and cortical atrophy, develops quantitive striatal neuronal loss at 12 
months of age (15-18%) (Slow et al., 2003). 
 
Finally, knock-in models are more faithful genetic models of the human condition 
because they carry the mutation in its appropriate genomic context. These animals, 
however, present a late onset of the disease and a mild progression of the pathology. 
None of the knock-in lines generated, develop neuronal loss (Menalled, 2005; Wheeler 
et al., 2002; Yu et al., 2003), although reactive gliosis can be detected in 111 and 150 
CAGs knock-in models (Lin et al., 2001; Wheeler et al., 2002). 
 
Stable cell lines, as a tool to study in vitro mutant huntingtin effects, have been 
generated from the HdhQ9 and HdhQ111 mice. Striatal precursors at embryonic day 
14 were immortalized with the simian vacuolating virus 40 Large T antigen. The 
generated cell lines are the control STHdh7Q/7Q and the Huntington’s disease cellular 
models STHdh7Q/111Q and STHdh111Q/111Q (Trettel et al., 2000).  
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1.4 - MOLECULAR MECHANISMS INVOLVED IN NEURONAL DYSFUNCTION IN 
HUNTINGTON’S DISEASE 
 
Although mutant huntingtin is ubiquitously expressed, neurons, and more precisely 
striatal medium-sized spiny neurons cells, are primarily affected in Huntington’s 
disease. All along the disease progression stressful events are continuously generated. 
However, the exact mechanisms that drive to the selective neuronal vulnerability and 
neuronal degeneration are still under debate. Much research has been performed to 
understand the process by which mutant huntingtin triggers neurodegeneration, and 
why some specific cells are primarily affected in Huntington’s disease. Several studies 
have indicated that huntingtin may be a scaffold protein involved in orchestrating sets 
of proteins for intracellular transport and signalling processes. Huntingtin has been 
implicated in vesicle transport and cytoskeletal anchoring (Gutekunst et al., 1998) as 
well as in clathrin-mediated endocytosis, neuronal transport processes and 
postsynaptic signalling (Harjes & Wanker, 2003; Landles & Bates, 2004; Li & Li, 2004).  
 
Figure 4.- Huntingtin and mutant huntingtin functions. The diagram shows huntingtin functions and possible toxic 
mechanisms triggering cell dysfunction/death together with mutant huntingtin. Figure adapted from Perez-Navarro et al., 
2006. 
 
Moreover, huntingtin is also localized in the nucleus, where it interacts with proteins 
involved in gene transcription (Harjes & Wanker, 2003; Landles & Bates, 2004; Li & Li, 
2004). Thus, it has been suggested that a loss of huntingtin function triggered by the 
mutation may contribute to the neuropathology of Huntington’s disease (Cattaneo et 
al., 2005) (Fig. 4). Together with this loss of function, several mechanisms, intrinsic of 
each neuronal population such as excitotoxicity, mitochondrial dysfunction and low 
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trophic supply, can also modulate neuronal degeneration in the presence of mutant 
huntingtin (Perez-Navarro et al., 2006) (Fig. 4). Finally, mutant huntingtin is very 
unstable and unfolds improperly giving rise to protein aggregates. It is under debate 
whether these aggregates could enhance mutant huntingtin-induced toxicity or be 
protective for cells (Arrasate et al., 2004; Scherzinger et al., 1997) (Fig. 4). 
 
 
1.4.1 - Aggregation in Huntington’s disease 
 
Huntington’s disease is characterized by the presence of protein aggregates that 
accumulate within cells, resembling what has been observed in various forms of 
spinocerebellar ataxia, as well as in other neurodegenerative disorders such as 
Alzheimer's and Parkinson's diseases (Bano et al., 2011). 
 
DiFiglia and collaborators performed in 1997 an extended immunohistochemical 
analysis of human brain post-mortem tissue, using an antiserum raised against N-
terminal huntingtin epitope. The most important finding was the presence of these 
mutant huntingtin clusters within nucleus of neurons that degenerate in Huntington’s 
disease. They found large nuclear inclusion bodies that were positioned variably 
throughout the nucleus, adjacent to or distant from the nucleolus, in neurons from all 
the cortical layers and in medium-sized spiny neurons, but they were not present in 
cerebellar neurons. Nuclear inclusion bodies were also absent in the brains of control 
individuals. Interestingly, they found a correlation between the onset of the disease and 
the frequency of the nuclear inclusions, being those more frequent in juvenile than in 
adult Huntington’s disease patients. The fact that with the antiserum against an epitope 
at the internal site of huntingtin they failed to detect nuclear inclusions, suggested that 
these clusters contained a cleaved fragment of N-terminal mutant huntingtin (DiFiglia et 
al., 1997). Similar findings were obtained in transgenic mice, with some differences 
though. In the transgenic mice nuclear inclusions were found also in neurons from the 
cerebellum, and dense accumulation of mutant huntingtin in the cytoplasm of neurons 
was also observed (Davies et al., 1997). Immunohistochemisrty of human brain tissue 
using another N-terminal antibody revealed also cytoplasmic aggregates, which were 
named neuropil aggregates (Gutekunst et al., 1999). These aggregates, seem to be 
present long before symptoms or neuropathology is detectable, suggesting that 
inclusion formation precedes the onset of symptoms in both transgenic mice and in 
human brain (Davies et al., 1997; Gutekunst et al., 1999). Finally, in the conditional 
animal model of Huntington’s disease, not only symptomatic amelioration of the 
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behavioural phenotype was observed, but also disappearance of inclusions when 
abolishing the transgene expression (Yamamoto et al., 2000) 
 
These findings, in addition to results showing that the same polyQ length threshold 
causes both aggregates and pathogenicity, have implicated aggregates in triggering 
neurodegeneration (Scherzinger et al., 1997). However, the function of aggregate 
formation along the progression of the disease has not yet been elucidated, and the 
toxic effect still remains controversial. Nevertheless, it has been suggested that 
aggregate formation promoters might protect neurons by decreasing the levels of toxic 
diffuse forms of mutant huntingtin (Arrasate et al., 2004; Bodner et al., 2006). Although 
the mechanism by which mutant huntingtin could trigger toxicity is unknown, it is well 
known that mutant huntingtin is not only prone to aggregate with itself but also has the 
tendency to aggregate with other selected proteins (Busch et al., 2003; Steffan et al., 
2000). This suggests, that besides the toxic function that mutant huntingtin has per se, 
it can induce additional cell toxicity by sequestering and impairing the function of other 
proteins. 
 
Aggregates are formed not only by one single specific mutant huntingtin fragment, 
but also by a broad range of different N-terminal mutant huntingtin fragments (Hoffner 
et al., 2005). Mutant huntingtin is target of a number of specific proteases such as 
caspases, calpains and matrix metalloproteinases, which generate these N-terminal 
fragments. It was suggested that huntingtin cleavage by caspases is a normal 
physiological event, since caspase-cleaved huntingtin was detected both in wild-type 
and Huntington’s disease mouse models as well as in control human and Huntington’s 
disease brains (Wellington et al., 2002), although this caspase-dependent cleavage is 
more efficient as polyQ length increases (Goldberg et al., 1996). In contrast to the 
controversy raised around the toxicity of mutant huntingtin aggregates, unanimity does 
exist when considering the toxicity of soluble or oligomerized N-terminal mutant 
huntingtin fragments (Graham et al., 2006; Wellington et al., 2002). In addition, small 
N-terminal fragments have been observed to redistribute to the nucleus and be 
required for neurodegeneration (Hodgson et al., 1999). It has been recently suggested 
that the polyQ sequence possesses NES activity itself (Chan et al., 2011), and thus 
mutant huntingtin but not the wild-type, would interact with exportin-1 (Xpo-1) to 
translocate out from the nucleus (Chan et al., 2011; Hilditch-Maguire et al., 2000). A 
reduction in the levels of Xpo-1 with age, which occurs in a Huntington’s disease 
mouse model, could account for the permanence of mutant huntingtin within the 
nucleus and contribute to cellular toxicity and aggregation (Chan et al., 2011). 
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It has been hypothesized that the fact that unfolded proteins do not accumulate in 
aggregates in unstressed cells, despite their continued production, is due in part to the 
existence of a cellular ‘quality control’ machinery, which ensures the fidelity of 
transcription and translation, by chaperoning nascent or unfolded proteins, and by 
selectively degrading these improperly folded proteins (Kopito, 2000; Ross & Poirier, 
2004). Thus, a proper efficiency of degradation mechanisms within the cells is highly 
important to avoid neurodegeneration in Huntington’s disease. 
 
 
2 - MECHANISMS THAT COULD TRIGGER CELL SURVIVAL IN HUNTINGTON’S 
DISEASE 
 
2.1 - MECHANISMS TO DEGRADE ABERRANT PROTEINS OR ORGANELLES 
 
Every eukaryotic cell has two main systems to degrade intracellular components, 
the ubiquitin-proteasome system (UPS) and autophagy. While the proteasome is 
responsible for rapid protein turnover, autophagy degrades long-lived proteins and 
other intracellular components such as organelles, lipid deposits and even pathogens. 
Upon failure of both systems in degrading misfolded proteins, protein aggregates start 
to accumulate. 
 
 
2.1.1 - UPS 
 
The UPS plays an essential role in the degradation and clearance of soluble short-
lived, misfolded and mutant proteins in eukaryotic cells, in both cytoplasm and nucleus 
(Rockel et al., 2005). Therefore, it is a main regulator of several crucial processes, 
such as cell division, transcription, antigen processing and signal transduction (Ding & 
Keller, 2001; Goldberg et al., 1995; Low, 2011). 
 
The UPS consists of both substrate recruiting and substrate-degradation 
machinery. On one hand, the substrate-degradation machinery, called the 26S 
proteasome, is a large elongated cylinder with multiple peptidase activities, composed 
by a 20S core particle capped by a 19S regulatory particle at one or both ends. In the 
inner part of the 20S complex, there are three types of catalytic subunits that execute 
the corresponding catalytic activities of the proteasome: trypsin-like, chymotrypsin-like, 
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and peptidylglutamyl-peptide hydrolyzing activity (Li & Li, 2011). The 19S functions in 
recognizing polyubiquitinated proteins, leading the substrate to enter in the proteolytic 
chamber and unfolding the substrate to be able to fit inside the narrow chamber 
(Ciechanover, 2005). On the other hand, an ubiquitin chain tag is required for the 
substrate to be recognized by the 19S. Ubiquitin is a small and heat-stable protein, 
which is highly conserved among species and plays a role, among others, in recruiting 
substrate for degradation (Ciechanover, 2005). Ubiquitins are progressively added to 
the substrate through iso-peptide bonds that link the terminal residue of one ubiquitin 
and the internal lysine 48 of the previously conjugated one (Thrower et al., 2000). This 
reaction requires the sequential actions of ubiquitin-activating (E1), -conjugating (E2) 
and -ligating (E3) enzymes (Tan et al., 2008). Once the 19S complexes have 
recognized polyubiquitinated substrates, deubiquitnating enzymes disassemble, then, 
polyubiquitin chains into ubiquitin monomers that can be reused (Kawakami et al., 
1999). 
 
Important mediators of the UPS, that help ubiquitinated proteins entering the 
proteasome, are chaperones (Slavotinek & Biesecker, 2001). These proteins not only 
prevent improper folding and aggregation but also facilitate formation of a correct 
conformation of misfolded proteins, often through cycles of ATP-regulated binding and 
release. Molecular chaperones typically recognize and bind to the exposed 
hydrophobic residues of misfolded proteins, by non-covalent interaction (Hartl, 1996; 
Slavotinek & Biesecker, 2001). 
 
Although the UPS is the primary machinery of polyubiquitinated protein 
degradation, it has been reported that it fails in the digestion of stable protein 
complexes or aggregates (Venkatraman et al., 2004). In the same study they showed 
that the UPS is not capable of degrading long polyQ stretches and cuts only at the 
flanking residues of the stretch. This leads to the generation of fragments that are more 
hydrophobic and aggregate more readily.  
Thus, lysosomal degradation has emerged as a crucial mechanism for maintaining 
cellular homeostasis in diseases characterized by protein aggregation. 
 
 
2.1.2 - Autophagy 
 
Autophagy, which from the Greek means, ‘self eating’, is a process within the cell 
relevant in mediating the degradation of cell components inside the lysosomes. It is a 
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catabolic process to degrade and recycle cell components, therefore it is important in 
maintaining both protein and organelle turnover. The macromolecules that result from 
the degradation can be reused again.  
From a reductionist point of view, autophagy is an adaptation to starvation. 
Autophagy is activated as soon as a cell lacks nutrient supply, since the cell is forced to 
catabolise its own reserves to keep alive until the situation improves (Mizushima et al., 
2008). This adaptation process has been observed from single-cell organisms to more 
complex organisms such as mammals. Autophagy-deficient yeasts rapidly die under 
poor nutrition conditions (Tsukada & Ohsumi, 1993). Moreover, during embryogenesis 
autophagic level is low, but after birth autophagy is immediately up-regulated until the 
levels restore to basal, 1 or 2 days later. This phenomenon has been proposed to be 
an adaptation to the nutrient interruption that the neonate faces just after birth until 
nutrient supply is restored through milk. In agreement, homozygous knockout neonate 
mice deficient for Atg5 or Atg7, two essential proteins in autophagy, die within 1 day, 
although minimal abnormalities are detected at birth (Komatsu et al., 2005; Kuma et al., 
2004). 
However, besides induced autophagy, constitutive autophagy at a low level is 
needed, since down-regulation of the process has been proposed to contribute to 
pathological conditions such as neurodegeneration, hepatic dysfunction and 
cardiovascular disorders (Hara et al., 2006; Komatsu et al., 2005, 2006; Takemura et 
al., 2009). 
Although autophagy initially seems to be protective, in the past few years it has 
been also linked to a type of programmed cell death. There is a complex interplay 
between autophagy and apoptosis, since both processes can work in synergy but also 
one can counteract the other (Eisenberg-Lerner et al., 2009). Some proteins from the 
autophagy machinery have been linked to activate apoptosis, for example Atg5 can 
undergo calpain-mediated cleavage to generate a pro-apoptotic fragment that functions 
in the intrinsic mitochondrial death pathway, or p62/SQSTM1 (p62) induces caspase-8 
aggregation leading to full activation of the protease (Jin et al., 2009; Yousefi et al., 
2006). 
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Figure 5.- Types of autophagy. The diagram shows the three ways by which the cell delivers the autophagic cargo into 
the lysosomes: microautophagy, chaperone-mediated autophagy and macroautophagy. Figure adapted from  Martinez-
Vicente & Cuervo, 2007. 
 
 
Lysosomes are central in the autophagic process since they contain all the acid 
hydrolases needed for degradation. The way in which the autophagic cargo is delivered 
within the lysosomes distinguishes types of autophagy (Cuervo, 2010). There are three 
ways of delivering the cargo into the lysosomes: microautophagy, chaperone-mediated 
autophagy and macroautophagy (Fig. 5). 
 
 
2.1.2.1 - Microautophagy 
 
In the case of microautophagy the cargo is sequestered by the lysosome itself. 
Cytosolic components are internalized through invaginations at the lysosome 
membrane and, once in the lumen, the whole internalized vesicle is degraded (Shpilka 
& Elazar, 2011). Organelles such as peroxisomes or mitochondria can be engulfed and 
self-digested through microautophagy processes (Farre et al., 2009). By electron 
microscope abnormal lysosomal structure morphology can be detected, such as 
elongated forms with arm-like membrane extensions or large lysosomes with multiple 
submembrane compartments. These kinds of structures are interpreted as 
microautophagic events. However, since there is a lack of reliable markers to track and 
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specific techniques to analyze microautophagy, aside from electron microscope, the 
knowledge of this process in mammalian cells is limited (Mijaljica et al., 2011).  
Multivesicular bodies, which are defined as organelles with vesicular structures 
trapped in their lumen, degrade mainly transmembranal proteins by internalization and 
sorting to the lysosomes. To get degraded, these multivesicular bodies fuse to an 
autophagosome from the macroautophagy pathway forming a hybrid organelle called 
amphisome. In a final step this intermediate structure will get degraded when fusing to 
a lysosome (Fader & Colombo, 2009). It has been suggested that alterations in the 
multivesicular bodies biogenesis block the degradation of some proteins through 
autophagy (Rusten & Simonsen, 2008). Since the formation of multivesicular bodies in 
late endosomes resembles that of microautophagy, some groups have hypothesized 
that microautophagy can occur also in late endosomes (Cuervo, 2010; Fader & 
Colombo, 2009; Sahu et al., 2011). 
 
 
2.1.2.2 - Chaperone-mediated autophagy 
 
Chaperone-mediated autophagy differs from the other two autophagic pathways in 
many ways. It does not involve vesicle formation, it is saturable, it is a process for 
degradation of cytosolic soluble proteins, and it is highly selective. In this case, cargo, 
which is recognized by cytosolic chaperones, directly translocates into the lysosome 
across the lysosomal membrane with the help of a set of lysosomal proteins (Kon & 
Cuervo, 2010).  
Proteins destined for lysosomal degradation have the pentapeptide motif KFERQ 
in its sequence. This tag is only recognized by the cytosolic chaperone Heat shock 70 
kDa protein (HSC70), which delivers the cargo to the lysosomes. Mutations in the tag 
sequence impair both recognition and degradation of proteins. More than one KFERQ 
motif in the sequence of a protein does not imply more degradation, since translocation 
of proteins into the lysosomal lumen is a saturable process. Delivery of the cargo into 
the lysosomes does not involve vesicle formation nor membrane budding, but the 
presence of the single-span lysosome-associated membrane protein (LAMP2A) on the 
lysosomal surface, which acts as a receptor for chaperone-mediated autophagy 
through the C-terminal (Cuervo, 2010). The substrate binding to LAMP2A monomers 
drives its multimerization to a 700 KDa complex that has been elucidated to be 
essential for protein translocation. HSC70, together with a subset of co-chaperones, 
help unfolding the substrate at the lysosomal surface. Finally, to complete the 
translocation of substrate proteins into lysosomes, a form of HSC70 resident in the 
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lysosomal lumen is needed. Although the mechanism by which lysosomal-HSC70 
mediates substrate translocation is still unclear, blocking the chaperone strongly 
impairs chaperone-mediated autophagy (Bejarano & Cuervo, 2010). 
 
 
2.1.2.3 - Macroautophagy 
 
In the case of macroautophagy, the cargo delivery to the lysosomes is mediated 
by another 400-900 nm vacuolar structure called autophagosome. When 
autophagosomes are forming, they engulf a portion of cytoplasm and retain it in its 
lumen. Since autophagosomes do not have the enzyme machinery to degrade its 
content they fuse to lysosomes in a later step. From now on, this process will be simply 
referred as autophagy. 
 
The sequestration of the cargo is triggered by a double-bilayered membrane, 
called phagophore, which expands until enclosure around a portion of cytoplasm. The 
resulting double-layered organelle is the aforementioned autophagosome. 
Autophagosome formation, thus, requires three steps: phagophore nucleation, 
phagophore expansion and autophagosome maturation (Geng & Klionsky, 2008). The 
molecular basis of this process was not understood until 1993, when Ohsumi and co-
workers isolated in yeast the first autophagy-related genes (Atg), which elucidated the 
core autophagic machinery (Tsukada & Ohsumi, 1993). To date, 34 different Atgs and 
their orthologs in mammals have been identified, implying a conserved autophagic 
mechanism from yeast to higher eukaryotes (Weidberg et al., 2011) (Fig. 6). However, 
the process is highly complex and many aspects still need to be understood. Anyhow, 
the Atg involved in this core autophagic machinery can be subclassified into four main 
functional groups depending on which stage of autophagsome formation they act: (1) 
the Atg1–Atg13–Atg17 kinase complex and (2) the class III phosphatidylinositol 3-
kinase (PI3K) complex I, consisting of Vps34, Vps15, Atg6/Vps30 and Atg14, are 
required for the phagophore nucleation; (3) two ubiquitin-like protein conjugation 
systems (Atg12 and Atg8) and (4) Atg9 and its cycling system, are involved in the 
expansion steps of the phagophore (Yang & Klionsky, 2010). 
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Figure 6.- Atg12 and Atg8 in autophagosome formation. (A) The diagram shows the two ubiquitin-like (Ubl) protein 
conjugation systems, Atg12 and Atg8, that mediate Atg8 lipidation and recruitment to the autophagosome membrane. 
(B) The Atg12-Atg5-Atg16L complex is recruited to the phagophore to ensure Atg8 lipidation and recruitment, which 
supports the phagophore expansion. On completion of the autophagosome, the Atg12–Atg5-Atg16L complex 
dissociates from the vesicle, and Atg4 proteolytically releases the Atg8 that is present on the external surface. Note that 
the initiation of the phagophore is initially Atg12-Atg5-Atg16L independent. Figure from Geng & Klionsky, 2008. 
 
The nucleation of the phagophore mainly requires the participation of many Atg 
proteins, which are recruited to the phagophore-assembly site. Many of these sites can 
be detected throughout the cytoplasm in mammalian cells (Weidberg et al., 2011). An 
essential complex for autophagy is the class III PI3K complex 1, composed by the 
kinase Vps34, Beclin-1 (in yeast Atg6/Vps30), Vps15 and Atg14. This complex 
produces phosphatidylinositol 3-phosphate (PI3P), which is present at the inner part of 
the autophagosomes and recruits PI3P-binding proteins important for autophagosome 
formation. Another important set of Atg important in the autophagosome formation is 
UNC-51–like kinase (ULK) 1/2 (Atg1 in yeasts), which participates in a cytosolic 
complex, together with Atg13, Atg101 and Focal adhesion kinase family interacting 
protein of 200 kDa (FIP200), and is recruited to the phagophore upon autophagy 
induction in a very early stage (Noda et al., 2010; Weidberg et al., 2011). There is still 
no data that would link ULK1/2 with the class III PI3K complex 1. 
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The main molecular regulatory mechanism for the phagohore expansion consists 
of two ubiquitin-like conjugation systems, Atg12 and Atg8 conjugation systems. They 
induce LC3 (in yeast Atg8) lipidation and membrane association (Suzuki & Ohsumi, 
2007), a crucial event that causes phagophore elongation in vitro (Nakatogawa et al., 
2007). Like the canonical ubiquitin system, Atg12 is an ubiquitin-like Atg protein that 
gets activated by Atg7, which is an E1-like enzyme. After activation, Atg12 is 
transferred to Atg10, an E2-like enzyme, and finally conjugated to the target protein 
Atg5 through an isopeptide bond, without the participation of an E3 enzyme. Atg5 
interacts with Atg16L, which homo-oligomerizes generating an Atg12-Atg5-Atg16L 
complex. In this second ubiquitin-like conjugation system, LC3 is attached to a 
phosphatidylethanolamine (PE). LC3 is first proteolytically processed to expose a 
glycine. This LC3 form is named LC3I. LC3I is activated by Atg7 and transferred to the 
E2-like enzyme Atg3. The Atg12-Atg5 complex, which binds both Atg3 and PE, is the 
E3-like complex from the second conjugation system that can transfer LC3 to the PE. 
This lipidated membrane-bound form of LC3 is called LC3II. LC3 lipidation is reversible 
and LC3 can be recycled, since Atg4b can release LC3 from the PE (Geng & Klionsky, 
2008; Hanada et al., 2007; Ichimura et al., 2004). Since LC3II is essential for the 
phagophore elongation and it is the only one known protein specifically present at the 
autophagosome and autolysosome membranes, but at no other vesicles, it is 
considered to be a good autophagic marker, and its levels correlate with the number 
and size of autophagosomes and autolysosomes (Rubinsztein et al., 2009). In addition 
to the ubiquitin-like conjugation systems, Atg9 is an integral membrane protein that 
cycles between autophagosomes to Golgi and endosomes compartments and vice 
versa. Although the mechanism and regulation of this cycle has been further analyzed, 
the function in autophagy is still unknown. However, it has been hypothesized that Atg9 
can regulate the autophagosome size, that it can be a carrier of lipids to forming 
autophagosomes and can regulate LC3 lipidation (Webber & Tooze, 2010). 
 
Once formed, autophagosomes start moving linearly toward the perinuclear region 
where lysosomes are localized. These dynamics rely on the microtubule network and 
the dynein/dynactin motor complex (Kimura et al., 2008; Maday et al., 2012). Fusion to 
lysosomes is what is referred as autophagosome maturation, and the resulting vesicle 
is called autolysosome. The autophagic body, the structure surrounded by the inner 
lipid bilayer, is released into the lumen of the vacuole and is consequently degraded by 
vacuolar hydrolases (Suzuki & Ohsumi, 2007). The resulting products will be released 
back to the cytosol through permeases (Chen & Klionsky, 2011). Lumenal lysosomal 
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environment is at pH 4.6-5, which is maintained by proton-pumping vacuolar ATPases 
(Luzio et al., 2007). Continuous lysosomal turnover of cellular constituents delivered by 
autophagy and endocytosis is crucial for cellular homeostasis. Lysosomal dysfunction 
in lysosomal storage disorders, caused by a disruption of the internal environment, can 
lead to neurodegeneration and present accumulations of autophagosomes that cannot 
be degraded (Nixon et al., 2008). 
 
 
2.1.2.3.1 - Selective autophagy 
 
Since its discovery, autophagy has been always defined as a bulk degradation 
system. However, there are increasing number of evidences that autophagy is rather 
selective, or at least some autophagy processes require selectivity. Whereas 
starvation-induced autophagy is a non-selective process, basal autophagy has been 
hypothesized to be more selective, since it is an important quality control that removes 
damaged organelles, such as peroxisomes (pexophagy) and mitochondria (mitophagy) 
and other substrates targeted for lysosomal degradation. These last processes require 
both cargo targeting and recognition, carried out by specific autophagy receptors that 
would connect the cargo to the core autophagic mechanism (Knaevelsrud & Simonsen, 
2010). In mammalian cells, the selectivity comes from proteins that contain the WXXL 
motif in their sequence, also named LC3 interaction region (LIR) (Noda et al., 2010). 
Thus, these proteins can work as autophagy cargo receptors, since they can recognize 
specifically the cargo that needs to be degraded and LC3 through the LIR motif. The 
cargo needs to be correctly ubiquitinated to be recognized by the receptors 
(Knaevelsrud & Simonsen, 2010; Weidberg et al., 2011).  
 
p62, Neighbour of BRCA1 gene 1 (NBR1), Nix and Nuclear dot protein 52 
(NDP52) are recently discovered autophagic cargo receptors that have an ubiquitin-
associated (UBA) domain and a LIR motif in their sequences (Yamamoto & Simonsen, 
2011). To achieve selectivity, a molecular tag or marker is required for recognition of 
the structures that must be degraded by autophagy. Alternatively to the UPS system, 
ubiquitin chains linked through lysine 63 may represent a strategy for defining 
autophagy cargo, since lysine 63-linked ubiquitin chains have been implicated in 
inclusion biogenesis in many neurodegenerative diseases and these inclusions are 
preferentially cleared by autophagy (Lim et al., 2005; Tan et al., 2007, 2008). 
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Both p62 and NBR1 function as autophagic cargo receptors and they are 
themselves substrates of autophagy, since they are degraded together with the cargo. 
Autophagy regulates its levels, which do not seem to be altered by proteasomal 
degradation (Bjorkoy et al., 2005; Kirkin et al., 2009; Pankiv et al., 2007). Both p62 and 
NBR1 have been shown to interact with protein aggregates and to regulate their 
clearance (Kirkin et al., 2009). Additionally, p62 also interacts with peroxisomes, 
mitochondria and even intracellular bacteria (Geisler et al., 2010; Kim et al., 2008; 
Zheng et al., 2009). Both proteins can even interact together to co-operate (Kirkin et 
al., 2009). 
 
 
Figure 7.- Schematic diagram of p62 and NBR1 proteins. p62 and NBR1 with their domains and functional motifs are 
represented on the scheme. Both proteins contain and UBA domain and a LIR motif that are both essential for selective 
autophagy. Their sequences also contain a PB1 domain that is important for their oligomerization.  Figure adapted from 
Lamark et al., 2009. 
 
p62, a 440 amino acid protein, was the first cargo receptor discovered in 
mammalian cells for selective autophagy of ubiquitinated proteins. NBR1, on the other 
hand, is twice larger than p62 with 966 amino acids in its sequence. Although is larger, 
NBR1 follows a similar domain architecture as p62 and therefore both cargo receptors 
share key functional features. Both proteins have an N-terminal Phox and Bem1 (PB1) 
domain important for oligomerization, a LIR motif to interact with LC3, and a C-terminal 
UBA domain to associate with ubiquitin (Lamark et al., 2009). Moreover, LIR motif has 
been proved to be important for the localization of p62 into autophagosomes and for its 
lysosomal degradation (Shvets et al., 2008) (Fig. 7). However, findings from 
Mizushima’s group, who have examined how p62 and NBR1 are loaded into the 
autophagic vesicles, show that LC3 interaction might be important for the enclosure of 
p62 into the autophagosomes and for its degradation, but not for the presence of p62 
and NBR1 at the autophagosome formation site (Itakura & Mizushima, 2011). 
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Besides the mechanism by which these receptors interact with LC3 and the 
autophagsomes, it is also important to take into consideration the way they bind the 
tagged-cargo. In the brain, the absence of p62 results in the abnormal hyper-
accumulation of aggregated insoluble lysine 63-polyubiquitinated proteins, such as 
Tropomyosin receptor kinase A (TrkA) (Wooten et al., 2008). This suggests that p62 
and lysine 63-linked polyubiquitin may be together involved in directing clearance of 
protein inclusions by autophagy (Tan et al., 2007). On the other hand, NBR1 UBA 
domain has been reported to bind both lysine 48 and lysine 63-linked polyubiquitin 
chains (Kirkin et al., 2009). 
 
p62 and NBR1, however, are multifunctional scaffold proteins involved in many 
other cellular processes such as cell signalling and receptor internalization. This 
functional diversity is due to the several protein-interacting domains of their sequence 
(Moscat et al., 2007). p62 signalling has been studied in a broad branch of processes, 
such as osteoclastogenesis, inflammation, differentiation, neurotrophin biology and 
obesity, since it can associate to tumour necrosis factor α signalling adaptor, receptor 
interacting protein, tumour necrosis factor α receptor-associated factor 6 and others. As 
an example, some mutant alleles of the p62 gene with deleted or non-functional UBA 
domain have been linked to the adult onset Paget’s disease of the bone, causing 
defects in signalling and aberrant osteoclastogenesis (Moscat et al., 2007). NBR1 has 
been linked to hereditary muscle diseases, since it interacts with the sarcomeric protein 
kinase Titin and with p62 in the M line of the sarcomer. Mutations in Titin cause 
dissociation of the complex and dissolution of the M line (Lange et al., 2005). 
Moreover, NBR1 loss of function leads to bone remodelling and an increase in bone 
volume and density, through a hyper-activation of p38 Mitogen-activated protein kinase 
(MAPK) that favours osteoblastogenesis (Whitehouse et al., 2010). Due to such 
amount of interacting partners, p62 knockout mice present a complex phenotype. It has 
been reported that these mice develop mature-onset obesity, leptin resistance, as well 
as impaired glucose and insulin intolerance (Rodriguez et al., 2006). Moreover, 
deficiency of p62 leads to a mature-onset (6 months old mice) accumulation of hyper-
phosphorylated Tau, neurofibrillary tangles, and neurodegeneration, followed by 
increased anxiety, depression, loss of working memory, and reduced serum Brain-
derived neurotrophic factor (BDNF) levels (Wooten et al., 2008). Younger p62 knockout 
mice (4-8 weeks of age) lack liver and neuronal abnormalities (Komatsu et al., 2007).  
 
In addition to p62 and NBR1, there are other autophagic receptors such as Nix 
and NDP52. Nix mediates the damaged mitochondrial clearance. Binding studies have 
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shown that Nix, as well as p62 and NBR1, also interacts with LC3. Nix function on 
mitochondrial turnover is LC3 dependent, since an ablation of this interaction retards 
the mitochondrial clearance (Novak et al., 2010). NDP52 has been studied in the field 
of removing cytosolic bacteria from the cytoplasm of cells, and share with the others 
the ability to bind LC3 and ubiquitinated cargo (Mostowy et al., 2011; Thurston et al., 
2009). 
 
 
2.1.2.3.2 - p62 and NBR1 in aggregate formation and clearance 
 
p62 has been found in inclusion bodies in many neurodegenerative disorders such 
as Alzheimer’s and Parkinson’s diseases, and also in the R6/2 mouse hippocampus 
and cortex, and in a cellular model of Huntington’s disease (Bjorkoy et al., 2005; 
Nagaoka et al., 2004; Nakaso et al., 2004; Zatloukal et al., 2002). NBR1 has been 
detected in Mallory bodies of the liver and in Lewy Bodies (Kirkin et al., 2009; Odagiri 
et al., 2012). Moreover, both proteins are required for the formation of ubiquitinated 
protein aggregates, also called p62 bodies, sequestosomes or aggresome-like 
inducible structures mediated by they self-oligomerization through the PB1 domain and 
ubiquitin binding (Bjorkoy et al., 2005; Ichimura et al., 2008; Kirkin et al., 2009; 
Knaevelsrud & Simonsen 2010; Lamark et al., 2009). 
As commented before, lack of p62 does not induce protein aggregation, at least in 
young mice. Interestingly, when autophagy is impaired, a marked p62-positive inclusion 
accumulation can be observed, that can be reverted by p62 gene depletion (Komatsu 
et al., 2007). In addition to this, also fewer p62 bodies were formed in cells after 
knocking down NBR1 when compared to control cells (Kirkin et al., 2009). 
These results have lead to the proposal of the following model for the role of NBR1 
and p62 in aggregate formation and protein clearance: (1) Under conditions of 
increased misfolded protein production, soluble and toxic oligomeric proteins 
accumulate and poly-ubiquitin chains are conjugated to these oligomers; (2) 
ubiquitinated cargo is recognized by NBR1 and p62 and delivered to the forming 
autophagosomes via interaction with membrane-bound Atg8 family proteins; (3) if 
degradation of these soluble complexes is incomplete due to autophagy disruption, 
NBR1 and p62 promote formation of p62 bodies; (4) both NBR1 and p62 participate in 
autophagic degradation of p62 bodies (Kirkin et al., 2009). 
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2.1.2.3.3 - Autophagy regulation 
 
Autophagy is tightly regulated in order to generate a rapid response when needed. 
The identification of the mammalian target of rapamycin kinase (mTOR) together with 
the fact that rapamycin (an mTOR inhibitor) could up-regulate autophagy processes, 
was a key breakthrough to start understanding the complex signalling that lead to 
autophagy regulation (Blommaart et al., 1995; Heitman et al., 1991). Another important 
finding was that autophagy was distinctly regulated by class I and class III PI3K. While 
class III PI3K product, PI3P, promotes autophagy in an mTOR-independent manner, 
the class I PI3K products, phosphatidylinositol (3,4)-bisphosphate (PIP2) and 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), have inhibitory effects (Blommaart et 
al., 1997; Petiot et al., 2000).  
Thus, autophagy regulation could be classified in mTOR-dependent and 
independent signalling pathways (Fig. 8). 
 
A) mTOR-dependent pathway 
mTOR was first described after many genetic and biochemical approaches to 
identify the target of the immunosuppressant rapamycin, a compound produced by a 
soil bacterium found on Easter Island (Zoncu et al., 2011). mTOR, which is a 289 kDa 
serine/threonine kinase, is a member of the PI3K-related protein kinases family and is 
an energetic imbalance sensor that relies at the interface between cellular growth and 
starvation, regulating, upon activation, the biosynthetic program in contraposition to 
catabolic pathways. 
 
mTOR, however, does not work alone. It is the catalytic core of two complexes, 
the mTOR complex (mTORC) 1 and 2, first described as sensitive and insensitive 
complexes to rapamycin. The complex that has been shown to negatively regulate 
autophagy, but also to regulate protein synthesis and translation, is mTORC1, by 
directly phosphorylating the ULK1/2-Atg13-FIP200 complex, 4E-binding protein 1 
(4EBP1) and p70 ribosomal S6 protein kinase-1 (S6K1) (Gibbons et al., 2009). 
mTORC1 generates a convergent pathway integrating information from nutrient, 
metabolic and hormonal signals to regulate autophagy. 
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Figure 8.- Autophagy regulation. The diagram represents the two pathways that regulate autophagosome synthesis, 
the mTOR-independent and the mTOR-dependent pathways. Metabolic impairment, insulin and amino acids converge 
to regulate the mTOR-dependent pathway. Class I and class III PI3K regulate autophagy in opposite ways. Figure 
adapted from Duran et al., 2011 and Mizushima et al., 2008. 
 
Insulin and amino acids have been shown to regulate autophagy in an mTOR-
dependent manner (Arico et al., 2001; Blommaart et al., 1995; Kanazawa et al., 2004). 
Insulin signal transduction leads to the activation of the class I PI3K, which is followed 
by the production of PIP3 that enables AKT to be recruited to the membrane and get 
activated. Expression of an active form of AKT inhibits autophagy, which can be 
reverted by rapamycin-inhibition of mTOR (Yang & Klionsky, 2010). Therefore, mTOR 
is downstream of AKT in the insulin-signalling pathway. Amino acids, on the other 
hand, have been shown to enhance mTORC1 activity via the Ras-related GTPase 
(Rag) and thus, to block autophagy (Inoki et al., 2012; Sancak et al., 2010). p62 has 
also been reported to play a role in the mTORC1 complex activation since it is a 
binding partner of Raptor and Rag proteins and mediates their interaction as well as 
Rags activation (Duran et al., 2011). Whereas p62 deletion has no effect on the insulin-
activated mTORC1, p62 is selectively required for mTORC1 activation and to signal 
nutrient sensing. 
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The first autophagy target downstream of mTORC1 is the ULK1/2-Atg13-FIP200 
complex, which is, as commented before, an important mediator of phagophore 
nucleation. ULK1/2-Atg13-FIP200 complex is regulated upon multiple phosphorylation 
events (Bach et al., 2011). Under basal conditions mTORC1 is associated to this 
complex and phosphorylates both ULK1/2 and Atg13, resulting in autophagy inhibition. 
However, as soon as mTORC1 activity is inhibited, ULK1/2 and Atg13 are rapidly 
dephosphorylated, leading to the complex activation (Hosokawa et al., 2009; Kamada 
et al., 2000, 2010; Kim et al., 2011a). ULK1/2 is a serine/threonine protein kinase that 
once it is dephosphorylated, results enzymatically active. This leads to other 
phosphorylation events on Atg13, FIP200, and ULK1/2 itself (Mizushima, 2010). 
 
Elevated levels of protein kinase A (PKA) activity are shown to inhibit autophagy, 
and inactivation of the PKA pathway is sufficient to induce an autophagic response 
(Stephan et al., 2009). In yeast, the regulation is triggered by directly phosphorylating 
Atg1 and Atg13 independently of TORC1 (Budovskaya et al., 2005; Stephan et al., 
2009). To date, there have been no reported evidences that PKA can regulate ULK1/2 
in the mammalian system. However, PKA can regulate mTOR by directly 
phosphorylation and thus, leading to autophagy inhibition (Blancquaert et al., 2010; 
Mavrakis et al., 2006). 
 
Finally, 5' AMP-activated protein kinase (AMPK), a key energetic sensor, pathway 
can also activate autophagy by inhibiting either directly or indirectly mTORC1 (Gwinn et 
al., 2008; Inoki et al., 2003). Moreover, it has been recently described that under 
conditions of glucose starvation AMPK can also directly phosphorylate ULK1/2 to 
activate the complex and promote autophagy in an mTOR-independent manner (Kim et 
al., 2011a). 
 
Thus, the ULK1/2-Atg13-FIP200 complex is a central regulatory unit in autophagy, 
which can be modulated by a lot of factors that are mostly integrated at the mTOR 
pathway. 
 
B) mTOR-independent pathway 
The generation of PI3P has been found to trigger a diverse cellular signalling 
mediated by proteins that are able to recognize it (Burman & Ktistakis, 2010). PI3P is, 
therefore, able to create platforms that serve to recruit specific effectors for membrane 
trafficking events. It has been hypothesized that in autophagy, PI3P may form the 
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platform for autophagosome biogenesis, since it is enriched at the inner membrane of 
the autophagosomes (Burman & Ktistakis, 2010; Obara & Ohsumi, 2011). Therefore, 
besides the ULK1/2-Atg13-FIP200 complex, class III PI3K are the second regulatory 
unit in autophagy. Thus, class III PI3K inhibitors, such as 3-methyladenine, are able to 
block autophagosome biogenesis. However, these kinases are part of the class III PI3K 
complex I (composed by Vps34, Beclin-1, Vps15 and Atg14), and any disruption of the 
complex leads to decreased PI3K activity. B-cell lymphoma-2 (Bcl-2) association to 
Beclin-1 leads to autophagy down-regulation (Furuya et al., 2005; Pattingre et al., 
2005). This Bcl-2-Beclin-1 partnership can be modulated by Bcl-2 proteolysis, 
phosphorylation of Bcl-2 by c-Jun N-terminal kinase-1 (JNK1) at sites that interfere with 
binding to Beclin-1, and by other factors that compete for Bcl-2 binding (Weidberg et 
al., 2011). Furthermore, autophagy/beclin-1 regulator-1 (AMBRA1) and Endophilin B1 
are factors that have been associated to the stabilization of Beclin-1 into the class III 
PI3K complex (Fimia et al., 2007; Takahashi et al., 2007).  
 
Finally, other factors can act both at mTOR-dependent and independent pathways 
to regulate autophagy. IKKβ is known to regulate autophagy both by enhancing AMPK 
phosphorylation-dependent mTOR inhibition and JNK1-mediated Bcl-2 phosphorylation 
(Criollo et al., 2010). Moreover, nitric oxide impairs autophagosome formation as it 
decreases JNK1 activity, and thus, Bcl-2 phosphorylation, and activates mTORC1 in an 
IKKβ dependent manner (Sarkar et al., 2011). 
 
 
2.1.3 - Protein degradation mechanisms in Huntington’s disease 
 
Huntingtin inclusions are positive for ubiquitin, indicating that these structures, or 
the monomers that compose them, are correctly tagged for their clearance (Davies et 
al., 1997; DiFiglia et al., 1997). However, mutant huntingtin progressively accumulates 
in affected neurons during the progression of Huntington’s disease (Zhou et al., 2003), 
suggesting that degradation pathways are not that efficient in clearing it. Moreover, the 
question if soluble or aggregated mutant huntingtin can directly alter the UPS or 
autophagy efficacy in the degradation of other substrates has also emerged. 
 
Colocalization of proteasome subunits, as well as chaperones, with mutant 
huntingtin inclusions has been observed in a cellular model of Huntington’s disease, 
suggesting an interaction of mutant huntingtin with the UPS degradation system 
(Warrick et al., 1999; Wyttenbach et al., 2000). Moreover, bacterial and yeast 
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chaperones, and even small molecule inducers of chaperones, decrease aggregate 
formation as well as cell death in Huntington’s disease cell culture models (Carmichael 
et al., 2000). Two hypotheses arise from these findings. Meanwhile the first one implies 
considering mutant huntingtin as substrate for the proteasome, the second one is about 
a putative UPS failure induced by mutant huntingtin. As previously commented, mutant 
huntingtin cannot be degraded by the proteasome, thus, proteasome may participate in 
its accumulation by inducing the formation of aggregates (Venkatraman et al., 2004). 
Another issue is if mutant huntingtin can alter the proteasome function leading to 
accumulation of other proteins that are normally degraded through the UPS. Some 
groups supported the idea that mutant huntingtin could impair the UPS function in 
Huntington’s disease models and also in post-mortem human tissue (Bence et al., 
2001; Bennett et al., 2005; Mitra et al., 2009; Seo et al., 2004), whereas other groups 
did not find any alteration (Bett et al., 2006; Diaz-Hernandez et al., 2003). Finally, two 
groups cross-mated mice models of Huntington’s disease with transgenic UPS green 
fluorescent protein (GFP) reporter mice (Bett et al., 2009; Ortega et al., 2010). With this 
approach, they were able to measure the UPS activity upon Huntington’s disease 
pathology. Bett and collaborators showed no alterations in the degradation of the UPS 
reporter in the R6/2 mouse model, meanwhile Ortega and collaborators found an early 
impairment of the UPS immediately after an acute expression of the mutant huntingtin 
transgene in the conditional HD94 mouse model. However, UPS activity recovered in a 
time-dependent manner correlating with inclusion bodies formation (Ortega et al., 
2010). Such finding could explain the contradictory findings explained above. 
Confirming this, mutant huntingtin filamentous aggregates inhibit proteasome activity, 
but only when they are not recruited into inclusion bodies (Diaz-Hernandez et al., 2006; 
Mitra et al., 2009). This fact strengthens the previously mentioned hypothesis that 
inclusion body formation is a protective mechanism by neutralizing the toxicity of 
intermediate mutant huntingtin species. 
 
Increases in components of the chaperone-mediated autophagy, LAMP2A and 
chaperone HSC70, have been observed in the knock-in HdhQ111 model. The authors 
suggest that chaperone-mediated autophagy activity is increased at early stages of 
Huntington’s disease contributing to degradation of truncated, but not full-length, 
mutant huntingtin. However, the efficiency of this compensatory mechanism may 
decrease with age contributing to cellular dysfunction (Koga et al., 2011). Moreover, in 
vivo attempting to selectively target mutant huntingtin for chaperone-mediated 
autophagy degradation, induced amelioration of motor symptoms (Bauer et al., 2010). 
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A blockage of the proteasome and chaperone-mediated autophagy may contribute 
to protein aggregation. Then, activation of autophagy would be important to degrade 
protein aggregates and reduce the pool of their soluble cytosolic forms that contribute 
to aggregate formation (Kon & Cuervo, 2010). Autophagy is one of the primary 
degradation pathways for various aggregate-prone proteins associated with 
neurodegenerative diseases (Ravikumar et al., 2004; Webb et al., 2003). An in vivo 
block of autophagy results in the accumulation of ubiquitinated proteins in inclusion 
bodies, which increase in size and number upon aging (Hara et al., 2006; Komatsu et 
al., 2006). Moreover, similarly to the UPS, components of the autophagy pathway have 
been found colocalizing with mutant huntingtin aggregates. mTOR is inactivated in a 
mouse model of Huntington’s disease as it is sequestered into aggregates, and p62 
has also been found into these mutant huntingtin inclusions in the R6/2 mouse model 
(Nagaoka et al., 2004; Ravikumar et al., 2004). These findings suggest that autophagy 
could participate in mutant huntingtin degradation, and that it could be compromised in 
Huntington’s disease pathology. It is for this reason that distinct pharmacological 
approaches have been performed to increase the autophagic levels in distinct models 
of the disease with the aim to degrade mutant huntingtin and ameliorate symptoms 
(Ravikumar et al., 2004; Sarkar et al., 2007a, 2007b). Although indeed autophagy 
seems a good therapeutic target, conflicting results exist when studying basal 
autophagy levels in Huntington’s disease. Induction of autophagy has been reported in 
human Huntington’s disease brain, in transgenic mice expressing mutant huntingtin 
fragments, in the HdHQ200 knock-in mice, and in cellular models of Huntington’s 
disease (Heng et al., 2010; Kegel et al., 2000; Ravikumar et al., 2004). In contrast, the 
autophagic response is partially impaired in embryonic fibroblasts and in striatal cells 
derived from the HdHQ111 knock-in mice (Martinez-Vicente et al., 2010). While 
autophagosomes are able to form and fuse with lysosomes, the authors report that 
expression of mutant huntingtin results in inefficient cargo loading, primarily affecting 
organelle sequestration, in particular that of lipid droplets, and mitochondria.  
 
 
2.2 - ALTERATION IN SIGNALLING PATHWAYS INVOLVED IN SURVIVAL AND 
APOPTOSIS 
 
Besides aggregate formation, mutant huntingtin can also trigger cellular stress, 
and even death, inducing alterations at signalling pathways. Among these pathways,  
 
INTRODUCTION 
35 
the AKT-mTOR and protein kinase C have been shown to be important in the 
regulation of cell survival and death. 
 
 
2.2.1 - AKT-mTOR signalling pathway 
 
AKT is a key regulator of a wide range of cellular processes including growth, 
proliferation, metabolism and cell survival. Alterations of this signalling pathway have 
been associated to many diseases such as cancer, diabetes and neurodegeneration.  
 
 
Figure 9.- The AKT-mTOR pathway. Hormone and growth factor signalling trigger AKT phosphorylation by both PDK1 
at the Thr308 and mTORC2 at the Ser473, residues that undergo dephosphorylation by the phosphatases PP2A and 
PHLPP, respectively. Once active, AKT inhibits the inhibitory TSC1-TSC2 complex, leading to mTORC1 activation in a 
Rheb-dependent manner. mTORC1 is also modulated by other factors such as RTP801 that is induced under stressful 
conditions. Positive feedback loops do exist, since both mTORC1 and its substrate S6K can phosphorylate IRS-1 and 
S6K can also phosphorylate the mTORC1 and mTORC2 complex.  Figure adapted from the Cell Signaling homepage, 
http://www.cellsignal.com. 
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All these functions are triggered through the activation of different downstream 
targets. Indirect activation of the aforementioned complex mTORC1, links AKT to many 
intracellular processes such as transcription, translation and autophagy (Liao & Hung, 
2010) (Fig. 9). 
 
 
2.2.1.1 - AKT 
 
The serine/threonine kinase AKT is a 60 KDa protein that was first described by 
three different groups who reported a high degree of homology with PKA and PKC 
(Bellacosa et al., 1993; Coffer & Woodgett, 1991; Jones et al., 1991). Mammalian cells 
express three different AKT isoforms, AKT1, AKT2 and AKT3, who share 80% amino 
acid sequence homology although being encoded by different genes. Akt1 is 
ubiquitously expressed at high levels, whereas Akt2 is highly expressed in insulin-
sensitive tissues including the liver, skeletal muscle and adipose tissue. Akt3 is mostly 
expressed in the brain and testis, and in contrast, lower expression levels are found in 
intestinal organs and muscle tissue (Bellacosa et al., 1993; Coffer & Woodgett, 1991; 
Jones et al., 1991; Nakatani et al., 1999). All three isoforms have a similar structure 
that is critical for their activation. A pleckstrin homology (PH) domain responsible for 
phospholipid binding is found at the N-terminus of AKT, followed by a catalytic domain 
or activation loop that contains one of the phosphorylation sites important for its 
activation (threonine 308 in AKT1; Thr308). Finally, the C-terminus of the protein 
contains a hydrophobic domain with a serine residue important for its full activation 
(Ser473 in AKT1) (Matheny & Adamo, 2009). 
 
AKT is activated in response to hormone and growth factor signalling that trigger 
the generation of PIP3 by the class I PI3K (Franke et al., 1997). PIP3 act as docking 
sites at the membrane that recruit both AKT and PDK1 through binding to its PH 
domain (Alessi et al., 1997). Once at the membrane, AKT can be phosphorylated at 
Thr308 by the 3-phosphoinositide dependent protein kinase-1 (PDK1), which results in 
a conformational change of AKT that is followed by mTORC2-dependent 
phosphorylation at the Ser473, leading its full activation and detachment from the 
membrane (Andjelkovic et al., 1997). Phosphorylation at the catalytic domain has been 
proposed to be sufficient for activation of AKT, however full activation is achieved when 
both the catalytic and hydrophobic domains are phosphorylated (Alessi et al., 1996). 
AKT signalling comes to an end with the participation of phosphatases. PH domain 
leucine-rich repeat protein phosphatase (PHLPP) specifically dephosphorylates the 
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hydrophobic motif of AKT, resulting in a decrease of its activity, whereas the Thr308 
site is dephosphorylated by protein phosphatase 2A (PP2A) (Brognard et al., 2007, 
Gao et al., 2005). Moreover, levels of PIP3, and thus membrane-recruiting of AKT, are 
down-regulated specifically by the phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), which is activated upon dephosphorylation (Rahdar et al., 
2009). 
 
Once AKT is active, is ready to phosphorylate its downstream targets. Among 
them, there are pro-apoptotic targets such as Bcl-2–associated X protein, Bcl-2-
associated death promoter and members of the Forkhead Box O that become inactive 
by AKT-mediated phosphorylation (Brunet et al., 1999; Datta et al., 1997; Gardai et al., 
2004). Thus, one of the mechanisms by which AKT triggers cell survival is the direct 
inhibition of pro-apoptotic substrates. Active AKT can also exert a role in the regulation 
of the cell cycle by phosphorylating and inhibiting p21Cip1/WAP1 and p27Cip1/WAP1 (Liang et 
al., 2002). One of the most important targets of AKT due to the high number of 
pathways that can regulate is the glycogen synthase-3β (GSK3β), which is also 
inhibited upon phosphorylation (Cross et al., 1995). Phosphorylation of GSK3β by AKT 
can influence on cellular structure, growth and even apoptosis (Jope & Johnson, 2004). 
Finally, the main target of AKT in the context of cell growth pathway is the tuberous 
sclerosis protein (TSC) 2, which is inactivated by AKT-dependent phosphorylation and, 
when dephosphorylated and active, is able to promote the hydrolysis and inhibition of 
its downstream target Ras homolog enriched in brain (Rheb) that positively regulates 
mTORC1 through a still unknown mechanism (Inoki et al., 2002). Thus, activation of 
mTORC1 can be triggered indirectly by AKT to regulate other processes such as 
transcription, translation and autophagy. 
 
 
2.2.1.2 - mTOR 
 
Along the years, mTOR has attracted increasing scientific interest because of its 
involvement in many human diseases, such as several types of cancer (Zoncu et al., 
2011). 
 
The only difference between mTORC1 and mTORC2 complexes is the regulatory 
accessory protein that mTOR binds, which is a scaffold protein, used to assemble the 
complex and bind regulatory factors and substrates. Those are the regulatory-
associated protein of mTOR (Raptor) and the rapamycin-insensitive companion of 
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mTOR (Rictor) that define mTORC1 and mTORC2, respectively (Hara et al., 2002; 
Sarbassov et al., 2004) (Fig. 10). Rictor and Raptor, not only bind mTOR and its 
substrates, but also regulatory proteins. While Raptor binds the negative regulator 40 
kDa Pro-rich AKT substrate (PRAS40), Rictor binds the protein observed with Rictor 
(Protor), which also helps in assembling the complex, and the mammalian stress-
activated MAPK-interacting protein 1 (mSin1) (Zoncu et al., 2011). Besides Rictor and 
Raptor, both mTORC1 and mTORC2 also assemble positive and negative regulators, 
to the complexes, the mammalian lethal with SEC13 protein 8 (mLST8/GβL) and the 
DEP domain-containing mTOR-interacting protein (Deptor), which are positive and 
negative regulators respectively (Peterson et al., 2009). Thus, mTORC1 contains four 
associated regulatory proteins, Raptor, PRAS40, Deptor and mLST8/GβL, and 
mTORC2 contains Rictor, mSin1, Protor, Deptor and mLST8/GβL. 
 
Figure 10.- mTOR complexes, mTORC1 and mTORC2. The diagram shows the two complexes that mTOR 
generates, mTORC1 and mTORC2, as well as the specific mTOR-interacting partners, substrates and functions of each 
complex. Figure adapted from Bove et al., 2011 and Zoncu et al., 2011. 
 
All these regulatory proteins bound to mTOR permit specific regulation of both 
complexes. As an example, rapamycin binds the small protein 12 kDa FK506-binding 
protein (FKBP12) and, together, bind the FKBP12-rapamycin-binding domain of 
mTOR. This binding inhibits mTORC1 activity, probably by disrupting the association of 
Raptor to mTOR, and thus preventing the access of mTOR to its substrates (Bove et 
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al., 2011; Kim et al., 2002). Although rapamycin effects are specific for the complex 
mTORC1, prolonged treatments can also affect mTCORC2 by impeding the assembly 
of mSin1 and Rictor with mTOR (Sarbassov et al., 2006). mTORC1 and mTORC2 
assemblies occur both in the cytoplasm and in the nucleus. However, while mTORC2 
assembly is abundant in both cellular compartments, mTORC1 complex assembly 
predominantly occurs in the cytoplasm, despite high protein levels of raptor can be 
found in both the cytoplasm and the nucleus (Rosner & Hengstschlager, 2008). 
 
Up to date, six phosphorylation sites have been described at the mTOR sequence. 
In order of discovery those are Ser2448, Ser2481, Thr2446, Ser1261, Ser2159 and 
Thr2164, being the first two the ones far most characterized (Foster & Fingar, 2010) 
(Fig. 11). While Ser2481 is an autophosphorylation site, and thus serves as a 
biomarker to analyze intrinsic mTOR activity (Soliman et al., 2010), phosphorylation at 
Ser2448 is regulated by both AKT and S6K1, and is sensitive to rapamycin treatment 
(Holz & Blenis, 2005; Nave et al., 1999). AMPK, in response to low nutrient levels, and 
also S6 kinase 1 (S6K1) have been suggested to phosphorylate mTOR at Thr2446, 
with less information about its physiological significance (Cheng et al., 2004; Holz & 
Blenis, 2005). Both Thr2446 and Ser2448 phophorylation sites are found in a negative 
regulatory domain of mTOR that, at least upon AKT-mediated Ser2448 
phosphorylation, gets inactivated leading to increased mTOR activity (Sekulic et al., 
2000). Ser1261 phosphorylation event may participate in promoting mTOR catalytic 
activity, although the kinase responsible of this phosphorylation still remains unknown 
(Acosta-Jaquez et al., 2009).  
 
 
Figure 11.- Schematic diagram of the mTOR protein. The diagram shows the domain architecture of mTOR and its 
phosphorylation sites. Figure adapted from Acosta-Jaquez et al., 2009; Ekim et al., 2011; Foster & Fingar, 2010; Zoncu 
et al., 2011. 
 
While phopsphorylation at Ser 2448 is mainly associated to mTORC1, there is 
higher stoichiometry of mTOR Ser2481 autophosphorylation in mTORC2 (Copp et al., 
2009). However, Ser2481 autophosphorylation is also found associated to mTORC1, 
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and is sensitive or insensitive to rapamycin treatments depending on which mTORC 
complex is analyzed (Soliman et al., 2010). At last, novel mTOR Ser2159 and Thr2164 
phosphorylations promote mTORC1 signalling through weaken the inhibitory raptor-
PRAS40 interaction (Ekim et al., 2011). 
Finally, all the regulatory proteins present in either mTORC1 and mTORC2 can 
also run phosphorylation events and thus, finely tune mTORC1 and mTORC2 
signalling (Foster & Fingar, 2010). 
 
 Regulatory components of mTORC1 and mTORC2 not only permit specific 
regulation of their functions but also dictate substrate specificity. On one hand, 
mTORC1 phosphorylates and activates S6K1, and inhibits 4EBP1, thus increasing the 
rate of protein synthesis by enhancing mRNA translation initiation and progression. 
mTORC1 also enhances the activity of some transcription factors implicated in the lipid 
synthesis and mitochondrial metabolism (Zoncu et al., 2011). At the same time, and as 
previously explained, mTORC1 inhibits autophagosome synthesis by directly 
phosphorylating ULK1/2 and Atg13 (Kim et al., 2011a). On the other hand, mTORC2 
phosphorylates members of the AGC kinase family, such as AKT, serum and 
glucocorticoid-regulated kinase (SGK) and some members of the PKC family (Garcia-
Martinez & Alessi, 2008; Ikenoue et al., 2008; Sarbassov et al., 2005). Moreover, it has 
also been suggested that mTORC2 could be implicated in the reorganization of actin 
cytoskeleton (Jacinto et al., 2004). 
 
mTORC1 is not only activated upon growth factor stimulation, but as previously 
mentioned also senses amino acids, insulin and ATP. Even the Ras-MAPK pathway 
and the PKC pathway have been suggested to regulate mTORC1 activity by 
phosphorylating TSC2 and inhibiting the TSC1-TSC2 complex (Ma et al., 2005; Roux 
et al., 2004). However, very little is known about mTORC2 activation mechanisms, and 
some suggestions have emerged during the last few years. mTORC2 is activated in 
response to PI3K, since mTORC2 gets active in response to growth factors and 
pharmacological inhibition of PI3K reduces mTORC2 kinase activity (Huang et al., 
2008). Moreover, and contrary to the inhibitory effect on mTORC1, the TSC1–TSC2 
complex is able to activate mTORC2 in vitro (Huang et al., 2008). Finally, ribosomes 
have been suggested to play a role in mTORC2 activation and signalling (Zinzalla et 
al., 2011). 
Downstream mTORC1-effector S6K1 might participate in important feedback 
loops. On one hand, it is able to phosphorylate mTOR, potentially participating in a 
positive feedback loop on mTORC1 (Holz & Blenis, 2005). On the other hand, it 
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participates in a negative regulatory feedback loop, since it is able to phosphorylate the 
insulin receptor substrate-1 resulting in a decrease in its protein stability and decreased 
AKT signalling (Tzatsos & Kandror, 2006). mTORC2 would also integrate mTORC1 
activity, since S6K1 is also able to phosphorylate and inhibit Rictor (Julien et al., 2010). 
Finally, stress conditions such a hypoxia or DNA damage can increase RTP801 
levels, a stress-responsive protein who is expressed at very low levels within different 
tissues being brain, muscle and intestine the tissues that express this protein at a 
lowest levels (Shoshani et al., 2002). The increase in RTP801 levels, in turn, inhibits 
mTORC1 activity promoting the TSC1-TSC2 complex activity (Corradetti et al., 2005). 
 
 
2.2.1.3 - AKT-mTOR pathway in the nervous system and deregulation in Huntington’s 
disease 
 
The AKT-mTOR pathway has been extensively studied in order to find therapies 
against tumors. Within the nervous system, this pathway has also been involved in 
pathologies including neurodegenerative diseases, since both AKT and mTOR are 
linked to neuronal survival and maintenance of synaptic contacts, and rapamycin 
treatment has been an approach to reverse and ameliorate the symptoms of diverse 
diseases. 
AKT is present at low levels in the adult brain (Owada et al., 1997), but its 
expression and activation increase dramatically in neurons during cellular stress or 
injury (Chong et al., 2005). For instance, activated AKT has been proposed as an 
important neuroprotective pathway in distinct acute (Endo et al., 2007; Owada et al., 
1997; Zhang et al., 2006) and chronic models of neurodegeneration (Gines et al., 2003; 
Saavedra et al., 2010). Moreover, in vivo delivery of a dominant negative form of AKT 
within the substantia nigra reduced the number of dopaminergic neurons and doubled 
the incidence of apoptotic neurons (Ries et al., 2009). Besides promoting neuronal 
survival, accumulating data suggest a role for AKT in promoting neurite outgrowth, 
enhancing the diameter of processes and also increasing axonal branching and 
regeneration (Gavalda et al., 2004; Kwon et al., 2006; Markus et al., 2002; Namikawa 
et al., 2000). 
On the other hand, mTOR is crucial in the adult brain for numerous physiological 
processes such as synaptic plasticity, learning, memory, and brain control of food 
uptake (Garelick & Kennedy, 2011; Swiech et al., 2008). Moreover, the activation of 
mTOR pathway is involved in neuronal development, dendrite development and spine 
morphogenesis (Swiech et al., 2008). An induction of RTP801 in both in vitro and in 
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vivo models of Parkinson’s disease is known to promote neuronal death by 
suppressing activation and signalling of mTOR (Malagelada et al., 2006). One of the 
mechanisms that could account for this neuronal death is a suppression of the mTOR-
dependent AKT activation (Malagelada et al., 2008). 
 
In Huntington’s disease, reduced levels of PHLPP1 were detected in the striatum, 
cortex and hippocampus of several mouse models of the disease, that were due to 
reduced PHLPP1 gene expression (Saavedra et al., 2010). In good correlation with this 
phenomenon, increased phosphorylation levels of striatal AKT (pSer473 AKT) have 
been observed in different models of Huntington’s disease (Gines et al., 2003; 
Saavedra et al., 2010). Moreover, an increase in the phosphorylation of AKT targets 
GSK3β (Ser9) and FoxO (Ser256) has been also detected. Although PHLPP1 levels 
were also deregulated in the cortex and hippocampus of R6/1 mice, this was not the 
case for pSer473 AKT levels, indicating that other factors, than the reduction of 
PHLPP1 levels, would contribute to increase pSer473 AKT levels in vivo (Saavedra et 
al., 2010). Interestingly, in the striatum of HD94 mice after shutting-down the 
expression of mutant huntingtin, PHLPP1 protein levels returned to control levels, while 
pSer473 AKT levels were only partially reverted (Saavedra et al., 2010). These results 
suggest that increased levels of pSer473 AKT is a specific mechanism taking place in 
striatal neurons expressing mutant huntingtin, which could be the sum of increased 
activation of kinases that phosphorylate AKT and decreased levels of PHLPP1 
(Saavedra et al., 2010). Interestingly, in an acute rat model of Huntington’s disease 
showing massive cell death, a decrease in pSer473 AKT levels has been observed 
during cell dysfunction, just before neurodegeneration occurs (Colin et al., 2005). It has 
been hypothesized that increased AKT activation could counteract mutant huntingtin 
toxicity, raising the threshold, above which apoptotic signals can occur (Saavedra et 
al., 2010). 
 
mTOR has also been studied, but from a more therapeutic point of view, since its 
inhibition may account for increased autophagy and thus, mutant huntingtin aggregates 
degradation. Inhibition of mTOR with rapamycin improves behavioural performance 
and decreases aggregate formation in a mouse model of Huntington’s disease 
(Ravikumar et al., 2004). Interestingly, the same authors have found that mTOR is 
sequestered in the mutant huntingtin aggregates, which impairs its kinase activity and 
induces autophagy (Ravikumar et al., 2004). 
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2.2.2 - PKC signalling pathway 
 
PKC, which is another member of the AGC kinase family, is a serine/threonine 
kinase that play key roles in many signalling pathways that control from cellular growth, 
proliferation and differentiation to cell death (Freeley et al., 2011). 
Figure 12.- Schematic diagram of the three main PKC subfamilies. The diagram represents the differences in 
domain architecture of the three PKC subfamilies: cPKC, nPKC and aPKC. The scheme also represents the 
phosphorylation sites at the A-loop, TM and HM that occur at the PKC catalytic domain. Figure adapted from 
Duquesnes et al., 2011. 
 
Up to date, nine different PKC isoforms, transcribed from separate genes, have 
been described and characterized. All of them can be classified in three main 
subfamilies, depending on structural features and cofactor requirements, the 
conventional PKCs (cPKCs; comprise PKC α, βI/βII and γ isoforms), the novel PKCs 
(nPKCs; comprise δ, ε, η and θ) and the atypical PKCs (aPKCs; comprise PKC ζ and ι) 
(Freeley et al., 2011) (Fig. 12). All of them, however, share a similar primary structure, 
which contains an N-terminal regulatory domain and a C-terminal catalytic domain 
(Duquesnes et al., 2011). The N-terminal domain contains regions where second 
messengers, cofactors and even scaffold proteins may bind, and also a 
pseudosubstrate sequence that binds and inhibits the catalytic domain. Upon second 
messenger and cofactor PKC-binding, the pseudosubstrate sequence undergoes 
proteolysis and PKC becomes catalytically active (Orr & Newton, 1994).  
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Figure 13.- From cPKC activation to cPKC degradation. Newly synthesized PKC is processed by ordered and 
coupled phosphorylations. First, PDK1 phosphorylates the A-loop and, then, mTORC2 phosphorylates the TM and the 
HM, leading to a mature PKC. Upon second messengers, such as Ca2+ and DAG, PKC is recruited to the membranes 
where it adapts an open conformation allowing downstream signalling. This open conformation is sensitive to PHLPP-
mediated dephosphorylation on the HM. Further dephosphorylation on the A-loop, TM and HM, triggers PKC 
degradation. Figure adapted from Newton, 2010. 
 
Whereas the catalytic domain and the pseudosubstrate sequence are common 
regions into all PKC isoforms, the regulatory domain is slightly different and, thus, the 
activation system. cPKCs are activated by a combination of diacylglycerol (DAG) and 
phospholipid binding to their conserved region 1 (C1) domains and Ca2+-dependent 
phospholipid binding to their conserved region 2 (C2) domains. nPKCs are similarly 
activated by DAG and phospholipids, but do not respond directly to Ca2+. Unlike cPKCs 
and nPKCs, aPKCs do not depend on Ca2+ or DAG for activation since they lack C1 
and C2, but are instead activated by other means such as interaction with the 
partitioning defective 6–CDC42 complex through their PB1 domain (Rosse et al., 
2010). 
 
Activation of PKCs involves two steps in which PKC first undergoes maturation 
followed by activation in a second messenger-dependent manner. Maturation of PKC 
requires ordered phosphorylations at different motifs, the activation loop site, the turn 
motif and the hydrophobic motif (Keranen et al., 1995) (Fig. 13). PDK1 is the kinase 
involved in phosphorylating all PKC isozymes at the activation loop site, which is 
required for both PKC activation and PKC stability (Balendran et al., 2000). 
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Phosphorylations at the turn motif and hydrophobic motif are triggered by the complex 
mTORC2 (Facchinetti et al., 2008; Ikenoue et al., 2008). Fully phosphorylated and 
mature PKCs localize to the cytosol until second messengers, such as DAG and Ca2+, 
recruit them to membranes. Membrane-bound PKC allows downstream signalling 
(Newton, 2010). Some exceptions do exist in this classical model for PKC activation. 
PKCδ contains an acidic glutamate at position 500 that assumes the role of the 
phosphorylated activation-loop (Steinberg, 2004). Interestingly, phosphorylation at the 
activation-loop of PKCδ, at Thr505, targets the kinase for degradation (Srivastava et 
al., 2002). Finally, autophosphorylation might also play a role in phosphorylating the 
turn motif of PKCδ (Li et al., 1997; Parekh et al., 1999). 
Membrane-bound and active PKC, however, is highly sensitive to 
dephosphorylation and, as previously commented, the phosphatase PHLPP 
dephosphorylate both cPKCs and nPKCs, but not aPKCs, at the hydrophobic motif 
(Brognard & Newton, 2008). This event has been suggested to trigger further 
dephosphorylation, enzyme instability and degradation (Gao et al., 2008). In addition, 
phosphorylated PKC may also get ubiquitinated and degraded, by the proteasome 
(Leontieva & Black, 2004; Lu et al., 1998; Srivastava et al., 2002). Finally, a third 
degradation mechanism has been suggested for PKCα, which might undergo 
monoubiquitinization at the membrane, thus facilitating its internalization, followed by 
transport along the endosomal pathway, ubiquitin-independent proteasomal delivery 
and degradation (Melnikov & Sagi-Eisenberg, 2009).  
Spatial and temporal control of PKC signalling is not only regulated by 
phosphorylation events and second messengers, but also via interaction with 
scaffolding proteins that anchor the PKCs to various intracellular locations in the cell, 
thus generating PKC responses in specific cellular microdomains. Among scaffold 
proteins that have been characterized to influence PKC function there are Receptors 
for Activated C Kinases (RACKs) (Ron et al., 1994), A-Kinase Anchoring Proteins 
(AKAPs) (Klauck et al., 1996), 14-3-3 proteins (Van Der Hoeven et al., 2000) and even 
p62 (Sanchez et al., 1998). 
 
The identification 30 years ago of PKC as one of the targets of the phorbol esters, 
natural products with tumour-promoting activity, pushed PKC to the cancer research 
field (Griner & Kazanietz, 2007). Tumour-related processes such as proliferation and 
cell cycle progression, invasion and angiogenesis, are both positively and negatively 
regulated by distinct PKC isozymes (Griner & Kazanietz, 2007).  
However, PKCs are involved in a broad spectrum of other cellular processes. 
Isozyme and cell type, are two main factors that define precise PKCs effects and 
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functions. Different isozymes can trigger overlapping functions or even opposite effects 
(Mischak et al., 1993). PKCs regulation of actin cytoskeleton dynamics has also been 
described, inducing further effects, not only on cell migration, but also on neurite 
outgrowth and cellular morphology (Larsson, 2006). Even autophagy might also be 
regulated by PKCs (Chen et al., 2008). PKCs are also important in mediating survival 
and apoptosis. While PKC α, β, γ and ε are mainly considered to induce cell survival, 
PKCδ classically triggers apoptosis (Reyland, 2007). However, findings that PKCδ can 
also trigger cell survival in some proliferating cells suggest a more PKC functional 
complexity, depending on the cell type were they are expressed (Chen et al., 2011b).  
 
Figure 14.- Model for PKCδ induction of apoptosis. PKCδ undergoes specific phosphorylation events at tyrosines 64 
and 155 that are essential for its nuclear translocation. Once in the nucleus, it is cleaved by caspase-3 at the hinge 
region generating the δCF. Both PKCδ and δCF induce apoptosis. Figure adapted from DeVries-Seimon et al., 2007. 
 
Upon apoptotic stimuli, PKCδ undergoes PKCδ-specific phosphorylation events at 
tyrosines 64 and 155 that are essential for nuclear translocation and apoptosis 
induction (Adwan et al., 2011; Humphries et al., 2008) (Fig.14). Once in the nucleus, 
PKCδ is cleaved by caspase-3 at the hinge region that link the regulatory domain to the 
catalytic domain, generating a constitutive catalytic fragment (δCF), which is sufficient, 
but not essential to induce apoptosis (DeVries-Seimon et al., 2007; Emoto et al., 1995; 
Ghayur et al., 1996). PKCδ can regulate different apoptotic events, including caspase 
activation and DNA fragmentation, as well as loss of mitochondrial membrane potential 
(Matassa et al., 2001). 
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2.2.2.1 - cPKCs and nPKCs in the nervous system and in Huntington’s disease 
 
PKC isoforms are involved in a broad range of neuronal functions, and have been 
implicated in learning and memory, and in long-term potentiation (Bank et al., 1988). 
PKC activation directly increases the formation of mature synapses during learning 
procedurals, and regulates changes of pre- and post-synaptic ultra-structure 
(Hongpaisan & Alkon, 2007). Reduced PKC activity has been observed in post-mortem 
brains of suicide victims (Pandey et al., 2004), suggesting an involvement of PKCs in 
cognition and mood regulation. However, different results are obtained when studying 
PKCs under pathological conditions since sustained activation of PKCs might be also 
detrimental to spine morphology, as seen in in vitro studies of hippocampal pyramidal 
cells that have shown that sustained activation of PKC induces spine loss and collapse 
of the spine's actin cytoskeleton (Calabrese & Halpain, 2005). Similar results have 
been observed in vivo, in the rat pre-frontal cortex, where inhibition of PKC signalling 
prevents spine loss and protects working memory performance during chronic stress 
exposure (Hains et al., 2009). The authors suggest that PKC inhibitors may be 
neuroprotective in disorders with deregulated PKC signalling, such as bipolar disorder, 
schizophrenia and post-traumatic stress disorder.  
All these studies suggest that PKCs must be tightly regulated within the nervous 
system, and that any alteration in their signalling can impair neuronal function. 
 
PKCs have also been implicated in neurodegenerative diseases. Reduced PKC 
activity has been observed within Alzheimer’s disease (Cole et al., 1988). 
Administration of non-specific PKC activator is capable of lowering β-amyloid protein 
levels in neurons (Hung et al., 1993), an effect that is triggered by both PKCα and 
PKCε (Hongpaisan et al., 2011; Kim et al., 2011b). Chronic administration of bryostatin-
1, a PKCα and PKCε activator, into a mouse model of Alzheimer’s disease, restored 
the levels of PKCα and PKCε, reduced the level of soluble β-amyloid, prevented the 
loss of hippocampal synapses and memory impairment, and even prevented the 
reduction in BDNF expression in the CA1 pyramidal neurons (Hongpaisan et al., 2011). 
In Parkinson’s disease, PKCδ has been suggested to play a role in the dopaminergic 
neuronal apoptosis. An irreversible and competitive peptide inhibitor that mimic the 
caspase-3 cleavage site of PKCδ, rescued the MPP+ and 6-hydroxydopamine-induced 
toxicity in mouse primary mesencephalic cultures (Kanthasamy et al., 2006). PKCδ is 
also increased during kainate-induced neuronal death, and the authors suggest this 
isoform could contribute to the apoptotic responses that occur after excitotoxic insults 
(Kaasinen et al., 2002). 
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In Huntington’s disease, less published data do exist about PKC isozymes. 
However, PKCβII immunoreactivity was found decreased in both caudate nucleus and 
putamen from Huntington’s disease patients (Hashimoto et al., 1992). Moreover, 
PKCβII expression levels were also decreased in the striatum and cortex in the R6/2 
mouse model of the disease (Harris et al., 2001). Finally, also alterations in PKCδ were 
found, since this isozyme was detected in mutant huntingtin inclusions in cerebellar 
mouse-tissue sections (Zemskov et al., 2003). In the same group, however, the authors 
failed to find differences in the pro-apoptotic δCF, despite the previously reported 
activation of caspase-3 in the same mouse model (Chen et al., 2000). 
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Huntington’s disease is a progressive neurodegenerative disorder with an onset 
that depends on the CAG repeat length. Mutant huntingtin induces a large amount of 
toxic effects that trigger cell dysfunction. However, before the symptoms start to 
emerge gradually, individuals are healthy. Thus, it is plausible that compensatory 
mechanisms may be activated to regulate a balance between cell death and survival 
(Butler et al., 2006). These compensatory mechanisms might be responsible for the 
gradual nature of Huntington’s disease progression. We have studied three different 
mechanisms, which could enhance cell survival and delay cell dysfunction, along the 
progression of the disease in R6/1 mouse model brains. We first studied selective 
autophagy, since it could represent one of those mechanisms, participating in the 
degradation of the toxic protein, thus releasing cells from the toxic insult (Fig. 15).  
 
 
 
Figure 15. Scheme indicating the different aims developed in this work. On one hand, we have analyzed the 
selective autophagic flux, since maintained levels of this process are important to degrade mutant huntingtin and 
release the cells from its toxicity. On the other hand, we have analyzed the role of mTOR in the regulation of autophagy 
and also the pro-survival kinase AKT. Finally, we have analyzed the levels of some members of the PKC protein family 
since previous results suggest their deregulation, due to decreased levels of the phosphatase PHLPP that shunts PKC 
for degradation. 
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Interestingly, autophagy-deficient mice develop neurodegenerative decline even in 
the absence of harmful gene products such as mutant huntingtin (Komatsu et al., 
2006). Moreover, pro-survival signalling pathways can also counteract cell death.  
 
Previous results from our group have revealed an interesting imbalance between 
the pro-survival kinase AKT and PHLPP1. They observed an AKT over-activation that 
could be partially mediated by a decrease in PHLPP1 protein levels (Saavedra et al., 
2010). Thus, we have further studied the role of pro-survival and pro-apoptotic kinases 
in Huntington’s disease. On one hand, we have examined the mTOR pathway, since 
mTOR regulates both autophagy and AKT-mediated cell survival (Fig. 15). On the 
other hand, we have also focused our interest in both pro-survival and pro-apoptotic 
PKC isoforms, since their levels are regulated by PHLPP-mediated dephosphorylation 
(Gao et al., 2008) (Fig. 15). 
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AIM 1. – To study the regulation of selective autophagy along the progression of 
Huntington’s disease. 
 
 
1.1. To analyze p62 and NBR1 protein levels along the progression of the 
disease in different brain regions affected in Huntington’s disease, as an 
indicator of selective autophagic activity. 
 
1.2. To analyze p62 and NBR1 intracellular localization in cells expressing 
mutant huntingtin in a mouse model and in human Huntington’s disease 
brains. 
 
1.3. To analyze age-dependent mechanisms that could regulate autophagy.  
 
 
AIM 2. – To characterize the regulation and the role of pro-survival and pro-
apoptotic protein kinases in Huntington’s disease. 
 
 
2.1. To define the role of mTOR in the regulation of both autophagy and the 
AKT pro-survival pathway in Huntington’s disease. 
 
2.2. To study the regulation of different members of the PKC protein family in 
Huntington’s disease. 
 
 
 
 
 
  54 
  55 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. METHODS 
 
 
  56 
 
METHODS 
57 
1 - HUNTINGTON’S DISEASE MOUSE MODELS 
 
For the development of the objectives of this Thesis, we have used the R6/1 
mouse model of Huntington’s disease that was originally obtained from Jackson 
Laboratory (Bar Harbor, ME, USA). R6/1 mice express an N-terminal exon 1 fragment 
of mutant huntingtin, originally containing a stretch of 115 CAG repeats (Mangiarini et 
al., 1996). However, the CAG repeat sequence is highly unstable, and CAG repeat-
length determination in the mice used here revealed a longer CAG stretch (Giralt et al., 
2011b). Thus, our R6/1 mouse colony, with a B6CBA background, express the exon 1 
of mutant huntingtin with 145 CAG repeats. Mice were genotyped and CAG repeat-
length was determined by PCR amplification of the repeat using HD1 and HD2 
fluorescently labelled primers as previously described by the Huntington's Disease 
Collaborative Research Group (HDCRG, 1993), and subsequent size determination in 
an ABI 3100 analyzer. Results were double checked by Laragen, Inc. (Los Angeles, 
CA, USA). Male R6/1 mice were used for all the experiments, and results were 
compared to non-transgenic wild-type mice. Transgenic and non-transgenic mice were 
littermates. 
Animals were housed with access to food and water ad libitum in a colony room 
kept at a constant temperature in between 19-22ºC and at 40-60% humidity, under a 
12:12 hours light/dark cycle. Upon birth, litters containing distinct genotypes were being 
housed together. Microchips were implanted on the back subcutaneously, and were 
used to number all mice and have access to recorded genotype data.  
All animal-related procedures were performed in compliance with the National 
Institute of Health Guide for the care and use of laboratory animals, and approved by 
the local animal care committee of the Universitat de Barcelona (99/01), and the 
Generalitat de Catalunya (99/1094), in accordance with the Directive 86/609/EU of the 
European Commission. 
 
 
2 - HUMAN BRAIN TISSUE 
 
All human brain samples were obtained from the Neurological Tissue Bank of the 
Biobanc-Hospital Clinic-IDIBAPS, Barcelona (NTB-Biobanc-HC-IDIBAPS) (Table 2). 
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Case nº Pathological diagnosis CAG repeats Gender Age (years) 
1 Normal - Female 81 
2 Normal - Male 31 
3 Normal - Female 68 
4 Normal - Male 56 
5 Normal - Male 64 
6 Normal - Female 71 
7 Normal - Female 60 
8 Normal - Male 39 
9 HD, Vonsattel grade 4 62 Female 28 
10 HD, Vonsattel grade 4 44 Male 59 
11 HD, Vonsattel grade 4 43 Male 60 
12 HD, Vonsattel grade 3-4 - Male 55 
13 HD, Vonsattel grade 3 45 Male 53 
14 HD, Vonsattel grade 1 40 Male 73 
 
Table 2. Human post-mortem Huntington’s disease (HD) brains. Among the post-mortem brains that were provided 
by the NTB-Biobanc-HC-IDIBAPS, 8 were histopathologically non-related to Huntington’s disease, 5 were 
histopathologically diagnosed with Vonsattel grade 3-4 and 1 with Vonsattel grade 1. 
 
Half brain was fixed in 10% buffered formaldehyde solution for 4 weeks and then, 
25 brain areas were selected for histopathological evaluation, including frontolateral 
and orbitofrontal, temporal, parietal and occipital cortices, anterior cingulate, anterior 
and posterior basal ganglia, anterior, medial and posterior thalamic nuclei, 
hippocampus, amygdala, midbrain, pons, medulla oblongata, olfactory bulb, cerebellar 
vermis, hemisphere and dentate nucleus, and cervical spinal cord. 
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3 - CELL CULTURE 
 
A conditionally immortalized striatal neuronal progenitor cell line (STHdhQ7/Q7) was 
used, which was derived from striatal precursors isolated from HdhQ7 mice at 
embryonic day 14 and immortalized with the SV40 Large T antigen (Trettel et al., 
2000). Cells were grown at 33°C in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma Chemical Co, St. Louis, MO, USA) supplemented with 10% fetal bovine serum, 
1% streptomycin-penicillin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 400 µg/ml 
G418 (Geneticin; Invitrogen, Carlsbad, CA, USA). 
 
 
4 - PHARMACOLOGICAL TREATMENTS 
 
Cells were treated with different drugs in a different time-course and concentration 
depending on the planned experiment. Xpo-1 was inhibited with the irreversible 
inhibitor Leptomycin B (LMB; 10 nM; Sigma Chemical Co, St. Louis, MO, USA), which 
inactivates Xpo-1 by alkylation at one single cysteine residue (Kudo et al., 1999). To 
inhibit the vacuolar ATPase and thus lysosomal acidification and lysosomal-dependent 
degradation, we used Bafilomycin A1 (BafA1; 100 nM; Merck, Darmstadt, Germany) 
(Bowman et al., 1988; Yoshimori et al., 1991). A combination of NH4Cl (20 mM; Merck, 
Darmstadt, Germany) and leupeptin (0.1 mM; Sigma Chemical Co, St. Louis, MO, 
USA) was used to more effectively block lysosomal-dependent degradation without 
affecting other proteolytic systems (Fuertes et al., 2003). Protease and phosphatase 
inhibitors were used to avoid protein degradation and dephosphorylation events in 
protein extracts.  
 
 
5 - PLASMIDS AND TRANSFECTION 
 
The Tandem Fluorescent-tagged LC3 construct (tf-LC3) was a kind gift from Dr. 
Yoshimori (Department of Cellular Regulation, Research Institute for Microbial 
Diseases, Osaka, Japan). This plasmid contains a bacterial resistance to kanamycin 
and expresses rat LC3 together with mRFP and GFP as tags, and was generated by 
inserting mRFP cDNA to a pEGFP-LC3 plasmid with kanamycin resistance (Kimura et 
al., 2007). 
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Exon-1 huntingtin plasmids, expressing either 16 or 94 polyQ repeats and tagged 
with the cyan-fluorescent protein (CFP), were a kind gift from Dr. Lucas (Centre for 
Molecular Biology ‘Severo Ochoa’, Madrid, Spain). They were generated with ampicillin 
resistance. It is important to note that the 94 polyQ stretch is interrupted by an 
arguinine residue (40Q+1R+54Q). 
 
A plasmid construct to over-express PKCδ with a C-terminal Haemmagglutinin 
(HA) epitope tag was kindly supplied by Dr. Weinstein through the Addgene platform 
(Addgene plasmid 16386; Cambridge MA, USA). The plasmid was generated at the Dr. 
Weinstein laboratory by ligating full-length PKCδ open reading frame into the 
mammalian expression vector pHACE, which contains a bacterial resistance to 
ampicillin (Soh & Weinstein, 2003). 
 
To expand the plasmid, E. Coli (Subcloning EfficiencyTM DH5αTM Competent Cells; 
Invitrogen, Carlsbad, CA, USA) were transformed by thermal shock. Plasmid (250 ng) 
was added to 50 μl-cultured bacteria and left incubating on ice for 15 min. To induce 
transformation, the mixture was incubated for 1.5 min at 42ºC and quickly placed again 
on ice for 2 min. Lysogeny broth media (LB; 800 μl) was added, and was incubated for 
1h at 37ºC at 250 rpm to let transformed E. Coli grow. Finally, the transformation (200 
μl) was spread on a pre-warmed agar plate containing 20 μg/ml kanamycin or 500 
μg/ml ampicillin. Colonies were left growing overnight at 37ºC. 
Plasmid isolation was performed from 5 ml bacterial culture using the Wizard Plus 
SV Minipreps and Maxipreps DNA purification system from Promega (Madison, WI, 
USA). 
 
Transfection procedures were carried out using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA, USA) as instructed by the manufacturer. Cells at 50% confluence were 
transfected with 1μg of plasmid in Opti-MEM media. Media was replaced 6 hours later 
by serum-supplemented DMEM media. 
 
 
6 - PROTEIN EXTRACTION 
 
6.1 - Mouse and human brain tissue 
 
Animals were killed by decapitation at different steps of the disease. The brain was 
quickly removed and the striatum, cortex and hippocampus were quickly dissected out.  
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All mouse and human samples were homogenized by sonication in lysis buffer 
containing 1% Triton X-100, 50 mM Tris-HCl (pH 7.5), 10 mM EGTA, 150 mM NaCl, 
protease inhibitors (2 mM phenylmethylsulphonyl fluoride, 10 μg/μl aprotinin, 1 μg/μl 
leupeptin) and phosphatase inhibitors (2 mM Na3VO4, 100 mM NaF). 
 
 
6.2 - Cell culture 
 
STHdhQ7/Q7 cells were washed once with PBS (phosphate-buffered saline) and 
total cellular proteins were extracted by incubating cells in lysis buffer containing 1% 
Triton X-100, 50 mM Tris-HCl (pH 7.5), 10 mM EGTA, 150 mM NaCl, protease 
inhibitors (2 mM phenylmethylsulphonyl fluoride, 10 μg/μl aprotinin, 1 μg/μl leupeptin) 
and phosphatase inhibitors (2 mM Na3VO4).  
 
Samples were centrifuged at 16,100 x g for 20 min at 4ºC, and supernatants were 
collected. Protein concentration was determined using the Dc protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA). 
 
 
7 - SUBCELLULAR FRACTIONATION 
 
7.1 - Mouse tissue 
 
For subcellular fractionation, fresh tissue was homogenized in a teflon-glass potter 
in lysis buffer containing 4 mM HEPES, 0.32 M sucrose, 1 mM PMSF, 10 μg/ml 
aprotinin, 1 μg/ml leupeptin, 2 mM sodium orthovanadate, 0.1 mg/ml benzamidine. 
Homogenates were centrifuged at 3,000 x g for 10 min to obtain cytosolic (supernatant) 
and nuclear (pellet) enriched fractions. Nuclear enriched fraction was resuspended in 
lysis buffer containing 10 mM Tris-HCl (pH 7.5), 0.25 M sucrose, 2 mM PMSF, 10 
mg/μl leupeptin, 2 mM Na3VO4 and was sonicated afterwards.  
 
 
7.2 - Cell culture 
 
STHdhQ7/Q7 cells were rinsed once and pelleted with PBS. Pellets were 
homogenized in lysis buffer containing 10 mM Tris-HCl (pH 7.4), 0.25 M sucrose, and 
protease and phosphatase inhibitors as above. Samples were centrifuged 10 min at 
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3,000 x g to obtain cytosolic (supernatant) and nuclear (pellet) fractions. Nuclear 
fractions were resuspended in lysis buffer, sonicated and centrifuged 20 min at 16,100 
x g. Supernatant was kept as a nuclear enriched fraction and pellet was discarded. 
 
 
8 - WESTERN BLOT ANALYSIS 
 
Western blot analysis was performed following a standard protocol. Proteins were 
denatured in 62.5 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% glycerol, 140 mM β-
mercaptoethanol and 0.1% (w/v) bromophenol blue and heated at 100ºC for 5 min. 
They were resolved in denaturing polyacrylamide gels (SDS-PAGE) at different 
polyacrylamide concentrations; at 35 mA during 1 h. Proteins were then transferred to 
a nitrocellulose membrane (Whatman Schleicher&Schuell; Dassel, Germany) during 
1.5 hours at 90 V and at 4ºC to avoid excessive warming. Nitrocellulose membranes 
were blocked in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) solution plus 
5% bovine serum albumin and 5% skimmed milk during 1h at room temperature. 
Membranes were washed twice in TBS-T and blotted overnight at 4ºC with the 
following primary antibodies (Table 3):  
 
Antigen Molecular weight Host specie Dilution Source 
Catalase 60 KDa Rabbit 1:6,000 Millipore (Massachusetts, CA, USA) 
4EBP1 15-20 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
4EBP1 (pThr37/46) 15-20 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
Exportin-1 112 KDa Mouse 1:1000 BD Biosciences (Franklin Lakes, NJ, 
USA) 
Huntingtin (181-810 aa) 350 KDa Mouse 1:1000 Millipore (Massachusetts, CA, USA) 
Huntingtin (EM48) over 350 KDa Mouse 1:1000 Millipore (Massachusetts, CA, USA) 
LC3B 14, 16 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
mTOR 289 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
mTOR (pSer2481) 289 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
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mTOR (pSer2448)  289 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
NBR1 150 KDa Mouse 1:1000 Abnova (Taipei, Taiwan) 
PKCα 80 KDa Mouse 1:1000 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
PKCα (pSer422) 80 KDa Goat 1:1000 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
PKCβII 80 KDa Rabbit 1:1000 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
PKCδ 78 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
PKCδ 78 KDa Mouse 1:1000 BD Biosciences (Franklin Lakes, NJ, 
USA) 
PKCδ (pThr505) 78 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
p62 62 KDa Guinea Pig 1:1000 Progen (Heidelberg, Germany) 
Raptor 150 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
Rictor 200 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
S6K1 (pSer371) 70-85 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
S6 Ribosomal Protein 
(pSer235/236) 
32 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
SGK 48 KDa Mouse 1:1000 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
SGK (pSer657) 48 KDa Goat 1:1000 Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) 
TFEB 53 KDa Goat 1:1000 Abcam (Cambridge, UK) 
ULK1 140 KDa Rabbit 1:1000 Abcam (Cambridge, UK) 
ULK1 (pSer757) 140 KDa Rabbit 1:1000 Cell Signaling (Beverly, MA, USA) 
 
Table 3. Primary antibodies for western blot. A list of primary antibodies is provided, as well as their source and the 
dilution that was used for western blot. 
 
After primary antibody incubation, membranes were washed three times for 10 min 
with TBS-T and incubated for 1h at room temperature with the appropriated 
horseradish peroxidase-conjugated secondary antibody (Table 4). 
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Secondary antibody Dilution Source 
Guinea Pig IgG 1:2,000 Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Donkey Anti-Goat IgG 1:2,000 Promega (Madison, WI, USA) 
Anti-Mouse IgG  1:2,000 Promega (Madison, WI, USA) 
Anti-Rabbit IgG 1:2,000 Promega (Madison, WI, USA) 
 
Table 4. Secondary antibodies for western blot. A list of secondary antibodies is provided, as well as their source 
and the dilution that was used for western blot. All antibodies are conjugated to the horseradish peroxidase. 
 
Membranes were washed again three times for 10 min to remove secondary 
antibody remains and the reaction was finally visualized with the Western Blotting 
Luminol Reagent (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Western blot 
replicates were scanned and densitometries were quantified using the GelPro analyzer 
program version 4.0. 
For protein loading control, membranes were incubated 15 min with an antibody 
against α-tubulin or α-actin. Anti-Lamin B and NeuN antibodies were used for loading 
control in nuclear fractions (Table 5). 
 
Antigen Molecular weight Host specie Dilution Source 
α-Actin 45 KDa Mouse 1:20,000 MP Biomedicals (Aurora, OH, USA) 
Lamin B 67 KDa Goat 1:500 Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) 
NeuN 46-48, 66 KDa Mouse 1:1000 Millipore (Massachusetts, CA, USA) 
α-Tubulin 55 KDa Mouse 1:50,000 Sigma Chemical Co (St. Louis, MO, USA) 
 
Table 5. Primary antibodies used for loading controls in western blot. A list of primary antibodies is provided, as 
well as their source and the dilution that was used for western blot. All these antibodies were used to detect loading 
control proteins. 
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9 - GENE EXPRESSION ASSAY 
 
Total RNA was extracted from fresh striata and cortex of 8-, 12- and 30-week-old 
wild-type and R6/1 mice using the Nucleospin RNA II kit from Macherey-Nagel (Düren, 
Germany) following the manufacturer’s instructions. cDNA  was synthesized from 500 
ng of RNA with random primers by using the StrataScript First Strand cDNA Synthesis 
System (Stratagene, La Jolla, CA). To provide negative controls and exclude 
contamination by genomic DNA, we omitted the reverse transcriptase in the negative 
control condition.  
cDNA was then analyzed by Q-PCR using the TaqMan Gene Expression Assays 
from Applied Biosystems (Foster City, CA, USA) or PrimeTime Mini qPCR Assays from 
Integrated DNA Technologies (Coralville, IA, USA. Q-PCR was performed in a 25 μl 
reaction buffer containing 12.5 μl Brilliant Q-PCR Master Mix, 1.25 μl TaqMan Gene 
Expression Assays and 10 ng of cDNA (Table 6). Both control and experimental 
reactions were placed in a thermal-cycler to undergo the following thermal-cycling 
program: 40 cycles of a two-step PCR; 95°C for 30 s and 60°C for 1 min, after initial 
denaturing at 95°C for 10 min. PrimeTime Mini qPCRs were performed in a 12.5 μl 
reaction buffer containing 6.25 μl Mater Mix from Takara Bio Inc. (Shiga, Japan) and 
0.625 μl PrimeTime Mini qPCR Assays and 5 ng of cDNA (Table 6).  
 
Gene Assay Source 
18S Hs99999901_s1 Applied Biosystems (Foster City, CA, USA) 
18S PrimeTime Std qPCR Assay Integrated DNA Technologies (Coralville, IA, USA) 
NBR1 Mm.PT.45.6651111 Integrated DNA Technologies (Coralville, IA, USA) 
p62/SQSTM1 Mm00448091_m1 Applied Biosystems (Foster City, CA, USA) 
PKCα Mm00440852_m1 Applied Biosystems (Foster City, CA, USA) 
PKCδ Mm00440891_m1 Applied Biosystems (Foster City, CA, USA) 
 
Table 6. Gene expression probes. A list of probes, together with their source, is provided. 
 
Thermal-cycling program was slightly different from the TaqMan Gene Expression 
Assays and was the following: 40 cycles of a two-step PCR; 95°C for 5 s and 60°C for 
20 s, after initial denaturing at 95°C for 30 s. All Q-PCR assays were performed in 
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duplicate and samples were subjected to the PCR reaction in the same way for each 
TaqMan Gene Expression. 
Data were analyzed and quantified using the Comparative Quantitation Analysis 
program of the MxProTM Q-PCR analysis software version 3.0 (Stratagene) with the 
18S gene expression as internal loading control. Results were normalized to cDNAs of 
wild-type mouse striata and expressed as a percentage of these data. 
 
 
10 - MORPHOLOGICAL ANALYSIS  
 
10.1 - Immunocytofluorescence 
 
Cells were grown on cover glasses and fixed in 4% paraformaldehyde in PBS for 
10 min after different treatments. Cells were incubated with 0.2 M glycine during 20 min 
to block paraformaldehyde. After that, cells were permeated in PBS with 1% bovine 
serum albumin and 0.1% saponin for 10 min. Blocking was performed with 1% bovine 
serum albumin in PBS for 1 hour before incubating specimens overnight at 4ºC with the 
primary antibody diluted in the same blocking buffer (Table 7). Remaining primary 
antibody was removed in three consecutive washes with PBS and specimens were 
incubated with the subtype-specific fluorescent secondary antibody (Table 8). To stain 
nuclei, cells were incubated during 5 min at room temperature with Hoechst 33258 
(1:10,000; Invitrogen, Carlsbad, CA, USA) and washed afterwards with PBS. Finally 
cover glasses were mounted with Mowiol-mounting media (Merck, Darmstadt, 
Germany). 
 
STHdhQ7/Q7 cells were transfected with the tf-LC3 were fixed as described above 
and nuclei were stained with Hoechst 33258. STHdhQ7/Q7 cells transfected with CFP-
16Q, CFP-94Q, HA, and HA-PKCδ, were fixed 72h after transfection. 
Immunocytofluorescence was performed against HA and nuclei were stained with 
Hoechst 33258. All cover glasses were mounted with Mowiol-mounting media (Merck, 
Darmstadt, Germany). 
 
 
10.2 - Immunohistofluorescence 
 
Animals were deeply anesthetized with pentobarbital (60 mg/kg) and intracardially 
perfused with a 4% paraformaldehyde in 0.1mM phosphate buffer. Brains were 
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removed and post-fixed for 2h in the same solution, cryoprotected with 30% sucrose in 
PBS with 0.02% sodium azide and frozen in dry-ice cooled isopentane. Serial coronal 
cryostate 30 μm-thick sections were collected in PBS as free-floating sections and 
processed for immunohistofluorescence. 
Antigen Host specie Dilution Source 
poly-Glutamine (clone 5TF1-1C2) Mouse 1:10,000 Millipore (Massachusetts, CA, USA) 
Huntingtin (EM48) Mouse 1:150 Millipore (Massachusetts, CA, USA) 
mTOR Rabbit 1:100 Cell Signaling (Beverly, MA, USA) 
pSer2481 mTOR Rabbit 1:100 Cell Signaling (Beverly, MA, USA) 
pSer2448 mTOR Rabbit 1:100 Cell Signaling (Beverly, MA, USA) 
NBR1 Mouse 1:100 Abnova (Taipei, Taiwan) 
p62 Guinea Pig 1:100 Progen (Heidelberg, Germany) 
p62 Mouse 1:500 BD Biosciences (Franklin Lakes, NJ, USA) 
PKCδ Mouse 1:500 BD Biosciences (Franklin Lakes, NJ, USA) 
Ubiquitin Rabbit 1:400 DAKO (Glostrup, Denmark) 
HA Rabbit 1:100 Sigma Chemical Co, (St. Louis, MO, USA) 
 
Table 7. Primary antibodies for immunofluorescence and immunohistochemistry. A list of primary antibodies is 
provided, as well as their source and the dilution that was used for immunofluoresce and immunohistochemistry. 
 
Sections were washed twice with PBS and incubated with NH4Cl 50 mM during 30 
min to block free fixation-remaining aldehydes and stop aldehyde-induced 
fluorescence. Tissue was permeated along 20 min by treatment with PBS containing 
0.5% Triton X-100 and blocked during 1h at room temperature in PBS plus 0.2% 
bovine serum albumin, 0.2% lysine, 0.2% glycine, 0.2% sodium azide, 0.5% Triton X-
100 and 5% normal horse serum (Pierce Biotechnology, Rockford, IL, USA). Slices 
were incubated overnight at 4°C with the corresponding primary antibodies in a buffer 
containing PBS plus 0.3% Triton X-100, 0.2% bovine serum albumin and 0.2% sodium 
azide (Table 7). After primary antibody incubation, slices were washed in PBS twice for 
10 min and incubated 2h at room temperature with subtype-specific fluorescent 
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secondary antibodies (Table 8). After two consecutive 10 min-washes, slices were 
incubated 10 min at room temperature with Hoechst 33258 (1:4000; Invitrogen, 
Carlsbad, CA, USA) for nuclear staining and washed again twice with PBS before 
being mounted with Mowiol (Merck, Darmstadt, Germany) on silane-coated slides. No 
signal was detected in controls incubated in the absence of the primary antibody. 
The protocol used for mTOR and phospho-mTOR immunohistofluorescence stains 
was slightly different. Washes were performed in TBS and slices were blocked in TBS 
containing 0.3% Triton X-100 and 5% normal goat serum (Pierce Biotechnology, 
Rockford, IL, USA). Primary and secondary antibodies were diluted in the same buffer 
and Hoechst 33258 was prepared in TBS. Incubation times were the same as the 
standard protocol already described. 
 
Antibody Dilution Source 
DAKO Envision System HRP Labelled 
Polymer anti-mouse 
Ready-to-
use system 
DAKO (Glostrup, Denmark) 
Alexa Fluor 647 Goat Anti-Mouse IgG 
(H+L) 
1:500 Invitrogen (Carlsbad, CA, USA) 
Alexa Fluor 647 Goat Anti-Rabbit IgG 
(H+L) 
1:500 Invitrogen (Carlsbad, CA, USA) 
Cy2 AffiniPure Goat Anti-Mouse IgG 
(H+L) 
1:200 Jackson ImmunoResearch (West Grove, PA, USA) 
Cy3 AffiniPure F(ab')2 Fragment Goat 
Anti-Rabbit IgG, F(ab')2 Fragment 
Specific 
1:200 Jackson ImmunoResearch (West Grove, PA, USA) 
Cy3 AffiniPure F(ab')2 Fragment 
Rabbit Anti-Mouse IgG, F(ab')2 
Fragment Specific 
1:200 Jackson ImmunoResearch (West Grove, PA, USA) 
DyLight 488 AffiniPure Donkey Anti-
Rabbit IgG (H+L) 
1.200 Jackson ImmunoResearch (West Grove, PA, USA) 
DyLight 488 AffiniPure Goat Anti-
Guinea Pig IgG (H+L) 
1:200 Jackson ImmunoResearch (West Grove, PA, USA) 
DyLight 549 AffiniPure F(ab')2 
Fragment Goat Anti-Guinea Pig IgG 
1.200 Jackson ImmunoResearch (West Grove, PA, USA) 
 
Table 8. Secondary antibodies for immunofluorescence and immunohistochemistry. A list of secondary 
antibodies is provided, as well as their source and the dilution that was used for immunofluoresce and 
immunohistochemistry. 
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10.3 - Immunohistochemistry 
 
Five μm-thick paraffin-embedded sections were obtained from frontal cortex and 
caudate nucleus of human post-mortem brains and mounted on slides. To 
deparaffinize and rehydrate the tissue, slides were heated at 56ºC for 1h and washed 
sequentially with xylene, absolute ethanol, 96% ethanol and milliQ H2O. For antigen 
retrieval slides were then incubated in 98% formic acid (5 min) at room temperature, 
followed by 20 min incubation in 10 mM sodium citrate buffer at pH 6.0 at 95ºC. Slides 
were then incubated (15 min) at room temperature in a wash buffer from DAKO 
(Glostrup, Denmark) with 3% normal goat serum. Just after this blocking step, slides 
were washed three times in wash buffer and incubated 30 min with the primary 
antibody, diluted in DAKO Real TM antibody diluent (Glostrup, Denmark) (Table 7). 
Three washes were needed to remove the remaining antibody and slides were 
incubated 30 min with the DAKO Envision System HRP Labelled Polymer anti-mouse 
secondary antibody (Glostrup, Denmark) (Table 8).  
 
 
Figure 16. Control of NBR1 immunoreactivity. Images (A and a) illustrate human liver with abundant NBR1 
immunoreactive Mallory bodies. Note the diffuse cytoplasmic granular staining pattern in a higher magnification (a). (B 
and b) No immunoreactivity is observed after omitting the primary antibody in human frontal cortex of a Huntington’s 
disease case with pathological severity Vonsattel grade 3. 
 
Finally, detection of immunostaining was performed using the Envision kit (DAKO, 
Glostrup, Denmark), diaminobenzidine (DAB) was used as chromogen and sections 
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were counterstained with hematoxilin for 1 min with the DAKO automation Hematoxylin 
Histologial Staining Reagent (Glostrup, Denmark).  
To perform p62 immunohistochemistry, antigen retrieval was performed incubating 
slides directly in citrate buffer, avoiding treatment with formic acid. 
 
A section of cirrhotic human liver tissue with abundant Mallory bodies was used as 
positive control for anti-NBR1 immunohistochemistry (Fig. 16A). The primary antibody 
was omitted in brain samples to evaluate staining specificity (Fig. 16B). 
 
 
11 - IMAGE UPTAKE AND ANALYSIS 
 
Stained tissue sections and cells were examined by using an Olympus BX60 
epifluorescence microscope (Olympus, Tokyo, Japan) equipped with an Orca-ER 
cooled CCD camera (Hamamatsu Photonics, Hamamatsu, Japan) or Leica TCS SP5 
laser scanning spectral confocal microscope (Leica Microsystems Heidelberg GmbH, 
Manheim, Germany) with Argon and HeNe lasers attached to a Leica DMI6000 
inverted microscope. Confocal images were taken using a HCX PL APO lambda blue 
63.0x 1.40 OIL UV objective with a standard (one Airy disk) pinhole.  
 
Images for the tf-LC3 experiment were obtained by using the confocal microscope, 
with a 63x objective with a 2.0 digital zoom and standard (one Airy disk) pinhole. For 
each cell, the entire three-dimensional stack of images from the ventral surface to the 
top of the cell was obtained by using the Z drive in the Leica TCS SP5 microscope. The 
size of the optical image was 0.5 μm. Co-localization was measured by using the 
‘colocalization’ plug-in of the freeware ImageJ v1.33 by Wayne Rasband (National 
Institutes of Health, Bethesda, MD, USA). Briefly, for each cell stack, the cell area was 
delineated and the total number of double-positive pixels for mRFP and GFP for each 
cell was summed. This value was divided by the number of total positive pixels for 
mRFP in the stack, and multiplied by 100 (Kimura et al., 2007). 
 
Images of CFP-16Q or CFP-94Q and HA or HA-PKCδ double-transfected 
STHdh7Q/7Q cells, were obtained by using the Olympus BX60 epifluorescence 
microscope with the 40x objective. Only double-transfected cells were examined, and 
those with condensed or fragmented nuclei were considered apoptotic (Xifro et al., 
2011). The percentage of cell death was calculated by normalizing the amount of 
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condensed nuclei to the total nuclei examined. At least 200 cells were evaluated for 
each condition in each independent experiment. 
 
 
12 - HUNTINGTIN IMMUNOPRECIPITATION 
 
Striatal and cortical tissue were sonicated in immunoprecipitation buffer containing 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% IGEPAL, 2 mM PMSF, 2.5 mM NaF, 1 mM 
NaVO4 and 1:1000 protease inhibitor cocktail and centrifuged at 16,100 x g for 20 min 
at 4ºC. Supernatant protein-concentration was determined and 300 µg protein was 
incubated overnight at 4ºC on a rotary mixer with anti-huntingtin antibody (MAB2166 or 
EM48, 1 μg; both from Millipore, Massachusetts, CA, USA) in immunoprecipitation 
buffer. The immune complexes were precipitated overnight at 4ºC with the addition of 
5% protein A-Sepharose Cl-4B (Sigma Chemical Co, St. Louis, MO, USA). Beads were 
collected by centrifugation, and washed sequentially with immunoprecipitation buffer, 
immunoprecipitation buffer-PBS (1:1) and PBS. Finally the immune complexes were 
denatured by 10 min-boiling in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% (w/v) 
SDS, 10% glycerol, 140 mM β-mercaptoethanol and 0.1% (w/v) bromophenol blue. The 
Immune complexes were finally resolved on a 6% SDS-PAGE, and western blot 
analyzes were carried out as described above. Negative controls were obtained by 
incubating protein lysates with AffiniPure Mouse Anti-Human IgG or AffiniPure Rabbit 
Anti-Mouse IgG from Jackson Laboratory (Bar Harbor, ME, USA). 
 
 
13 - PULSE AND CHASE 
 
This method was used to determine long-lived protein proteolysis, and it is based 
on the incorporation of a radiolabelled amino acid in the proteins synthesized during 
the labelling period (pulse), followed by tracking the released radiolabelled amino acids 
into the medium that are the labelled proteins that have undergone degradation 
(chase). 
 
STHdhQ7/Q7 cells were plated at an approximately 40% confluence in 12-well plates 
with serum-supplemented DMEM medium. Pulse was performed as soon as cells 
reached 60-70% confluence with 2 μCi/ml per well of [2,3,4-H3]-L-valine (1 mCi/ml; 
American Radiolabeled Chemicals, St. Louis, MO, USA). Pulse was 48h long to 
maximize long-lived proteins labelling, and was performed at 33ºC, the same 
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temperature at which cells normally grow. After 48 h, pulse medium was washed twice 
with 1x HBSS (Gibco, Paisley, UK) and replaced by chase medium, containing serum-
supplemented DMEM with 2.8 mM non-radioactive valine. Cells were again incubated 
at 33ºC and chase-aliquots were taken at different time-points (0, 6, 18, 24 h). 
Chase-aliquots contain non-degraded proteins as well as small peptides and 
amino acids. To discriminate between degraded protein radioactivity (peptides and 
small amino acids) and non-degraded protein radioactivity, 20% trichloroacetic acid 
was added to chase-aliquots to a final concentration of 10%. Precipitation in 
trichloroacetic acid was facilitated by addition of bovine serum albumin at a final 
concentration of 0.5 mg/ml. Samples were placed at 4ºC for at least 1h and then 
centrifuged 10 min at maximum speed. Supernatants were transferred into individual 
scintillation liquid vials with 5 ml scintillation liquid. Counts per minute (CPM) were 
measured during 3 min in a Wallac 1409 liquid scintillation counter (Wallac Oy, Turku, 
Finland).  
To calculate the total amount of radioactivity incorporated by the cells during the 
labelling time, cells were washed twice with Hanks’s solution and solubilised at 33ºC 
during 2h in 2 ml of buffer containing 0.1 N NaOH and 0.1% sodium deoxycholate, after 
taking the last chase-aliquot. Once cells were dissolved, 15 μl of 1 M HCl were added 
to neutralize the lysate. The whole amount of lysate was transferred to scintillation 
liquid vials with 5 ml scintillation liquid and counted together with the chase-aliquots. 
Proteolysis was considered as the amount of radioactivity incorporated by the cells 
during the labelling time transformed in acid soluble radioactivity (peptides and amino 
acids) at each time-point during the incubation time. It was calculated as the acid 
soluble radioactivity divided by the total amount of radioactivity (acid soluble 
radioactivity plus radioactivity incorporated by the cells during the labelling time) and 
multiplied by 100 (Martinez-Vicente et al., 2010). 
 
Pulse and chase was performed equally and at the same time for control and 
Leptomycin B-treated cells. Leptomycin B treatment was first added to the pulse 
medium 6h prior to the chase, to reach the time point 0 of the chase with exportin-1 
already inhibited. Cells were exposed to Leptomycin B treatment during all the rest of 
the experiment time, since it was again added when pulse medium was replaced for 
chase medium. 
Moreover, the experiment with or without Leptomycin B was also performed in 
cells grown in serum-deprived medium and in cells grown in complete medium with 
NH4Cl and leupeptin, conditions in which protein degradation is enhanced or 
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repressed, respectively. Serum deprivation and NH4Cl and leupeptin treatments started 
at the same time of the chase. 
 
 
14 - STATISTICAL ANALYSIS 
 
All the results were expressed as the mean ± SEM. Statistical analysis was 
performed using the Student’s t test or the one- or two-way ANOVA, followed by 
Bonferroni’s post hoc test as appropriate and indicated in the figure legends. A 95% 
confidence interval was used and values of p < 0.05 were considered as statistically 
significant. 
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1 - SELECTIVE AUTOPHAGY REGULATION ALONG THE PROGRESSION OF 
HUNTINGTON’S DISEASE 
 
Huntington’s disease is characterized by the formation of protein aggregates, 
which can be degraded by selective autophagy. Autophagic response has been found 
increased upon mutant huntingtin exposure, but has been mainly studied in vitro. We 
wondered here whether selective autophagy is altered by mutant huntingtin expression 
in vivo, in brain regions that degenerate in Huntington’s disease, by analyzing the R6/1 
mouse brain. To do so, we used two autophagy cargo receptors, p62 and NBR1, as 
autophagic activity reporters. We examined the protein levels and intracellular 
distribution of these two cargo receptors in the striatum, cortex and hippocampus of 
R6/1 mice along the progression of the disease. Their intracellular distribution was also 
analyzed in human Huntington’s disease caudate nucleus and frontal cortex. 
 
 
1.1 - p62 AND NBR1 PROTEIN LEVELS IN THE STRIATUM, CORTEX AND 
HIPPOCAMPUS ALONG THE PROGRESSION OF THE DISEASE 
 
1.1.1 - p62 and NBR1 protein levels are deregulated in the R6/1 mouse brain 
 
Protein levels of p62 and NBR1 were analyzed by western blot in the striatum, 
cortex and hippocampus of R6/1 mice at different ages. Protein levels of p62 and 
NBR1 were similarly deregulated along the progression of the disease, but differed 
between brain regions. Compared to wild-type mice striatum, both p62 and NBR1 
protein levels were decreased at 12 weeks of age (Fig. 17A and B), whereas at older 
ages p62 was increased (Fig. 17A) and NBR1 protein levels were not changed (Fig. 
17B). In the R6/1 mice cortex, p62 and NBR1 protein levels were significantly reduced 
from 12 and 8 weeks of age onwards, respectively (Fig. 17C and D), with a higher 
reduction of p62 (by about 50% at both ages; Fig. 17C) than of NBR1 (by about 30% at 
all the ages analyzed; Fig. 17D). In the R6/1 hippocampus, both p62 and NBR1 protein 
levels decreased at 12 weeks of age whereas both were up-regulated at 30 weeks of 
age (Fig. 17E and F).  
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Fig. 17. Regulation of p62 and NBR1 in R6/1 mice brain regions during the progression of the disease. (A, C, E) 
Protein levels of p62 and (B, D, F) NBR1 were analyzed by western blot in protein extracts obtained from (A, B) 
striatum, (C, D) cortex and (E, F) hippocampus of wild-type (WT) and R6/1 mice at different stages (W, weeks) of the 
disease progression. Representative immunoblots show the protein levels of p62, NBR1 and α-tubulin in WT and R6/1 
mice at different ages. The graphs show p62 and NBR1 protein levels in R6/1 mice with respect to their littermate 
controls at different stages of the disease progression. Values (obtained by densitometric analysis of western blot data) 
are expressed as percentage of WT mice (p62 or NBR1/α-tubulin ratio), and shown as mean ± s.e.m (n = 4-7). Data 
were analyzed by Student’s t-test. * P< 0.05 and ** P< 0.01 as compared with WT mice. 
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In summary, both proteins were similarly deregulated in the R6/1 mouse, being 
p62 and NBR1 protein levels reduced early in the disease in the three brain regions 
examined, meanwhile they accumulated in the striatum and hippocampus, but not in 
the cortex, at late stages of the disease. 
 
 
1.1.2 - p62, but not NBR1, gene expression is enhanced in the R6/1 mouse brain 
 
To check whether changes at the protein level could be due to transcriptional 
deregulation, p62 and NBR1 mRNA levels were analyzed by Q-PCR in both striatal 
and cortical samples from 8-, 12- and 30-week-old R6/1 mice. When compared to wild-
type levels, R6/1 mice striatum and cortex displayed enhanced p62 gene expression at 
all ages analyzed (Fig. 18A and B) whereas NBR1 mRNA levels were unchanged (Fig. 
18C and D).  
 
Figure 18. Regulation of p62 and NBR1 mRNA levels in R6/1 mice striatum and cortex at different stages of the 
disease. The graphs show (A, B) p62 and (C, D) NBR1 mRNA levels analyzed by Q-PCR in the (A, C) striatum and (B, 
D) cortex of 8-, 12- and 30-week-old (W) wild-type (WT) and R6/1 mice. Results were normalized to the 18S gene 
expression levels and are expressed as percentage of 8-week-old WT values. Data are the mean ± s.e.m (n = 4-7) and 
were analyzed by Student’s t-test. * P< 0.05, ** P< 0.01 and *** P< 0.001 as compared with WT mice. 
 
The transcription factor EB (TFEB) has been recently described as an important 
regulator of autophagy by driving the expression of both autophagic and lysosomal 
genes (Settembre et al., 2011). Upon ERK-2 dependent phosphorylation, TFEB 
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translocates from the cytosol to the nucleus to regulate gene expression (Settembre et 
al., 2011). The p62 gene is among its targets (Settembre et al., 2011). Thus, we 
analyzed whether TFEB protein levels were altered in 30-week-old R6/1 brain. We 
detected increased TFEB protein levels in both striatum (Fig. 19A) and cortex (Fig. 
19B) from 30-week-old R6/1 mice in comparison to wild-type mice. In addition, TFEB 
protein levels were increased in cortical nuclear enriched fractions of 30-week-old R6/1 
mice when compared to those in wild-type mice (Fig. 19C). 
 
 
Figure 19. Transcription factor TFEB protein levels are increased in the striatum and cortex of 30-week-old R6/1 
mice. Protein levels of TFEB were analyzed by western blot in protein extracts obtained from (A) striatum and (B) 
cortex. Moreover, TFEB protein levels were also analyzed in (C) nuclear-enriched fractions of 30-week-old mice cortex. 
Values obtained by densitometric analysis of western blot data and normalized to α-tubulin (for total extracts) or NeuN 
(for the nuclear-enriched extracts), are expressed as percentage of WT values. Data are the mean ± s.e.m (n= 3-6), and 
were analyzed by using the Student’s t-test. * P< 0.05, and ** P< 0.01 as compared with WT mice. 
 
These results show a transcriptional deregulation of p62, but not of NBR1, that 
could be in part due to an increase in the TFEB transcription factor protein levels and to 
its nuclear localization. In addition, they also indicate that the brain region-dependent 
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deregulation of p62 and NBR1 observed at a protein level is not triggered by means of 
gene expression. 
 
 
1.1.3 - p62 and NBR1 interact with mutant, but not with wild-type, huntingtin 
 
The interaction of p62 and NBR1 with mutant huntingtin might hamper their 
detection by western blot. Thus, we analyzed the interaction of p62 and NBR1 with 
huntingtin in 30-week-old wild-type and R6/1 mice striatum by immunoprecipitation. 
 
Figure 20. Both p62 and NBR1 interact with mutant huntingtin. Interaction of p62 and NBR1 with huntingtin was 
analyzed in protein extracts from the striatum of WT and R6/1 mice at 30 weeks of age by immunoprecipitation (IP). 
Wild-type huntingtin was immunoprecipitated with the 2166 antibody, mutant huntingtin with the EM48 antibody and 
mouse IgGs antibodies were used as control. Membranes were then subjected to immunoblotting with different 
antibodies as indicated in the representative immunoblot. – indicates protein extract without immunoprecipitation. 
 
Both proteins co-immunoprecipitated together with mutant, but not with wild-type, 
huntingtin in R6/1 mice striatum (Fig. 20). To be sure that p62 and NBR1 sequestration 
into mutant huntingtin aggregates would not alter their detection by western blot 
(Landles et al., 2010), we analyzed the stacking gels corresponding to samples of wild-
type and R6/1 mice striatum at different ages. We only detected mutant huntingtin in 
the stacking gels corresponding to samples of 30-week-old R6/1 mice striatum (Fig. 
21A). Thus, we analyzed p62 and NBR1 in the same conditions. Neither p62 nor NBR1 
were detected in the stacking gels (Fig. 21B), suggesting a non-covalent interaction 
between these proteins and ubiquitinated- mutant huntingtin, as has been previously 
shown for the interaction between p62 and ubiquitin (Vadlamudi et al., 1996). 
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Figure 21. p62 and NBR1 are not retained in the stacking gels. (A) The presence of mutant huntingtin was analyzed 
by western blot by using EM48 antibody in stacking gels corresponding to samples obtained from 12- and 30-week-old 
wild-type (WT) and R6/1 mice striatum. (B) The presence of p62 and NBR1 was also analyzed by western blot in 
stacking gels corresponding to samples obtained from WT and R6/1 mice striatum at 30 weeks of age. 
 
Thus, both p62 and NBR1 interact with mutant huntingtin, but this interaction 
does not interfere in their detection in the western blot. 
 
 
1.1.4 - The peroxisome marker catalase is deregulated in the R6/1 mouse brain  
 
All these results suggested that differences in p62 and NBR1 protein levels could 
be due to alterations in selective autophagic activity. The pathway involving ubiquitin 
and p62 is used by mammalian cells for targeting diverse types of substrates for 
autophagic degradation. Peroxisomes get monoubiquitinated and recognized by p62 to 
get degraded by selective autophagy (Kim et al., 2008). Thus, we wondered if at late 
stages of the disease, were we found distinct p62 and NBR1 protein levels within 
striatal and cortical tissue, we would find also differences in the degradation efficiency 
of this organelle. To do that, we analyzed by western blot the levels of the peroxisome 
marker catalase in 30 week-old mice cortex and striatum. In good correlation with p62 
and NBR1 protein levels, we detected unchanged and decreased protein levels of 
catalase in striatum (Fig. 22A) and cortex (Fig. 22B), respectively. 
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Figure 22. Catalase levels are decreased in the cortex, but not in the striatum, of 30-week-old R6/1 mice. 
Catalase protein levels were analyzed by western blot in the (A) striatum and (B) cortex of wild-type (WT) and R6/1 mice 
at 30 weeks of age. Representative immunoblots show catalase and α-tubulin in 30-week-old WT and R6/1 mice. The 
graphs show catalase protein levels in R6/1 mice with respect to their littermate controls. Values (obtained by 
densitometric analysis of western blot data) are expressed as percentage of WT mice (catalase/α-tubulin ratio), and 
shown as mean ± s.e.m. (n = 6). Data were analyzed by Student’s t-test. ** P< 0.01 as compared with WT mice. 
 
 
1.2 - p62 AND NBR1 INTRACELLULAR LOCALIZATION IN CELLS EXPRESSING 
MUTANT HUNTINGTIN 
 
1.2.1 - p62 is increased in the nuclear fraction of R6/1 mice brain 
 
The autophagic proteins, p62, Alfy, Beclin-1 and diabetes- and obesity-regulated 
gene shuttle between the cytoplasm and the nucleus (Knaevelsrud & Simonsen, 2010). 
However, autophagy is restricted to the cytoplasm since the nucleus is lack of 
membrane-limited proteolytic organelles. Thus, we wondered if the previously observed 
alterations in whole amount of p62 protein (Fig. 17) could be restricted to any of these 
two compartments. We analyzed by western blot p62 protein levels in cytoplasmic and 
nuclear enriched fractions obtained from wild-type and R6/1 mice striatum, cortex and 
hippocampus at different stages of the disease. At 12 weeks of age, p62 protein levels 
were decreased in cytoplasmic enriched fractions and unchanged in nuclear enriched 
fractions with respect to wild-type values (Fig. 23A). Interestingly, in 30-week-old R6/1 
mice striatum, we detected increased p62 protein levels in nuclear enriched fractions, 
whereas its levels were reduced in cytoplasmic enriched fractions (Fig. 23B). A similar 
regulation of p62 protein levels was observed in nuclear and cytoplasmic enriched 
fractions from 30-week-old R6/1 cortex (Fig. 23C) and hippocampus (Fig. 23D), 
although the increase in cortical nuclear p62 levels was much lower than in the other 
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regions (striatum: 406 ± 62%; hippocampus: 403 ± 25%; cortex: 191 ± 45% with 
respect to wild-type values). 
 
 
Figure 23. p62 is localized in the nucleus of R6/1 striatal, cortical and hippocampal cells at late stages of the 
disease. Protein levels of p62 were analyzed by western blot in nuclear (Nuc) and cytoplasmic (Cyt) fractions prepared 
from the striatum of wild-type (WT) and R6/1 mice at (A) 12 and (B) 30 weeks of age. Nuclear and cytoplasmic p62 
protein levels were also analyzed in 30-week-old WT and R6/1 (C) cortex and (D) hippocampus. Representative 
immunoblots show protein levels of p62 in cytoplasmic (loading control α-tubulin) and nuclear (loading control lamin) 
fractions from wild-type and R6/1 mice. Values, obtained by densitometric analysis of western blot data and normalized 
to α-tubulin or lamin, are expressed as percentage of WT values. Data are the mean ± s.e.m. (n= 4-8), and were 
analyzed using the Student’s t-test. * P< 0.05, ** P< 0.01 and *** P< 0.001 as compared with WT mice. 
 
These results indicate that only at late stages of the disease p62 accumulates in 
the nucleus. Among the regions examined, striatum and hippocampus present the 
highest accumulation of nuclear p62. 
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1.2.2 - p62 localizes in mutant huntingtin nuclear inclusions 
 
To further characterize p62 intracellular distribution in wild-type and R6/1 mice 
brain, we performed immunohistofluorescence stains on 30-week-old mice brain slices. 
In wild-type mice, p62 was mainly localized in the cytoplasm (Fig. 24A). In contrast, in 
R6/1 striatum and hippocampus, p62 was mainly detected in the nucleus where it 
colocalized with mutant huntingtin inclusions (Fig. 24B and C). In the cortex, p62 also 
colocalized with nuclear mutant huntingtin but to a lesser extent than in the striatum 
and hippocampus (Fig. 24C). 
Figure 24. p62 immunostaining in wild-type and R6/1 mouse brain. p62 was analyzed by immunohistochemistry in 
the striatum of (A) wild-type and (C) R6/1 30-week-old mice. p62 distribution was also analyzed in 30-week-old R6/1 
mice (B) cortex and (C) hippocampus. Nuclei were stained with Hoechst 33258 and mutant huntingtin with the EM48 
antibody. Merging (yellow) illustrates colocalization of p62 and EM48 in the nuclear inclusions. In the striatum and 
hippocampus, almost all EM48-positive inclusions are also positive for p62 staining whereas in the cortex there are 
EM48-positive inclusions that do not colocalize with p62 (arrows). Most of the cytoplasmic mutant huntingtin aggregates 
do not colocalize with p62 staining (arrow heads).Scale bar 20 μm. 
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Next, we analyzed whether changes in p62 intracellular distribution observed in 
R6/1 mouse brain also occur in the brain of Huntington’s disease patients.  
 
Figure 25. p62, but not NBR1, associates with mutant huntingtin nuclear inclusions in human Huntington’s 
disease brains. PolyQ and p62 were analyzed by immunohistochemistry in the (A-F) caudate nucleus and (G-L) frontal 
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cortex of two Huntington’s disease cases with different pathology: (A-C, G-I) case 1, Vonsattel grade 3, and (D-F, J-L) 
case 2, Vonsattel grade 1. Representative photomicrographs show (A, D, G, J) polyQ, (B, E, H, K) p62 and (C, F, I, L) 
NBR1 immunostaining in the caudate nucleus and frontal cortex of case 1 and case 2. (A) High amount of polyQ-
immunoreactive nuclei are detected in the most preserved areas of caudate nucleus, which also show compact nuclear 
aggregates (a). (B, b) p62 immunoreactivity (arrows in B) is mainly observed in compact intranuclear inclusions in a 
lower density when compared to polyQ immunostaining. (D, d, E, e) Fewer polyQ and less p62-immunoreactive diffuse 
and compact nuclear inclusions are detected in medium spiny neurons of case 2 compared to case 1. (C, c, F, f) NBR1 
immunohistochemistry shows a cytoplasmic granular pattern mainly in astrocytes, but not in neurons (note unstained 
lipofuscin granules). No nuclear inclusions are detected. (G) High and (J) moderate amount of polyQ-immunoreactive 
nuclei are detected in frontal cortex neurons, which show, in addition to compact nuclear inclusion bodies, abundant 
granular cytoplasmic aggregates (g, j). (H, h, K, k) p62 immunoreactivity is mainly observed in compact intranuclear 
inclusions in a lower density when compared to polyQ immunostaining (arrows in H). (I, i, L, l) NBR1 immunoreactivity 
shows a granular cytoplasmic staining pattern and no nuclear inclusion bodies are observed. Case 2 shows less polyQ- 
and p62-immunoreactive diffuse and compact nuclear inclusions and less NBR1 cytoplasmic granular immunoreactivity 
compared to case 1. Scale bars 50 mm for (A-L) and 10 mm for (a-l).  
 
To this end, we analyzed by immunohistochemistry different brain regions of two 
representative Huntington’s disease cases: (1) a 53 year old man with 45 CAG repeats 
and Vonsattel grade 3 severity of pathology, and (2) a 73 year old man with late onset 
disease, 40 CAG repeats and Vonsattel severity grade 1. In case 1, the maximal 
immunoreactivity was observed using the anti-polyQ-antibody (Fig. 25A and G), which 
showed a diffuse labelling of the nucleus of affected neurons, most of them harbouring 
smaller compact, rounded or elongated intranuclear inclusion bodies, varying in size 
and shape. In addition, a coarse granular cytoplasmic immunoreactivity was observed 
and few thin and thick neurites were present in the neuropil (Fig. 25A and G). Compact 
nuclear inclusions containing p62 were observed in all brain regions analyzed (Fig. 25B 
and H). NBR1 displayed a granular cytoplasmic staining pattern in frontal cortex, 
following in most, but not in all neurons, the distribution of lipofuscin granules (Fig. 25I). 
In the striatum, an irregular cytoplasmic granular pattern was mainly observed in 
astrocytes (Fig. 25C). In case 2, polyQ-immunoreactive nuclear and cytoplasmic 
inclusions were observed in the same anatomical areas as in case 1, but in a much 
lower density (Fig. 25D and J). A fraction of nuclear inclusions in the same brain areas 
was also stained with p62 (Fig. 25E and K), but not with NBR1, antibody (Fig. 25F and 
L). 
 
p62 contains NES and NLS signals in its sequence that enables it to shuttle 
between the nucleus and the cytoplasm (Pankiv et al., 2010). While nuclear import is 
usually mediated by importin-α, nuclear export is facilitated by exportin-1/CRM1 (Xpo-
1) binding to the NES (Kutay & Guttinger, 2005). It has been recently shown that Xpo-1 
decreases with age in whole brain lysates obtained from both wild-type and R6/2 mice 
(Chan et al., 2011). Thus, we analyzed whether changes in Xpo-1 levels could 
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participate in the nuclear accumulation of p62 in R6/1 mice neurons at late stages of 
the disease. 
 
 
Figure 26. Xpo-1 is decreased with age in the striatum and hippocampus, but not in the cortex, of R6/1 mice. 
Protein levels of Xpo1 were analyzed by western blot in the (A) striatum, (B) cortex and (C) hippocampus of R6/1 mice 
at 12 and 30 weeks (W) of age. Values in the graphs (obtained by densitometric analysis of western blot data) are 
expressed as percentage of values obtained in 12-week-old R6/1 mice (Xpo1/α-tubulin ratio), and shown as mean ± 
s.e.m (n = 5-10). Representative immunoblots show protein levels of Xpo1 and α-tubulin in 12- and 30-week-old R6/1 
mice (A) striatum, (B) cortex and (C) hippocampus. Data were analyzed by Student’s t-test. * P< 0.05 as compared with 
12-week-old R6/1 mice. 
 
 Western blot analysis revealed that Xpo-1 protein levels were similarly decreased 
with age by about 40% in the striatum and hippocampus of R6/1 mice (Fig. 26A and C). 
Interestingly, cortical Xpo-1 protein levels were not different between 12- and 30-week-
old R6/1 mice (Fig. 26B). 
 
 
1.3 - CHANGES IN XPO-1 PROTEIN LEVELS MAY CONTRIBUTE TO ALTERED 
AUTOPHAGY 
 
Since Xpo-1 decreases with age in both wild-type and R6 mouse models (Chan et 
al., 2011; present results) we wondered whether this reduction would affect autophagy 
by changing the localization of important proteins for the process. To simulate this 
situation, a striatal cell line was treated with LMB, an irreversible Xpo-1 inhibitor (Kudo 
et al., 1999). To be sure of the LMB treatment efficiency we analyzed nuclear and 
cytoplasmic levels of p62 after 24h of treatment. We detected increased nuclear p62 
levels in these conditions (Fig. 27).  
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Figure 27. p62 is retained in the nucleus after LMB treatment. A striatal cell line (STHdhQ7/Q7) was treated with LMB 
(10 nM) for 24h. Intracellular distribution of p62 was analyzed by immunocytochemistry in (A) control (Ctrl) and (B) LMB-
treated cells. Scale bar 10 μm. (C) Protein levels of p62 were analyzed by western blot in nuclear (Nuc) and cytosolic 
(Cyt) fractions prepared from control (Ctrl) and LMB-treated cells. Graph shows the results obtained by densitometric 
analysis of western blot data (normalized to lamin for nuclear extracts and to α-tubulin for cytoplasmic extracts). Data 
are expressed as percentage of control (Ctrl) values. (C) A representative immunoblot shows protein levels of p62 in 
cytosolic (loading control α-tubulin) and nuclear (loading control lamin) fractions. Data are the mean ± s.e.m (n = 5-10), 
and were analyzed by the Student’s t-test. * P< 0.05, and ** P< 0.01 as compared with values obtained in control (Ctrl) 
cells. 
 
Interestingly, LMB treatment for 24h increased LC3II protein levels (Fig. 28A). 
However, LC3II levels only correlate with the number of autophagosomes within cells 
at a snapshot time, and this can result from either increased autophagosome formation 
or reduced autophagosome degradation (Rubinsztein et al., 2009). To discern between 
these possibilities, we treated striatal cells with BafA1, a vacuolar-ATPase inhibitor, 
which impairs lysosomes and autophagosome degradation (Rubinsztein et al., 2009). 
This leaded to an accumulation of autophagosomal structures. As expected, BafA1 
treatment enhanced LC3II levels (Fig. 28A). Interestingly, when we treated the cells 
with BafA1 together with LMB, LC3II levels increased to the same extent as BafA1 
treatment alone (Fig. 28A). This result suggests that LMB inhibits autophagy at some 
point in a late step of the process, although not as efficiently as BafA1 does. To further 
analyze this hypothesis, we measured the rate of autophagosome degradation by 
transfecting striatal cells with a mRFP-GFP-LC3 (tfLC3) plasmid (Kimura et al., 2007).  
 
 
RESULTS 
90 
Figure 28. LMB treatment impairs autophagosome degradation but does not modify long-lived protein 
proteolysis. (A) Graph showing LC3II protein levels in STHdhQ7/Q7 cells after LMB (10 nM; 24h), BafA1 (100 nM, 6h) 
and LMB+BafA1 treatment. Values, obtained by densitometric analysis of western blot data and normalized to α-actin, 
are expressed as percentage of control (Ctrl) and shown as mean ± s.e.m. (n = 4-5). Data were analyzed by one-way 
Anova followed by Bonferroni’s post-hoc test. * P< 0.05, ** P< 0.01 as compared with control; + P< 0.05 as compared 
with LMB treatment. Immunoblot shows a representative experiment. (B) Representative images illustrating STHdhQ7/Q7 
transfected with mRFP-GFP-LC3 plasmid in control conditions and after LMB treatment. Graph shows the percentage of 
colocalization in control (Ctrl) and LMB-treated (LMB) cells. Data are represented as mean ± s.e.m. (n = 103 ± 3 cells 
from three independent experiments). Data were analyzed by Student’s t test. *** P< 0.001 as compared with % of 
colocalization in control (Ctrl) cells. Scale bar, 10 μm. (C) Degradation of long-lived proteins was analyzed in confluent 
STHdhQ7/Q7 cells that were labelled with [2,3,4-H3]L-valine (1 mCi/ml) for 48h at 33°C and then maintained in complete 
(10% FBS) medium with or without LMB treatment for 24h. Proteolysis was measured as the percentage of the initially 
acid-insoluble radioactivity (protein) transformed into acid-soluble radioactivity (amino acids and small peptides) at each 
time point. The experiment was performed in (c1) complete (Ctrl) or serum-deprived (S-) medium to enhance 
proteolysis, and in (c2) complete medium (Ctrl) with or without NH4Cl (20 mM) and leupeptin (0.1 mM) (Leu/NH4Cl) to 
inhibit lysosomal degradation. Data are the mean ± s.e.m of three independent experiments. 
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Briefly, GFP fluorescence is attenuated by acidic conditions and degraded by 
lysosomal hydrolases, whereas mRFP fluorescence remains relatively stable (Kimura 
et al., 2007). While autophagosomes correlated with puncta double positive for mRFP 
and GFP, autophagolysosomes were mRFP only puncta. Thus, using this approach, 
we were able to analyze the levels of non-degraded autophagosomes. LMB-treated 
striatal cells displayed an increase in the number of autophagosomes compared to 
non-treated cells (Fig. 28B), reinforcing the idea that autophagosome degradation was 
slightly impaired upon treatment. 
Most of the proteins that are degraded by lysosomes have long half-lives. Thus, 
the degradation rate of long-lived proteins correlates with lysosomal function (Kaushik 
& Cuervo, 2009). To analyze whether the alterations observed upon Xpo-1 inhibition 
could lead to alterations in the degradation of long-lived proteins, we performed 
metabolic labelling in pulse and chase assays and measured whole cellular proteolysis. 
The experiment was performed in complete or serum-deprived medium to enhance 
proteolysis, and complete medium with or without NH4Cl and leupeptin to inhibit 
lysosomal degradation. We observed that LMB treatment did not alter the degradation 
of long-lived proteins in any of the conditions analyzed (Fig. 28C). 
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2 - REGULATION OF PRO-SURVIVAL AND PRO-APOPTOTIC PROTEIN KINASES 
IN HUNTINGTON’S DISEASE 
 
2.1 - ROLE OF mTOR IN THE REGULATION OF BOTH AUTOPHAGY AND THE 
AKT PRO-SURVIVAL PATHWAY IN HUNTINGTON’S DISEASE 
 
In the previous aim, we wondered whether autophagy was impaired along the 
progression of the disease. The results that we obtained suggest that at early stages of 
the disease autophagy was enhanced, whereas at late stages of the disease 
autophagy was deregulated in a brain region-dependent manner. While in the cortex 
autophagy remained enhanced, in the striatum returned to control levels and in the 
hippocampus even seemed to collapse. One of the regulators of autophagy is mTOR, 
which in addition regulates AKT phosphorylation at Ser473. Previous results from our 
group have shown increased levels of pSer473 AKT (Saavedra et al., 2010). This 
increase in AKT activity occurred specifically in striatal neurons and was suggested to 
be a compensatory pro-survival mechanism in Huntington’s disease that was over-
activated, at least in part through PHLPP down-regulation (Saavedra et al., 2010). With 
this background, we wondered whether mTOR activity would be de-regulated in striatal 
neurons expressing mutant huntingtin. 
 
 
2.1.1 - mTOR phosphorylation is increased in the striatum of R6/1 mice 
 
One of the mechanisms to regulate mTOR is phosphorylation. Thus, to analyze 
mTOR activity, we examined the levels of mTOR phosphorylated at two different sites, 
Ser2448 (pSer2448 mTOR) and Ser2481 (pSer2481 mTOR). While the first site is 
phosphorylated by AKT and S6K1 to increase mTOR activity (Holz & Blenis, 2005; 
Nave et al., 1999), the second is an autophoshorylation event that monitors mTOR 
catalytic activity (Soliman et al., 2010). Protein levels of non-phosphorylated mTOR 
and both pSer2448 mTOR and pSer2481 mTOR were analyzed by western blot in 
homogenates obtained from the striatum of R6/1 mice at 8, 12, 20 and 30 weeks of 
age. While we found no changes in mTOR total protein levels in R6/1 mice striatum 
compared to values in control mice, levels of both phosphorylated forms of mTOR 
increased progressively from 12 weeks of age onwards. Both phosphorylated mTOR 
forms increased similarly, and doubled the levels detected in control mice striatum at 
30 weeks of age. 
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Our results suggest that mTOR might be catalytically more active in these models 
of the disease from 12 weeks ahead. 
 
Figure 29. Regulation of mTOR and its phosphorylation levels in the striatum of R6/1 mice along the 
progression of the disease. Protein levels of (A) mTOR, (B) pSer2448 and (C) pSer2481 mTOR were analyzed by 
western blot in protein extracts obtained from the striatum of wild-type (WT) and R6/1 mice at different stages of the 
disease progression (W, weeks). Representative immunoblots show the protein levels of mTOR, pSer2448 mTOR, 
pSer2481 mTOR and α-tubulin in WT and R6/1 mice at different ages. The graphs show mTOR, pSer2448 mTOR and 
pSer2481 mTOR protein levels in R6/1 mice with respect to their littermate controls at different stages of the disease 
progression. Values (obtained by densitometric analysis of western blot data) are expressed as percentage of WT mice 
(mTOR, pSer2448 mTOR or pSer2481 mTOR /α-tubulin ratio), and shown as mean ± s.e.m (n = 4-6). Data were 
analyzed by Student’s t-test. * P< 0.05 and ** P< 0.01 as compared with WT mice. 
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2.1.2 - mTOR is not sequestered in mutant huntingtin aggregates 
 
Contradictory data does exist about mTOR intracellular localization, which seems 
to vary between different cell types. While mTOR has been found in the nucleus of 
many types of cancer cells (Zhang et al., 2002), in HeK293 cells mTOR distributes 
predominantly in the cytoplasm (Kim & Chen, 2000; Zhang et al., 2002).  
 
Figure 30. Phosphorylated mTOR is mainly localized in the cytoplasm of striatal cells. pSer2448 mTOR and 
pSer2481 mTOR localization was determined by (A and B) western blot in nuclear and cytopasmic enriched fractions 
and by (C) immunohistofluorescence. Protein levels of (A) pSer2448 mTOR and (B) pSer2481 mTOR were analyzed by 
western blot in nuclear (Nuc) and cytoplasmic (Cyt) fractions of wild-type (WT) and R6/1 mice striatum at 30 weeks of 
age. Representative immunoblots show protein levels of pSer2448 mTOR and pSer2481 mTOR in cytoplasmic (loading 
control α-tubulin) and nuclear (loading control lamin) fractions from WT and R6/1 mice. mTOR, pSer2448 mTOR and 
pSer2481 mTOR were analyzed by immunohistochemistry in the striatum of 30-week-old (C) WT and (D) R6/1 mice. 
Nuclei were stained with Hoechst 33258 and mutant huntingtin with the EM48 antibody. Images illustrate mTOR, 
pSer2448 mTOR and pSer2481 mTOR, which do not colocalize (yellow) with EM48 in the nuclear inclusions. Scale bar 
10 μm. 
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Interestingly, previous results from David Rubinsztein’s group revealed in 2004 
that mTOR was getting sequestered into mutant huntingtin nuclear aggregates in the 
brain of N171-82Q mouse model of the disease and in human Huntington’s disease 
brains (Ravikumar et al., 2004). Since sequestration of mTOR into the mutant 
huntingtin aggregates could lead to decrease in its activity, we next wondered whether 
this could also take place in the striatum of R6/1 mice. 
 
We first analyzed whether intracellular distribution of phosphorylated mTOR was 
altered by mutant huntingtin. We analyzed both pSer2448 mTOR and pSer2481 mTOR 
by western blot in cytoplasmic and nuclear enriched fractions obtained from wild-type 
and R6/1 mice striatum. We found that both phosphorylated forms of mTOR were 
mainly cytoplasmic (Fig. 30A and B). While we failed to observe pSer2448 mTOR in 
the nuclear-enriched fractions (Fig. 30A), we detected pSer2481 mTOR in this fraction 
only in R6/1 mice brains (Fig. 30B), suggesting that at least pSer2448 mTOR was not 
getting sequestered into mutant huntingtin aggregates. As already observed in whole 
striatal lysates, R6/1 cytoplasmic enriched fractions presented more phosphorylated 
mTOR than in wild-type mice (Fig. 30A and B). To further examine if mTOR was 
getting sequestered into mutant huntingtin aggregates, brain slices from 30 week-old 
wild-type and R6/1 mice, were processed for immunohistofluorescence against non-
phosphorylated mTOR, pSer2448 mTOR and pSer2481 mTOR. R6/1 mice brain slices 
were also co-stained with EM48 antibody to detect mutant huntingtin and Hoechst 
33258 to highlight cellular nuclei. The staining of wild-type mice brain slices with 
pSer2448 mTOR, pSer2481 mTOR or mTOR, revealed that the three mTOR forms 
display different distribution. While mTOR and phosphorylated mTOR in Ser2448 
presented a more diffuse staining, and mainly cytoplasmic, pSer2481 mTOR formed 
bigger puncta that were distributed in the cytoplasm and also within the nucleus (Fig. 
30C). R6/1 mice striatum displayed a similar pattern of staining (Fig. 30C). We failed to 
detect any colocalization of mTOR with EM48 positive puncta in R6/1 mice striatum, 
indicating that mTOR is not sequestered into the mutant huntingtin aggregates, at least 
in the R6/1 mouse model (Fig. 30C). 
 
 
2.1.3 - Rictor, but not Raptor, is increased in the striatum of R6/1 mice 
 
Association of mTOR with protein partners define its affinity for different substrates 
and regulates its activity. Thus, we analyzed the levels of two different protein partners 
of mTOR, Raptor and Rictor. While Raptor gives substrate specificity to the mTORC1 
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complex, Rictor is specific for the mTORC2 complex. We examined both protein levels 
by western blot in the striatum of R6/1 mice along the progression of the disease. While 
we found and increase in Rictor levels at all ages analyzed, Raptor protein levels 
remained unaltered (Fig. 31A).  
 
 
Figure 31. Raptor and Rictor protein levels in R6/1 mice and in human Huntington’s disease putamen. (A) Raptor 
and Rictor protein levels were analyzed by western blot in protein extracts obtained from the striatum of wild-type (WT) 
and R6/1 mice at different stages (W, weeks) of the disease progression. (B) Raptor and Rictor protein levels were also 
analyzed by western blot in protein extracts obtained from the putamen of Huntington’s disease brains. Representative 
immunoblots show the protein levels of Raptor, Rictor and α-tubulin in WT and R6/1 mice at different ages and in control 
(Ctrl) and Huntington’s disease (HD) brains. The graphs show (A) Raptor and Rictor protein levels in R6/1 mice with 
respect to their littermate controls at different stages of the disease progression and (B) in HD brains with respect to 
Ctrl. Values (obtained by densitometric analysis of western blot data) are expressed as percentage of WT mice or Ctrl 
brains (Raptor or Rictor/α-tubulin ratio), and shown as mean ± s.e.m (A, n = 4-13; B, n=5-8). Data were analyzed by 
Student’s t-test. * P< 0.05 as compared with WT mice or Ctrl brains. 
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Furthermore, we analyzed the protein levels of these mTOR-partners in the 
putamen of Huntington’s disease patients. According to the results obtained in mice, 
Raptor protein levels were unaltered and, interestingly, Rictor protein levels increased 
in the putamen of Huntington’s disease patients when compared with levels in the 
putamen of non-affected brains (Fig. 31B). 
Increased Rictor protein levels together with increased phosphorylated mTOR 
could lead to increased activity of the mTORC2 complex. 
 
 
2.1.4 - mTORC1 and mTORC2-specific substrates are deregulated in the striatum 
of R6/1 mice 
 
To further confirm our hypothesis that increases in phosphorylated mTOR could 
result into enhanced mTOR activity, we examined mTORC1 and mTORC2-specific 
targets. On one hand, mTORC1 inhibits autophagy by specifically phoshorylating 
ULK1, which results in its inhibition (Kim et al., 2011a), and also regulates translation, 
activating S6K1 and inhibiting 4EBP1 (Fingar et al., 2002). On the other hand, 
mTORC2 regulates survival and cytoskeleton reorganization through dependent 
phosphorylation and activation of AKT, PKCα and SGK (Dazert & Hall, 2011). Thus, we 
analyzed mTOR-specific phosphorylation sites of all these targets by western blot in 
the same wild-type and R6/1 mice striatal samples, where phosphorylated mTOR 
protein levels were increased. No differences were observed in the levels of pSer757 
ULK1 and ULK1 (Fig. 32A). pSer371 S6K1 was neither altered in any of the studied 
time points (Fig. 32C), and, consistently, S6 ribosomal protein, which is specifically 
phosphorylated by S6K1, was unaltered along the disease progression (Fig. 32D). In 
contrast, pThr37/46 4EBP1 levels were significantly increased in R6/1 mice at all the 
ages examined (from 8 to 30 weeks of age), while 4EBP1 total levels remained 
unchanged (Fig. 32B). Besides AKT, phosphorylation levels of other mTORC2 
substrates were not altered (Fig. 33A and B). Protein levels of both PKCα and SGK 
were down-regulated upon the disease progression, and so did their phosphorylated 
forms, pSer422 PKCα and pSer657 SGK (Fig. 33A and B). No alterations were 
observed when the phosphorylated levels of these two proteins were normalized to 
their total protein levels, to measure the relative phosphorylation amount (Fig. 33A and 
B). 
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Figure 32. Phosphorylation of mTORC1 substrates in R6/1 mice striatum. (A) pSer757 ULK1, (B) pThr37/46 
4EBP1 and (C) pSer371 S6K1 protein levels were analyzed by western blot in protein extracts obtained from the 
striatum of wild-type (WT) and R6/1 mice at different stages (W, weeks) of the disease progression. (D) Protein levels of 
a S6K1 substrate, pSer235/236 S6 ribosomal protein, were also analyzed by western blot in protein extracts obtained 
from the striatum of wild-type (WT) and R6/1 mice at different stages of the disease progression. Representative 
immunoblots show the protein levels of pSer757 ULK1, pThr37/46 4EBP1, pSer371 S6K1, pSer235/236 S6, actin and 
α-tubulin in WT and R6/1 mice at different ages. Representative immunoblots of (A) ULK1 and (B) 4EBP1 are also 
shown. The graphs show pSer757 ULK1, pThr37/46 4EBP1, pSer371 S6K1 and pSer235/236 S6 protein levels in R6/1 
mice with respect to their littermate controls at different stages of the disease progression. Values (obtained by 
densitometric analysis of western blot data) are expressed as percentage of WT mice (pSer757 ULK1/α-tubulin and 
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pThr37/46 4EBP1, pSer371 S6K1 or pSer235/236 S6/actin ratio), and shown as mean ± s.e.m (n = 5-12). Data were 
analyzed by Student’s t-test. * P< 0.05 and ** P< 0.01 as compared with WT mice. 
 
Figure 33. Phosphorylation of mTORC2 substrates. (A) pSer422 PKCα and (B) pSer657 SGK  protein levels were 
analyzed by western blot in protein extracts obtained from the striatum of wild-type (WT) and R6/1 mice at different 
stages (W, weeks) of the disease progression. Representative immunoblots show the protein levels of pSer422 PKCα, 
pSer657 SGK and α-tubulin in WT and R6/1 mice at different ages. Representative immunoblots of PKCα and SGK are 
also shown. The graphs show pSer422 PKCα and pSer657 SGK protein levels in R6/1 mice normalized to total protein 
(PKCα and SGK) with respect to their littermate controls at different stages of the disease progression. Values (obtained 
by densitometric analysis of western blot data) are expressed as percentage of WT mice (pSer422 PKCα/PKCα and 
pSer657 SGK/SGK ratio), and shown as mean ± s.e.m (n = 5-6). Data were analyzed by Student’s t-test. * P< 0.05 as 
compared with WT mice. 
 
 
These results show that mTORC1 and mTORC2 specific substrates are distinctly 
regulated along the progression of the disease in the striatum of R6/1 mouse model of 
Huntington’s disease. 
 
 
 
 
 
 
RESULTS 
100 
2.2 - REGULATION OF DIFFERENT MEMBERS OF THE PKC PROTEIN FAMILY IN 
HUNTINGTON’S DISEASE 
 
PKC family can trigger many functions within the cell, from actin cytoskeleton 
reorganization, to apoptosis. Results from other groups already show a down-
regulation of protein levels of several members of this protein family in Huntington’s 
disease mouse models and human samples. Contrary to this, previous results from our 
group have shown decreased levels of PHLPP1, a phosphatase that besides AKT also 
regulates PKC signalling termination and degradation, thus suggesting an increase in 
the PKC levels. Therefore, in this last aim, we studied whether the levels of different 
PKC isoforms could be altered in the striatum, cortex and hippocampus of R6/1 mouse 
model of Huntington’s disease at different stages of the disease progression. 
 
 
2.2.1 - Distinct PKC isoforms levels are decreased in R6/1 mice brains 
 
To determine whether there was a deregulation within the PKC protein family, we 
chose to analyze the protein levels of some PKC isoforms by western blot in R6/1 mice 
striatum, cortex and hippocampus at different stages of the disease. We examined two 
conventional PKCs, PKCα and PKCβII, and a novel PKC, PKCδ. As shown in figures 
34-36, the levels of all these isoforms decreased with the disease progression in all the 
R6/1 mouse brain regions analyzed, when compared with their littermate controls. 
PKCα protein levels decreased in the striatum and cortex of R6/1 mice from 12 weeks 
onwards, reaching a 30% reduction in 30-week-old R6/1 mice when compared to their 
littermate controls (Fig. 34A and B). In the hippocampus, PKCα protein levels also 
started to decrease at 12 weeks, but reached a 65% reduction in 30-week-old R6/1 
mice (Fig. 34C). PKCβII protein levels also decreased in the three brain regions, but at 
different stages of the disease. While in the striatum PKCβII protein levels started to 
decrease at 12 weeks of age (Fig. 35A), in the cortex they started to decrease at 20 
weeks of age (Fig. 35B), reaching a similar reduction in both regions at 30 weeks of 
age (of about 50%). In the hippocampus PKCβII protein levels decreased only slightly 
(20%) at 30 weeks of age (Fig. 35C). However, while PKCα and PKCβII presented a 
moderate decrease in their levels, PKCδ protein levels were markedly decreased from 
early stages of the disease (8 weeks of age) when compared to wild-type animals. We 
observed a marked and similar decrease of PKCδ protein levels (of about 50%) in the 
striatum and cortex of 8-week-old R6/1 mice compared to their wild-type littermates 
(Fig. 36A and B). In both regions, this decrease was more accentuated at later stages 
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with a reduction of more than 75% of total PKCδ protein levels (Fig. 36A and B). In the 
R6/1 mouse hippocampus we observed a drastic decrease (by about 80%) of PKCδ 
protein levels at 12 and 30 weeks of age (Fig. 36C). 
In the same blots, we analyzed δCF, the 40kDa proteolitically cleaved fragment of 
PKCδ, but we did not observe any alteration in its protein levels in R6/1 mouse 
striatum, cortex and hippocampus when compared to control littermates (Fig. 37).  
 
 
Figure 34. Regulation of PKCα in R6/1 mice brain regions during the progression of the disease. PKCα protein 
levels were analyzed by western blot in protein extracts obtained from (A) striatum, (B) cortex and (C) hippocampus of 
wild-type (WT) and R6/1 mice at different stages (W, weeks) of the disease progression. Representative immunoblots 
show protein levels of PKCα and α-tubulin in WT and R6/1 mice at different ages. The graphs show PKCα protein levels 
in R6/1 mice with respect to their littermate controls at different stages of the disease progression. Values (obtained by 
densitometric analysis of western blot data) are expressed as percentage of WT mice (PKCα/α-tubulin ratio), and shown 
as mean ± s.e.m (n = 4-12). Data were analyzed by Student’s t-test. * P< 0.05, ** P< 0.01 and *** P< 0.001 as 
compared with WT mice. 
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Figure 35. Regulation of PKCβII in R6/1 mice brain regions during the progression of the disease. PKCβII protein 
levels were analyzed by western blot in protein extracts obtained from (A) striatum, (B) cortex and (C) hippocampus of 
wild-type (WT) and R6/1 mice at different stages (W, weeks) of the disease progression. Representative immunoblots 
show protein levels of PKCβII and α-tubulin in WT and R6/1 mice at different ages. The graphs show PKCβII protein 
levels in R6/1 mice with respect to their littermate controls at different stages of the disease progression. Values 
(obtained by densitometric analysis of western blot data) are expressed as percentage of WT mice (PKCβII/α-tubulin 
ratio), and shown as mean ± s.e.m (n = 4-7). Data were analyzed by Student’s t-test. * P< 0.05, ** P< 0.01 and *** P< 
0.001 as compared with WT mice. 
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Figure 36. Regulation of PKCδ in R6/1 mice brain regions during the progression of the disease. PKCδ protein 
levels were analyzed by western blot in protein extracts obtained from (A) striatum, (B) cortex and (C) hippocampus of 
wild-type (WT) and R6/1 mice at different stages (W, weeks) of the disease progression. Representative immunoblots 
show protein levels of PKCδ and α-tubulin in WT and R6/1 mice at different ages. The graphs show PKCδ protein levels 
in R6/1 mice with respect to their littermate controls at different stages of the disease progression. Values (obtained by 
densitometric analysis of western blot data) are expressed as percentage of WT mice (PKCδ/α-tubulin ratio), and shown 
as mean ± s.e.m (n = 4-7). Data were analyzed by Student’s t-test. * P< 0.05, ** P< 0.01 and *** P< 0.001 as compared 
with WT mice. 
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Figure 37. Regulation of the PKCδ cleaved fragment δCF in R6/1 mice brain regions during the progression of 
the disease. δCF protein levels were analyzed by western blot in protein extracts obtained from (A) striatum, (B) cortex 
and (C) hippocampus of wild-type (WT) and R6/1 mice at different stages (W, weeks) of the disease progression. 
Representative immunoblots show protein levels of δCF and α -tubulin in WT and R6/1 mice at different ages. The 
graphs show δCF protein levels in R6/1 mice with respect to their littermate controls at different stages of the disease 
progression. Values (obtained by densitometric analysis of western blot data) are expressed as percentage of WT mice 
(δCF/α-tubulin ratio), and shown as mean ± s.e.m (n = 4-7). Data were analyzed by Student’s t-test. 
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2.2.2 - PKCα and δ mRNA levels are not altered in R6/1 mice brains 
 
Decreased PKCβII gene expression levels has been previously described in 
brains of R6/2 mice (Harris et al., 2001).  
 
 
Figure 38. Regulation of PKCα and PKCδ mRNA levels in R6/1 mice striatum and cortex at different stages of 
the disease. The graphs show (A, B) PKCα and (C, D) PKCδ mRNA levels analyzed by Q-PCR in the (A, C) striatum 
and (B, D) cortex of 8-, 12- and 30-week-old (W) wild-type (WT) and R6/1 mice. Results were normalized to the 18S 
gene expression levels and are expressed as percentage of 8-week-old WT values. Data are the mean ± s.e.m (n = 3-6) 
and were analyzed by Student’s t-test. 
 
Thus, to determine whether the decrease in PKCα and PKCδ levels was also 
associated with a down-regulation of mRNA expression in the presence of mutant 
huntingtin, we analyzed by Q-PCR the PKCα and PKCδ mRNA levels that were 
extracted from 8-, 12- and 30-week-old wild-type and R6/1 mice brains. Our results 
revealed that PKCα and PKCδ mRNA levels were unaltered in R6/1 mice compared to 
wild-type mice values in both striatum (Fig. 38A and C) and cortex (Fig. 38B and D) at 
all the ages analyzed. These data suggest that the mechanism involved in this acute 
down-regulation of PKCs protein levels is not at a transcriptional level, at least for 
PKCα and PKCδ. 
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2.2.3 - R6/1 mouse striatum displays decreased PKCδ levels both in the 
cytoplasm and in the nucleus 
 
For its pro-apoptotic induction, PKCδ undergoes phosphorylation events that 
trigger its nuclear translocation (Humphries et al., 2008). Thus, we analyzed whether 
the decrease in PKCδ protein levels could be restricted to any of the two 
compartments. 
Figure 39. PKCδ protein levels are reduced in both nuclear and cytoplasmic enriched fractions of R6/1 mice 
striatum, cortex and hippocampus at 30 weeks of age. Protein levels of PKCδ were analyzed by western blot in 
nuclear (Nuc) and cytoplasmic (Cyt) fractions prepared from (A) striatum, (B) cortex and (C) hippocampus of wild-type 
(WT) and R6/1 mice at 30 weeks of age. Representative immunoblots show protein levels of PKCδ in cytoplasmic 
(loading control α-tubulin) and nuclear (loading control lamin) fractions from WT and R6/1 mice. Values were obtained 
by densitometric analysis of western blot data and normalized to α-tubulin or lamin, and are expressed as percentage of 
WT values. Data are the mean ± s.e.m. (n= 3-6), and were analyzed using the Student’s t-test. * P< 0.05, ** P< 0.01 
and *** P< 0.001 as compared with WT mice. 
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Moreover, PKCδ could get sequestered into the intranuclear aggregates 
containing mutant huntingtin, as previously observed in cerebellar sections of R6/2 
mouse brains (Zemskov et al., 2003).  
 
To address these two issues, we analyzed PKCδ levels in cytoplasmic and nuclear 
enriched fractions obtained from the striatum, cortex and hippocampus of 30-week old 
mice. As figure 39 shows, PKCδ levels were significantly decreased in both nuclear 
and cytoplasmic-enriched fractions of 30-week-old R6/1 mice striatum, cortex and 
hippocampus compared to protein levels in wild-type mice (Fig. 39). In the nuclear-
enriched fractions, PKCδ levels displayed more than a 75% fall in the three brain 
regions (Fig. 39), indicating that it was not retained into the mutant huntingtin 
aggregates. The cytoplasmic compartment showed a similar pattern, with a decrease 
of about 75% in the striatum and hippocampus (Fig. 39A and C), whereas the cortical 
cytoplasmic-enriched fraction exhibited a 50% reduction of PKCδ protein levels respect 
to the wild-type animals (Fig. 39B).  
 
 
Figure 40. PKCδ does not colocalize with ubiquitin-positive nuclear aggregates in the striatum of R6/1 mice. 
PKCδ was analyzed by immunohistochemistry in the striatum of 30-week-old R6/1 mice. Nuclei were stained with 
Hoechst 33258 and nuclear aggregates were stained with an anti-ubiquitin antibody. Images show that PKCδ does not 
colocalize (yellow) with ubiquitinated nuclear inclusions. Scale bar 20 μm. (a) Higher magnification of the images is 
marked with a square. Scale bar 10 μm. 
 
We further evaluated the intracellular distribution of PKCδ in 30-week-old R6/1 
mouse brain slices by immunohistofluorescence in order to confirm that PKCδ was not 
retained into the mutant huntingtin aggregates in the R6/1 mouse model. As shown in 
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figure 40, although PKCδ was detected in the nucleus, it did not colocalize with 
ubiquitinated mutant huntingtin aggregates in R6/1 brains. 
 
 
2.2.4 - pThr505 PKCδ levels are increased in the striatum, cortex and 
hippocampus of R6/1 mice at late stages of the disease 
 
Although phosphorylation at the activation loop in PKCs is an essential event for 
their maturation (Stempka et al., 1997), the same phosphorylation in PKCδ at Thr505 is 
a tag for degradation (Srivastava et al., 2002).  
Figure 41. Regulation of pThr505 PKCδ in R6/1 mice brain regions at early and late stages of the disease. 
pThr505 PKCδ protein levels were analyzed by western blot in protein extracts obtained from (A) striatum, (B) cortex 
and (C) hippocampus of wild-type (WT) and R6/1 mice at 8 and 30 weeks (W) of age. Representative immunoblots 
show the protein levels of pThr505 PKCδ and PKCδ in WT and R6/1 mice at 8 and 30W. The graphs show pThr505 
PKCδ protein levels normalized to PKCδ in R6/1 mice with respect to their littermate controls at two different stages of 
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the disease progression. Values (obtained by densitometric analysis of western blot data) are expressed as percentage 
of WT mice (pThr505 PKCδ/PKCδ ratio), and shown as mean ± s.e.m (n = 3-6). Data were analyzed by Student’s t-test. 
* P< 0.05 and ** P< 0.01 as compared with WT mice. 
 
Thus, in order to know whether decreased levels of PKCδ could be related to 
changes in its phosphorylation, we examined the pThr505 PKCδ protein levels at 
different stages of disease progression. We observed an increase of pThr505 
PKCδ/PKCδ ratio in the striatum, cortex and hippocampus, of 30-week-old R6/1 mice 
(Fig. 41). However, at early stages of the disease, phosphorylated levels of PKCδ were 
not modified in any of the regions analyzed (Fig. 41). This phosphorylation might 
account for PKCδ degradation at late, but not early, stages of the disease, suggesting 
that in addition to phosphorylation at Thr505, other mechanisms could account for the 
down-regulation of PKCδ. 
 
 
2.2.5 - PKCδ protein levels are also decreased in the putamen of Huntington’s 
disease patients 
 
To know whether these changes in PKCδ also occur in Huntington’s disease 
patients, we analyzed its protein levels in the putamen of human Huntington’s disease 
brains.  
 
Figure 42. PKCδ protein levels are reduced in the putamen of Huntington’s disease human brain. Protein levels 
of PKCδ were analyzed by western blot in protein extracts obtained from the putamen of Huntington’s disease human 
brains. Representative immunoblots show the protein levels of PKCδ and α-tubulin in control (Ctrl) and Huntington’s 
disease (HD) brain patients. The graph shows PKCδ in HD human brains with respect to Ctrl. Values (obtained by 
densitometric analysis of western blot data) are expressed as percentage of Ctrl brains (PKCδ/α-tubulin ratio), and 
shown as mean ± s.e.m (n=5-8). Data were analyzed by Student’s t-test. * P< 0.05 as compared with Ctrl brains. 
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As observed in the striatum of R6/1 mice, PKCδ protein levels were significantly 
decreased in human Huntington’s disease putamen when compared to control cases 
(by about 60% decrease; Fig. 42). 
 
 
2.2.6 - Over-expression of PKCδ induces cell death only in cells expressing the 
exon 1 of mutant huntingtin 
 
We hypothesized that a general decrease in PKCδ protein levels could represent a 
compensatory pro-survival mechanism generated to delay mutant huntingtin-induced 
toxicity.  
 
Thus, we asked if over-expression of PKCδ in striatal cells expressing the exon 1 
of the mutant huntingtin could enhance their cell death. The striatal cell line STHdh7Q/7Q 
was transfected with the huntingtin exon 1 with 16Q or 94Q plus HA-PKCδ or HA-only. 
Immunocytofluorescence to detect HA and nuclei staining with Hoechst 33258 were 
performed 72h after transfection, and apoptotic nuclei were counted. Mutant huntingtin 
expression induced a significant increase in cell death (Fig. 43B). We observed that 
cells expressing mutant huntingtin, but not cells expressing wild-type huntingtin, 
presented a 5% increase in cell death after over-expression of PKCδ, when compared 
to cells transfected with the HA-empty vector (Fig. 43B).  
This result reinforces the hypothesis that a general decrease in PKCδ in brains of 
R6/1 mice can represent a compensatory pro-survival mechanism, which is induced 
from early stages of the disease to protect neurons from mutant huntingtin toxicity. 
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Figure 43. Over-expression of PKCδ increases cell death in striatal cells expressing the exon 1 of the mutant 
huntingtin. STHdhQ7/Q7 cells were transfected with CFP-16Q or CFP-94Q plasmid in combination with HA-only or HA-
PKCδ plasmid. Cells were fixed 72h after transfection and condensed nuclei from cells that were transfected with both 
huntingtin and HA were counted. (A) Representative images illustrate STHdhQ7/Q7 cells transfected with either CFP-16Q 
or CFP-94Q plasmid in combination with HA-PKCδ plasmid. Nuclei were stained with Hoechst 33258. (B) Graph shows 
the percentage of apoptotic nuclei in CFP-16Q or CFP-94Q-transfected cells, co-transfected with either HA-only or HA-
PKCδ plasmid, normalized to the whole number of double-transfected cells. Data are represented as mean ± s.e.m from 
five independent experiments (an amount of 200-400 nuclei were examined in each condition of every experiment). 
Data were analyzed by two-way Anova followed by Bonferroni’s post-hoc test. *** P< 0.001 as compared with the 
percentage of apoptotic nuclei in CFP-16Q. ++ P< 0.01 as compared with the percentage of apoptotic nuclei in CFP-
94Q co-transfected with HA-only plasmid. Scale bar, 20 μm. 
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Selective autophagy contributes to the clearance of aggregate-prone proteins, and 
pharmacological up-regulation of this pathway could lead to symptomathic amelioration 
in protein aggregation diseases (Ravikumar et al., 2004; Sarkar et al., 2009; Webb et 
al., 2003). The first aim of this Thesis consisted in studying the selective autophagic 
response along the progression of Huntington’s disease, and to put this aim into 
practice, we analyzed the levels of p62 and NBR1, two cargo receptors for selective 
autophagy, in the brains of R6/1 mice at different ages, which covered the whole 
pathology. An accumulation of p62 has been used as a marker for autophagy inhibition 
or defects in autophagic degradation (Bjorkoy et al., 2005; Hara et al., 2008; Komatsu 
et al., 2007; Settembre et al., 2008), and a decrease in p62 levels as a marker for 
autophagy induction (Mizushima et al., 2008; Tasdemir et al., 2008), p62 has been 
suggested to be a proper tool to study autophagic activity (Bjorkoy et al., 2009). Since 
p62 and NBR1 are both cargo receptors for selective autophagy, both could be used as 
reporters for monitoring autophagic flux (Larsen et al., 2010).Thus, we considered the 
alterations in the protein levels of these two receptors as endogenous reporters of the 
selective autophagic flux. We have found that both proteins levels were similarly 
altered along the progression of the disease in a region- and age-dependent manner. 
At an early stage of the disease, both proteins levels were decreased in all regions 
examined, suggesting an over-activation of selective autophagy. At later stages of the 
disease this over-activation was still occurring in the cortex of R6/1 mice. However, this 
was not the case in the striatum and hippocampus, were p62 and NBR1 protein levels 
returned to control levels or even increased. We found that this deregulation was due 
to different mechanisms. While p62 accumulated in the nuclear aggregates, mainly in 
the striatum and hippocampus, NBR1 remained cytoplasmic. We found that, besides 
mutant huntingtin, an age-dependent decrease of Xpo-1 levels could also contribute to 
this nuclear p62 accumulation in the mutant huntingtin aggregates. Finally, we 
observed that in vitro inhibition of Xpo-1 could impair autophagy. 
 
Since our results suggested alterations in the autophagic flux, we wondered 
whether these could result from changes in mTOR activity. Thus, the second aim of 
this Thesis consisted in dissecting out the mTOR pathway along the progression of the 
disease to understand its contribution to the possible autophagic deregulation, and to 
the previously reported over-activation of the pro-survival kinase AKT in the striatum, 
but not in the cortex and hippocampus, of Huntington’s disease mouse models 
(Saavedra et al., 2010). Results obtained during the development of the second aim of 
this Thesis pointed to a deregulation in the AKT-mTOR pathway, but not in the mTOR 
regulation of the autophagic pathway in the striatum of R6/1 mice. We found that while 
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mTOR protein levels were not altered at any of the ages analyzed, protein levels of 
mTOR phosphorylated at two different sites, pSer2448 mTOR and pSer2481 mTOR, 
increased from 12 weeks of age onwards. Moreover, we found that Rictor, but not 
Raptor, protein levels were increased in the striatum of R6/1 mice at all ages analyzed, 
and in human Huntington’s disease putamen. Thus, we hypothesized that mTORC2 
complex would be over-activated in Huntington’s disease pathology. However, we 
failed to find further alterations in the levels of mTORC2 downstream-phosphorylated 
substrates, other than pSer473 AKT. Protein levels of two, out of three, mTORC1 
downstream-phophorylated substrates analyzed were not changed. However we found 
an increase in 4EBP1 levels from early 8 weeks onwards. Finally, since pSer757 ULK1 
levels were not altered at any of the time-points analyzed, we suggest that the 
alterations in autophagy that we have found in this model of the disease seem 
unrelated to mTOR signalling. 
 
Finally, analyzing several mTORC2 substrates, we found PKCα protein levels 
decreased in the striatum of R6/1 brains. Interestingly, different evidences suggest a 
deregulation of the PKC protein family. PKCβII protein levels are decreased in the 
striatum of human Huntington’s disease brains (Hashimoto et al., 1992). Moreover, 
PKCβII mRNA levels are decreased in brains of R6/2 mouse model of the disease 
(Harris et al., 2001). On the other hand, PHLPP1, whose protein levels are diminished 
in brains of R6/1 mice (Saavedra et al., 2010), is known to mediate dephosphorylation 
and degradation of some PKC isoforms (Gao et al., 2008), suggesting an accumulation 
of those in the same animal models of Huntington’s disease. Thus, we have also 
examined the protein levels of distinct PKC isoforms along the progression of the 
disease in the striatum, cortex and hippocampus of R6/1 mice. We have shown that all 
isoforms analyzed present a reduction in their protein levels in the R6/1 mouse model. 
Protein levels of PKCδ were the ones most importantly affected, starting to decrease 
already at 8 weeks of age, and could represent a compensatory pro-survival 
mechanism induced by mutant huntingtin expression. 
 
 
1 - DEREGULATION OF p62 AND NBR1 IN R6/1 MICE BRAINS 
 
We have shown that p62 and NBR1 protein levels are deregulated in R6/1 mice in 
brain-region- and age-dependent manner. Interestingly, the dynamics at a protein level 
of both cargo receptors were similar at all ages and regions analyzed in R6/1 mice 
brains when compared to their wild-type littermates. At early stages of the disease (12 
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weeks of age) p62 and NBR1 protein levels were lower than in the wild-type mice in all 
regions examined. However, this was not the case for later stages of the disease (30 
weeks of age) when p62 and NBR1 protein levels followed different dynamics in the 
cerebral regions examined. Their protein levels returned to control levels in the striatum 
and accumulated in the hippocampus, while in the cortex they kept decreased when 
compared to wild-type animals.  
 
Alterations at protein level might not be only caused by autophagy. Other factors 
could have a role in inducing these alterations, such as gene expression or degradation 
by other means distinct than autophagy. Thus, we analyzed by Q-PCR the expression 
of p62 and NBR1 within the striatum and the cortex, since in these two areas we 
observed totally distinct p62 and NBR1 protein levels dynamics. Since NBR1 
expression was not altered in any of the regions and ages analyzed, and p62 mRNA 
levels were increased in the striatum and cortex at ages at which p62 protein levels 
were decreased, the deregulation of p62 and NBR1 protein levels in the R6/1 mouse 
brain cannot be explained by changes in gene expression. Anyhow, the increase in 
both striatum and cortex of p62 mRNA levels is in accordance with a previous study, 
showing that p62 gene is up-regulated upon mutant huntingtin expression in an in vitro 
system (Nagaoka et al., 2004). Previous studies have established p62 as a stress 
response protein induced by oxidative stress, via the transcription factor Nrf2, and also 
by proteasome inhibitors (Ishii et al., 2000; Ishii et al., 1997; Jain et al., 2010). 
Interestingly, elevated lipid peroxidation appears to affect specifically vulnerable brain 
regions in R6/1 mice (Perez-Severiano et al., 2000). Moreover, p62 is among the 
targets that are up-regulated by the transcription factor TFEB (Settembre et al., 2011), 
and we have shown that protein levels of this transcription factor are increased in the 
two brain areas examined at 30 weeks of age. Our results are in good agreement with 
others that have observed an increase in the TFEB mRNA levels in induced pluripotent 
stem cells carrying the Huntington’s disease mutation (Castiglioni et al., 2012). The 
transcription factor TFEB regulates autophagy by inducing the expression of a large 
number of lysosomal and autophagic genes. TFEB plays a role in transcription, at least 
in response to starvation, and controls autophagy by positively regulating 
autophagosome formation and autophagosome-lysosome fusion (Settembre et al., 
2011). Moreover, an over-expression of this transcription factor induces lysosomal 
biogenesis and increases mutant huntingtin degradation (Sardiello et al., 2009). 
Although it is still unclear how exactly the cell regulates TFEB activity according to its 
needs, TFEB translocation to the nucleus seems to be finely regulated by 
phosphorylation at different residues (Pena-Llopis et al., 2011; Settembre et al., 2011, 
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2012). We finally show that the increase in TFEB protein levels is also observed in 
nuclear-enriched fractions. An increase in the TFEB levels could account, or at least 
participate in up-regulating the p62 gene. ERK and mTORC1 have been proposed to 
phosphorylate TFEB upon starvation, and regulate in an opposite way its nuclear 
translocation. While ERK phosphorylation on TFEB interferes with its nuclear 
localization, mTORC1 phosphorylation is needed for TFEB nuclear translocation 
(Settembre et al., 2011, 2012). In the R6/1 model of Huntington’s disease 
phosphorylated ERK protein levels increase at 20 and 30 weeks of age (Saavedra et 
al., 2011), not correlating with the nuclear increase in TFEB protein levels. mTORC1 
could participate in this TFEB nuclear increase, since another mTORC1 substrate, 
4EBP1, is increased from 8 weeks onwards. However, TFEB is phosphorylated in more 
than ten different sites, and other kinases and phosphatases could contribute to the 
nuclear accumulation of TFEB (Dephoure et al., 2008; Mayya et al., 2009; Yu et al., 
2011). 
 
Another mechanism that could explain the deregulation of p62 and NBR1 in the 
R6/1 mouse brain is an alteration in their degradation. On one hand, proteasomal 
inhibitors induce a prominent increase in the amount of p62 protein in cells (Kuusisto et 
al., 2001; Nagaoka et al., 2004; Thompson et al., 2003), thus indicating that p62 can be 
degraded by the proteasome. However, the same works also show a significant 
increase in p62 mRNA levels under the same conditions, which the authors attribute to 
a cell response to an increase in the level of ubiquitinated proteins, consistent with 
previous reports (Ishii et al., 2000). Moreover, autophagy could play a more important 
role than the proteasome in p62 degradation, since there is a marked elevation of p62 
in mouse embryonic fibroblasts and primary neurons, treated with agents that inhibit 
autophagy, such as chloroquine, NH4Cl and Baf A1, and in Atg5
−/− mouse embryonic 
fibroblasts (Myeku & Figueiredo-Pereira, 2011). Pulse and chase experiments, in which 
35S-labeled methionine was added in cells and p62 was specifically 
immunoprecipitated, indicate a half-life of p62 of 6 h, and almost all of the radiolabeled 
protein is lost after 24h of chase. Rapamycin treatment causes a decrease of 
endogenous p62, whereas treatment with BafA1 for 18h results in an accumulation of 
endogenous p62 (Bjorkoy et al., 2005). On the other hand, the role of the proteasome 
in NBR1 protein stability has been addressed by Kirkin et. al., who used the 
proteasomal inhibitors epoxomycin and proteasome inhibitor I. They found that 
proteasome inhibition did not significantly alter NBR1 protein levels (Kirkin et al., 2009). 
In fact, time course experiments using lysosomal inhibition by BafA1 showed that 
NBR1 is turned over by lysosomes considerably faster than p62 (Kirkin et al., 2009). 
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Moreover, Baf1 treatment leads to an accumulation of NBR1 in vesicle-like structures 
(Kirkin et al., 2009). Finally, and as already explained in the introduction, global 
proteasome system activity is not altered in the R6/1 mouse brain (Maynard et al., 
2009), thus, suggesting a relation between p62 and NBR1 protein levels and selective 
autophagic activity (Johansen & Lamark, 2011).  
 
The deregulation of these cargo receptors, and the fact that their protein levels 
followed similar dynamics along the progression of the disease and in different brain 
regions, suggested that autophagic activity was deregulated in the brains of R6/1 mice. 
At early stages of the disease, both p62 and NBR1 were reduced in all regions 
examined, suggesting that the expression of mutant huntingtin increases basal levels 
of selective autophagy by an unknown mechanism. Accordingly, autophagy is induced 
in striatal cells over-expressing full-length or truncated mutant huntingtin (Kegel et al., 
2000; Ravikumar et al., 2004), and in mouse models of Huntington’s disease (Heng et 
al., 2010; Ravikumar et al., 2004). Moreover, autophagy is activated as a 
compensatory response in other neurodegenerative conditions characterized by the 
presence of abnormal protein aggregates (Butler et al., 2006). However, at late stages 
of the disease, the deregulation observed for p62 and NBR1 was brain region-
dependent, which hinted that mutant huntingtin-induced changes in the selective 
autophagic flux were cell-type specific. Autophagy in cortical neurons seemed to keep 
over-activated at all the ages analyzed, whereas in the striatum and hippocampus this 
over-stimulation did not occur at late stages of the disease, in which autophagy 
seemed to function at normal levels in the striatum or even collapse in the 
hippocampus. Peroxisomes are degraded by selective autophagy (Kim et al., 2008). In 
good correlation with NBR1 protein levels, we detected decreased and unchanged 
levels of the peroxisome marker catalase in 30 week-old R6/1 mice cortex and 
striatum, respectively. These results reinforce the hypothesis that at late stages of the 
disease autophagy in R6/1 cortex is over-activated, while in the striatum is similar to 
that in control animals. 
  
 
2 - ACCUMULATION OF p62, BUT NOT NBR1, WITHIN MUTANT HUNTINGTIN 
NUCLEAR AGGREGATES 
 
It is well known that mutant huntingtin is not only prone to aggregate with itself but 
also has the tendency to aggregate with other selected proteins such as CBP, HSP70 
or p53, and disrupt their function (Busch et al., 2003; Steffan et al., 2000; Suhr et al., 
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2001). Moreover, p62 and NBR1 selectively bind ubiquitinated proteins that must be 
degraded by autophagy. Thus, we also explored the possibility that p62 and NBR1 
could get hampered into the mutant huntingtin aggregates and be retained in the 
stacking gels of the western blots, inducing alterations in their protein levels. Although 
p62 interaction with mutant huntingtin is an event that has been already shown by other 
groups (Martinez-Vicente et al., 2010; Nagaoka et al., 2004), NBR1 is only known to 
interact with ubiquitin and LC3, but any group has shown yet whether it is able to co-
immunoprecipitate together with mutant huntingtin. We show by immunoprecipitation 
for the first time that not only p62, but also NBR1, interact with mutant, but not with 
wild-type, huntingtin in the R6/1 mouse striatum and cortex. However, previous results 
from another group also showed an interaction of p62 with wild-type huntingtin in 
autophagic vacuoles (Martinez-Vicente et al., 2010). This difference could be due to 
the use of a different methodological approach, since here we used total protein 
extracts from the striatum of wild-type and R6/1 mice, and the authors of this study 
analyzed the interaction of p62 with huntingtin specifically in autophagic vacuoles 
obtained from a cell culture fractionation. Interestingly, the authors of the study show 
that the amount of p62 associated with mutant huntingtin was markedly higher than 
that associated with wild-type huntingtin. The fact that both p62 and NBR1 co-
immunoprecipitate with mutant huntingtin, means that both proteins recognize 
ubiquitinated mutant huntingtin and are both potentially able to direct it to the 
autophagy machinery. By analyzing the stacking gel of the western blots, we failed to 
detect p62 and NBR1, while we indeed found aggregated mutant huntingtin at 30 
weeks of age in the striatum of R6/1 mice. This is in agreement with the fact that p62 is 
recruited to polyQ protein aggregates as a result of its ability to bind polyubiquitin 
chains via its UBA domain (Donaldson et al., 2003), and that this binding is non-
covalent (Vadlamudi et al., 1996). Thus, the differences in p62 and NBR1 protein levels 
were more likely related to their turnover. 
 
Mutant huntingtin aggregates have been found progressively accumulated in 
brains from mice, and also human individuals, affected by Huntington’s disease, in both 
cytoplasmic and nuclear cell compartments (Davies et al., 1997; DiFiglia et al., 1997; 
Gutekunst et al., 1999). Further analyzis of p62 intracellular distribution in nuclear and 
cytoplasmic enriched fractions, and of its intracellular localization by 
immunohistochemistry, revealed an accumulation of p62 in the nucleus of R6/1 mice 
neurons, mainly in the striatum and hippocampus, only at late stages of the disease. At 
30 weeks of age, p62 colocalized with mutant huntingtin inclusions in neuronal nuclei, 
similarly to what has been previously observed in R6/2 mice brain (Nagaoka et al., 
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2004). Interestingly, we observed that most cytoplasmic mutant huntingtin aggregates 
were not positive for p62 labelling, according to decreased levels of p62 detected in 
cytoplasmic enriched fractions. Finally, we confirmed our results in human Huntington’s 
disease brains, where p62 is localized aggregated in the nucleus, but not in the 
cytoplasm, of striatal and cortical neurons. This finding adds Huntington’s disease to a 
list of human brain, liver and muscle pathologies characterized by protein aggregates 
also containing p62 (Kuusisto et al., 2008; Nogalska et al., 2009; Strnad et al., 2008; 
Zatloukal et al., 2002). 
 
Autophagy is a process that is restricted to the cytoplasm, and thus, it efficiently 
degrades polyQ aggregates that are located in the cytoplasm, but not the ones that are 
located within the nucleus (Iwata et al., 2005). p62 is able to shuttle between the 
nucleus and the cytoplasm, thanks to NLS and NES tags in their sequence. However, 
very little attention has been paid to this fact, although some functions have been 
already attributed to the p62 shuttling. On one hand, in the nucleus, p62 has been 
shown to recruit ubiquitinated proteins to promyelocytic leukemia bodies (Pankiv et al., 
2010) that function as one of the nuclear sites for proteasomal degradation of 
misfolded proteins (Rockel et al., 2005). Interestingly, nuclear mutant hutntingtin is 
localized in these structures (Kegel et al., 2002). On the other hand, p62 can also 
export ubiquitinated substrates from the nucleus into the more degradation-potent 
cytoplasmic compartment (Pankiv et al., 2010). Thus, it is tempting to speculate that 
nuclear p62 binds ubiquitinated mutant huntingtin in order to promote the degradation 
of the toxic protein by any of these two mechanisms. However, p62 could end up being 
trapped in the mutant huntingtin nuclear aggregates. 
 
p62 has been suggested to work also as a scaffold protein to generate protein 
aggregates. Some groups support the idea that p62 is actually indispensable for 
protein aggregation (Komatsu et al., 2007), since in autophagy deficient mice, protein 
aggregates accumulate in cells from liver and brain, which are present in a much lesser 
amount in autophagy and p62 deficient mice. However, we have found that p62 
colocalizes with nuclear mutant huntingtin aggregates, and with almost no cytoplasmic 
aggregates. Thus, we think that p62 is not needed for protein aggregation, or at least 
for mutant huntingtin aggregation, and p62 may be recruited into aggregates later on, 
in an attempt to get them degraded by autophagy. Our results are similar to previous 
studies showing that that aggregate formation also occurs in the absence of p62 
(Bjorkoy et al., 2005; Nagaoka et al., 2004). 
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In 30-week-old R6/1 mice, we found not only p62 nuclear accumulation, but also a 
decrease in the p62 cytoplasmic levels in all the brain areas examined. p62 is not only 
a cargo receptor for autophagy but also a scaffold protein that seems to play a 
pleiotropic role in the regulation of cellular signalling and homeostasis of multiple 
proteins. Thus, less levels of cytoplasmic p62 could impair its function in both 
autophagy and signalling, and induce pathology. p62 regulates cell survival and death 
signalling pathways (Moscat & Diaz-Meco, 2009), and has been recently shown to 
regulate the mTORC1 pathway (Duran et al., 2011). In fact, deficiency of p62 leads to 
an accumulation of hyperphosphorylated Tau, neurofibrillary tangles, and 
neurodegeneration, followed by increased anxiety, depression, loss of working 
memory, and reduced serum BDNF levels (Wooten et al., 2008). Increasing evidences 
link alterations in p62 to the pathology of Alzheimer’s disease, such as p62 retention in 
neurofibrillary tangles (Salminen et al., 2012), and a marked reduction of the 
cytoplasmic p62 levels that has been found in the frontal cortex of Alzheimer’s disease 
patients compared to that of control subjects (Du et al., 2009). This reduction might be 
the result of both impaired p62 transcription (Du et al., 2009), and also of the binding of 
p62 to neurofibrillary tangles (Babu et al., 2005). Reduced p62 protein levels have 
been linked to less p62 signalling in Alzheimer’s disease. It would be noteworthy to 
analyze whether similar alterations could be found in Huntington’s disease, since we 
show a reduction in the levels of cytoplasmic p62 in R6/1 mice that could lead to a 
reduction in the p62 signalling. 
 
In contrast to p62, any nuclear tag has been described in the sequence of NBR1, 
nor any role of this protein within the nucleus. Consistent with this are the results that 
we obtained by immunohistochemistry in human Huntington’s disease brains, showing 
that NBR1 displayed a granular cytoplasmic staining pattern, whereas no staining was 
observed within the nucleus. Thus, accumulation of NBR1 in whole cell lysates 
obtained from R6/1 mice brain at late stages of the disease seems to take place by a 
different mechanism than p62. Accumulation of NBR1 in 30-week-old R6/1 mice 
hippocampus should be the result of decreased selective autophagic flux, whereas 
nuclear accumulation of p62 could be due to its sequestration into intranuclear mutant 
huntingtin inclusions. In addition, and in contrast to that observed in human liver, 
muscle and neurological pathologies (D'Agostino et al., 2011; Kirkin et al., 2009; 
Odagiri et al., 2012), our results show that in Huntington’s disease p62 and NBR1 do 
not colocalize in the same aggregates, since p62 is sequestered in intranuclear mutant 
huntingtin inclusions whereas NBR1 remains cytoplasmic. This suggests that p62 and 
NBR1 may act independently and have redundant functions as previously shown 
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(Itakura & Mizushima, 2011; Waters et al., 2009). Therefore, in the absence of p62, 
cytoplasmic NBR1 may still exert its function as a cargo receptor in cells expressing 
mutant huntingtin, as long as autophagy works efficiently. In the p62 knockout mice, 
neuronal disturbances appear later in their lifespan, which indicates that other 
mechanisms, such as NBR1, could compensate for the deficiency of p62 protein (Kirkin 
et al., 2009). 
 
Our findings showed a significant nuclear redistribution of p62 from early to late 
stages of the disease, being more evident in the striatum and hippocampus than in the 
cortex. This progressive accumulation resembles that of mutant huntingtin, which is 
dependent upon Xpo-1 that guides NES-containing proteins nuclear export. p62, as 
well as mutant huntingtin, needs Xpo-1 to travel from the nucleus to the cytoplasm 
(Chan et al., 2011; Pankiv et al., 2010). In agreement with previous results showing 
reduced Xpo-1 levels in both aged wild-type and R6/2 mice whole brain (Chan et al., 
2011), we detected a decline of Xpo-1 protein levels in the striatum and hippocampus, 
but not in the cortex, of R6/1 mice at late stages of the disease. Thus, we conclude that 
lower Xpo-1 levels could trigger longer permanence of p62 within the nucleus, leading 
to higher probability of interaction with mutant huntingtin inclusions only in R6/1 brains, 
and could explain the differential accumulation of this protein in striatal, hippocampal 
and cortical neuronal nuclei. 
 
 
3 - INHIBITION OF XPO-1 AND AUTOPHAGIC ACTIVITY 
 
Here, we show a region-dependent deregulation of Xpo-1 along the progression of 
the disease. While in the striatum and hippocampus Xpo-1 levels decrease from an 
early to a late stage of the disease, correlating with a reduction in the selective 
autophagy, in the cortex, where autophagy is over-activated at all stages of the 
disease, Xpo-1 levels are unaltered. Thus, we analyzed if a decrease in the Xpo-1 
levels could impact in autophagy function, by impairing the functional localization of 
proteins essential for the process, such as p62. 
 
Treatment of striatal cells in vitro with an Xpo-1 inhibitor led to an accumulation of 
autophagosomes, due to a reduction in their clearance. However, we failed to detect 
alterations in long-lived protein degradation. Although acute treatment with an Xpo-1 
inhibitor in vitro did not alter long-lived proteins degradation, we cannot discard that a 
more chronic and progressive reduction in Xpo-1 levels, as observed in vivo, would 
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induce an impaired autophagy-mediated elimination of aggregates or damaged cellular 
organelles. Similarly, in autophagy-deficient neurons, accumulation of aggregates 
occurs gradually over time (Chan et al., 2011; Hara et al., 2006; Komatsu et al., 2006). 
 
The mechanism by which Xpo-1 could impair autophagy remains unknown, since 
over-expression or knock-down of p62 does not affect autophagosome numbers 
(Korolchuk et al., 2009). Moreover, p62 knock-down does not affect autophagic flux 
(Komatsu et al., 2007; Korolchuk et al., 2009; Shvets et al., 2008), although there is an 
accumulation of hyperphosphorylated Tau and neurofibrillary tangles in aged mice 
(Babu et al., 2005). Therefore, our results suggest that in addition to p62, other 
important proteins for autophagosome degradation should be retained in the nucleus 
after Xpo-1 inhibition. Besides p62, the autophagic proteins found to undergo 
nucleocytoplasmic shuttling so far are Beclin 1, diabetes- and obesity-regulated gene 
and Alfy (Knaevelsrud & Simonsen, 2010). While the first two are required for the 
induction of autophagy upon stress and starvation, the latter one, together with p62, is 
more implicated in selective autophagy. None of these proteins seem to participate in 
the autophagic disruption observed upon LMB treatment, since none of them 
participate in the fusion of autophagosomes to lysosomes (Knaevelsrud & Simonsen, 
2010). We speculate that some proteins important for autophagosome maturation 
might get impaired after LMB treatment, thus leading to autophagic dysfunction. The 
histone deacetylase (HDAC) 6 was first related to the formation of aggregates, by 
transporting miss-folded proteins along the microtubules through interaction with 
dynein (Kawaguchi et al., 2003). More recently, HDAC6 has also been implicated in the 
creation of an actin network that facilitates the autophagosome-lysosome fusion and 
clearance of autophagic substrates (Lee et al., 2010). This effect was specific to basal 
quality-control autophagy, and dispensable for starvation-induced autophagy. 
Moreover, a fraction of the cytosolic protein relocalizes into the nucleus upon LMB 
treatment (Verdel et al., 2000). Since HDAC6 is sensitive to Xpo-1 inhibition, nuclear 
relocalization of this histone deacetylase might impair the fusion of autophagosomes 
and lysosomes. Thus, it should be further explored whether autophagy inhibition upon 
LMB treatment could be in part HDAC6-dependent. 
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4 - NBR1 AND p62 AS MARKERS TO TRACK SELECTIVE AUTOPHAGY IN 
HUNTINGTON’S DISEASE 
 
We show that, although p62 and NBR1 have similar functions, in cells expressing 
mutant huntingtin they are differentially deregulated due to their distinct intracellular 
distribution. Since we observe that p62 is being sequestered into the nuclear mutant 
huntingtin aggregates as the disease progresses, we suggest that cytoplasmic NBR1 
may be important to maintain the flux of selective autophagy. In addition, our results 
put forward the analyzis of NBR1, but not p62, protein levels as an indicator of the 
basal selective autophagic activity in Huntington’s disease brain regions (Fig. 44). 
 
NBR1 protein levels alterations indicate that autophagy is induced at an early 
stage of the disease in the striatum, cortex and hippocampus. At later stages of the 
disease autophagy is still induced in the cortex but not in the other regions, where the 
autophagic flux recovers to normal levels, as seen in the striatum, or even collapses, 
as observed in the hippocampus. Interestingly, autophagy is also activated in other 
neuropathological situations characterized by the presence of protein aggregates, and 
this activation has been suggested to represent a compensatory response (Butler et 
al., 2006). Since mutant huntingtin is degraded by autophagy (Sarkar et al., 2008), 
activation of selective autophagy could hamper the formation of cytoplasmic mutant 
huntingtin aggregates, whereas a reduction as the disease progresses could result in 
more mutant huntingtin aggregation. Accordingly, cytoplasmic aggregates containing 
mutant huntingtin increase with age in R6/1 mice brain (Bayram-Weston et al., 2012; 
Cummings et al., 2007) and, at late stages of the disease, R6/2 mice display larger 
number of aggregates in the striatum and hippocampus than in the cortex (Weiss, et 
al., 2008). 
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Figure 44. Scheme showing changes in p62 and NBR1 during the disease progression in R6/1 mouse brain and 
the proposed consequences on selective autophagy. p62 and NBR1 recognize unfolded proteins (such as mutant 
huntingtin) and damaged organelles (peroxisomes and mitochondria) tagged with ubiquitin. (A) In control conditions, 
selective autophagy is functioning normally and p62 and NBR1 are degraded together with the cargo. (B) At early 
stages of the disease, p62 and NBR1 protein levels are decreased in all the brain areas examined compared to control 
condition where mutant huntingtin is lacking. These decreased levels of autophagic cargo receptors could be the result 
of increased selective autophagy in response to the presence of mutant huntingtin by an unknown mechanism. (C) At 
late stages of the disease, regulation of p62 and NBR1 differs depending on the brain region. p62 starts getting 
accumulated within the nucleus, probably by interacting with mutant huntingtin. (c1) In the striatum and hippocampus, 
Xpo-1 levels are decreased compared to levels detected at earlier stages, which might contribute to a longer 
permanence of p62 within the nucleus. Since p62 is retained in the nucleus, we detect higher levels of this protein 
compared to those in wild-type mice, in the striatum and hippocampus. Cytoplasmic NBR1 would be the hope for 
selective autophagy in these cerebral areas in front of a pathological redistribution of p62. However, we detect higher 
NBR1 protein levels in 30 week-old R6/1 mice hippocampus suggesting an impairment of selective autophagy with age, 
whereas in the striatum selective autophagy seems to function at similar levels as in wild-type animals. (c2) In contrast, 
in cortical tissue, p62 also interacts with nuclear mutant huntingtin, although it is less retained in the nucleus. In the 
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cytoplasm its function seems not to be impaired and, together with NBR1, is still degraded by autophagy at an 
enhanced rate, like peroxisomes. 
 
 
5 - PHOSPHORYLATION OF mTOR IN THE STRIATUM OF R6/1 MICE 
 
Since our previous results analyzing p62 and NBR1 indicated changes in 
autophagic activity in Huntington’s disease, we analyzed whether deregulation of 
mTOR activity could account for these changes. 
 
Four phosphorylation sites have been described for mTOR up to date. The ones 
that have been most deeply studied are the rapamycin-sensitive pSer2448 mTOR and 
the autophosphorylated pSer2481 mTOR. While the first one is regulated by both AKT 
and S6K1, and is sensitive to rapamycin treatment (Holz & Blenis, 2005; Nave et al., 
1999), the latter is the result of an autophosphorylation and, thus, it serves as a 
biomarker to analyze intrinsic mTOR catalytic activity (Soliman et al., 2010). We have 
found that protein levels of these two phosphorylation forms of mTOR are already 
increased from early stages of the disease (12 weeks of age) in the striatum of R6/1 
mice. In addition, mTOR protein levels trend to increase at 8 weeks of age, however, 
no changes were observed at any other time-point of the disease analyzed. These 
results, together with the fact that phosphorylated AKT at Ser473 increases at the 
same time-points as phosphorylated mTOR (Saavedra et al., 2010), suggested a 
deregulation of the whole pathway in the striatum of R6/1 mice. Consistent with this are 
the findings showing that short exposure to mutant huntingtin in a cell culture inhibits 
mTOR activity and AKT phosphorylation, which are reversed by longer exposure-times 
to mutant huntingtin in a time-dependent manner (Hyrskyluoto et al., 2012). Contrary to 
this, however, is the fact that mTOR gets sequestered into both nuclear and 
cytoplasmic mutant huntingtin aggregates in cells transfected with the exon 1 of mutant 
huntingtin, in brains of N171-82Q mice models of Huntington’s disease and in 
Huntington’s disease human brain (Ravikumar et al., 2004). These authors suggested 
that this interaction with mutant huntingtin inhibits mTOR function. Our 
immunohistofluorescence results show that increases in the phosphorylation of mTOR 
in the R6/1 mouse brain is not due to an accumulation and inactivation of this protein 
into the mutant huntingtin aggregates, as we fail to detect mTOR colocalizing with 
mutant huntingtin aggregates. Interestingly, we show that although both pSer2448 
mTOR and pSer2481 mTOR are mainly localized in the cytoplasm, they have a 
different distribution pattern that is conserved from wild-type to R6/1 mice, so this 
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intracellular distribution is mutant huntingtin-independent. While pSer2448 mTOR 
localization is more diffuse and cytoplasmic, pSer2481 is accumulated in denser 
puncta that are distributed in the cytoplasm, but also within the nucleus. mTOR was 
first considered a cytoplasmic kinase and very few data exist about its intracellular 
localization and also about of the complexes that it builds. Some evidences have 
revealed the capability of mTOR to shuttle to the nucleus. mTOR has been found 
predominantly in the nucleus of many types of cancer cells (Zhang et al., 2002), but 
also in the cytoplasm in HeK293 cells (Kim & Chen, 2000; Zhang et al., 2002). It is still 
not well known what functions it may have within the nucleus. Interestingly, it has been 
found that mTOR and also some of its partners, mLST8, Rictor and sin1, are 
predominantly cytoplasmic in non-immortalized human primary fibroblasts (Rosner & 
Hengstschlager, 2008). Although Raptor is also abundant in the nucleus, the mTORC1 
complex is predominantly cytoplasmic, whereas the mTORC2 complex is abundant in 
both compartments (Rosner & Hengstschlager, 2008). This might be consistent with 
our results showing a cytoplasmic localization of pSer2448 mTOR, which is enriched in 
the mTORC1 complex (Copp et al., 2009), whereas pSer2481 mTOR is part of both 
complexes (Soliman et al., 2010), and thus, shows a cytoplasmic and nuclear 
localization. 
 
 
6 - REGULATION OF mTORC1 AND mTORC2 COMPLEXES IN THE STRIATUM OF 
R6/1 MICE 
 
Increased levels of mTOR phosphorylation could indicate an increase in its 
activity. Thus, we dissected out whether mTOR partners and substrates could be 
altered at any time-point of the disease. 
 
Raptor, PRAS40, Deptor and mLST8/GβL are the four mTOR-partners that 
compose the complex mTORC1, to promote protein synthesis and cell growth, and 
inhibit autophagy (Zoncu et al., 2011). Here, we have shown that protein levels of 
Raptor are not altered along the disease progression in the striatum of R6/1 mice, and 
neither in human Huntington’s disease putamen. Raptor functions as a scaffolding 
protein that facilitates the recruitment of substrates containing a TOR signal motif to the 
mTOR kinase. Accordingly, rapamycin treatment results in a conformational change in 
mTORC1 that is believed to alter and weaken the interaction with Raptor, impeding the 
phosphorylation of its substrates. Moreover, reducing the endogenous levels of Raptor 
by siRNA methods significantly impairs the mTOR kinase activity towards 4EBP1 (Hara 
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et al., 2002). Thus, Raptor protein levels might be important to build up functional 
mTORC1 complexes. Unaltered levels of Raptor in the striatum of R6/1 mice might 
indicate that mTORC1 substrates are recruited to the mTOR kinase with the same 
efficiency as in control mice, thus leading to unaltered mTORC1 kinase activity. 
Similarly to mTORC1, mTOR and some accessory proteins compose the complex 
mTORC2 (Sarbassov et al., 2004). Deptor and mLST8/GβL are also present in this 
complex, and bind mTOR together with three mTORC2-specific accessory proteins, 
Rictor, Protor and mSIN1, to induce cell survival and actin cytoskeleton organization 
(Zoncu et al., 2011). In contrast to Raptor, Rictor levels increase from en early age (8 
weeks) onwards in the striatum of R6/1 mice when compared to their control 
littermates, and also in the putamen of Huntington’s disease patients. Rictor, similarly 
to Raptor, has been found to be essential for the mTORC2 complex signalling. Loss of 
Rictor in worm, fly, mouse and human cells results in complete loss of AKT 
phosphorylation at Ser473 (Sarbassov et al., 2005). Furthermore, Rictor knockout 
mice, which result in embryonic lethality, are, at the time of embryonic arrest (E10.5), 
slightly smaller and developmentally delayed compared to control littermates (Guertin 
et al., 2006). In contrast, over-expression of Rictor has been detected in gliomas, which 
correlates with mTORC2 elevated activity and AKT phosphorylation (Masri et al., 
2007). Interestingly, disruption of the Rictor-mTOR complex also leads to a decrease in 
pSer473 AKT (Chen et al., 2010), suggesting that not only protein levels of Rictor and 
mTOR are essential for AKT phosphorylation, but also their interaction in the mTORC2 
complex is very important. Finally, over-expression of Rictor increases its association 
with mTOR and decreases the association of Raptor with mTOR, thus affecting 
mTORC1 activity (Chen et al., 2010). 
 
Downstream substrates of mTORC1 include S6K1, 4EBP1, and ULK1 (Beretta et 
al., 1996; Fox et al., 1998; Hosokawa et al., 2009). While total levels of these three 
proteins were not altered in the brains of R6/1 mice, phosphorylated forms were 
differentially regulated. We have analyzed specific-mTOR phosphorylation levels of 
these substrates, and we show that while pSer371 S6K1 and pSer757 ULK1 were not 
altered at any time-point analyzed, phosphorylation at the Thr37/46 4EBP1 increases 
from early 8 weeks, and is maintained until the last age examined. Finally, we further 
show that phosphorylated levels of the S6K1-specific downstream substrate ribosomal 
protein S6 are neither altered, according to the pSer371 S6K1 levels. Thus, in the 
striatum of R6/1 mice, alterations in mTOR phosphorylation may not impact on protein 
translation through S6K1. Since the increase in phosphorylated 4EBP1 protein levels 
occurs at earlier time-points than pSer2481 mTOR, it is more likely that other 
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mechanisms would account for the regulation of 4EBP1 phosphorylation. We have only 
examined here mTOR and Raptor protein levels. However, it is believed that not only 
total protein levels of Raptor can modulate mTORC1 activity, but also phosphorylations 
on Raptor mediated by Rheb, RSK, AMPK and ERK, could finely tune mTORC1 
activity (Carriere et al., 2008; Carriere et al., 2011; Gwinn et al., 2008). mTORC1 
containing phosphorylation site-defective Raptor exhibits reduced in vitro kinase activity 
toward the substrate 4EBP1 (Carriere et al., 2008; Foster & Fingar, 2010). Interestingly 
RSK protein levels are increased at 8 weeks of age in the striatum of R6/1 mice (Xifro 
et al., 2011), which could result in an increase in phosphorylated Raptor and have a 
role in the increase of pThr37/46 4EBP1. Another possibility that could lead to an 
increase in pThr37/46 4EBP1 levels earlier than the increase in the mTOR 
autophosphorylation, is that 4EBP1 could be phosphorylated in an mTOR-independent 
manner (Choo & Blenis, 2009). Interestingly, mTORC1 inhibition with rapamycin or the 
rapamycin derivative RAD001 affects S6K1 but not 4EBP1 phosphorylation status 
(Choo et al., 2008; Nawroth et al., 2011). It has been suggested that 4EBP1 
phosphorylation is also regulated directly or indirectly by PI3K (Nawroth et al., 2011). 
This could lead to miss-interpretation of mTORC1 activity in vivo. One last explanation 
for this differential substrate regulation could be due to the fact that S6K1 interacts 
more weakly with Raptor than 4EBP1 does (Schalm & Blenis, 2002; Schalm et al., 
2003). It would be interesting to know whether ULK1 binds mTORC1 as weakly as 
S6K1 does, since that would explain the differences that exist when analyzing the 
phosphorylation levels of the three substrates. It should be interesting to know whether 
protein levels and phosphorylation levels of the other accessory proteins present in the 
mTORC1 complex could also have some influence in directing the mTOR kinase 
towards a specific substrate. Finally, alterations in mTORC1 activity seem not to 
influence autophagy, since pSer757 ULK1 levels are not modified along the disease 
progression. Thus, the ULK1-Atg13-FIP200 complex activity might not result impaired, 
at least in an mTOR-dependent manner, and this complex would exert its function in 
autophagosome nucleation in R6/1 at the same rate as it does in control brains. In the 
striatum of R6/1 mice we have detected an over-activation of autophagy at an early 
stage of Huntington’s disease (12 weeks), which returned to control levels at late 
stages of the pathology. At 12 weeks of age, autophagy could be induced in an mTOR-
independent manner. Thus, it would be interesting to examine the levels of the proteins 
that compose the class III PI3K complex (Vps34, Beclin-1, Vps15 and Atg14) and the 
activity of the complex, since an increase in its activity could result in an induction of 
autophagy (Fimia et al., 2007; Takahashi et al., 2007). 
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An increase in Rictor protein levels, together with enhanced pSer2481 mTOR, 
could lead to an increased activity of the mTORC2 complex in the striatum of R6/1 
mice brains. mTORC2 triggers phosphorylation on the hydrophobic motif of the AGC 
kinases AKT, SGK and PKCα (Gao et al., 2005; Garcia-Martinez & Alessi, 2008; 
Ikenoue et al., 2008; Sarbassov et al., 2005). Consistent with our results showing 
increased Rictor protein levels from early stages of the disease, and of enhanced 
pSer2481 mTOR from 12 weeks of age onwards in the striatum of R6/1 mice, pSer473 
AKT protein levels have been found increased also from 12 weeks of age onwards in 
the striatum of the same mouse model (Saavedra et al., 2010). However, we failed to 
find further increase in the phosphorylation levels of SGK and PKCα. Total amounts of 
SGK and PKCα protein levels were down-regulated upon the disease progression, and 
so did their phosphorylated forms. Similarly to mTORC1, differences in the 
phosphorylation levels of mTORC2 substrates could be due to other factors altered in 
the pathology that would govern substrate-specificity, however very few data do exist 
about this issue. In contrast to mTORC1, where TOR signal motif-containing substrate 
is recognized by Raptor, no such a motif has been found in mTORC2 substrates. Since 
AKT and SGK interact with mTORC2, but not mTORC1, the existence of a parallel 
mechanism that might be operating for mTORC2 substrates has been suggested (Lu et 
al., 2011). Interestingly, it has been shown that mSIN1, but not Rictor, recruits SGK, 
but not AKT, into the mTORC2 complex to undergo phosphorylation (Lu et al., 2011). 
Although mTORC2 mediates AKT phosphorylation, it may use a distinct strategy 
independent of mSIN1, such as binding to Rictor, thus suggesting a mechanism for 
differential regulation of these two signalling kinases. Furthermore, as well as Raptor, 
Rictor can also undergo phosphorylation events at multiple sites, having a role in the 
mTORC2-mediated AKT phosphorylation (Chen et al., 2011a). Interestingly, Rictor can 
also interact with Cullin1 in an mTOR-independent manner, acquiring the ability to 
ubiquitinate and degrade SGK (Gao et al., 2010). Furthermore, in accordance with the 
decreased SGK protein levels detected in the striatum of R6/1 mice, the expression of 
SGK is elevated in Rictor null cells (Gao et al., 2010), suggesting that a sustained 
induction of Rictor in the R6/1 could account for the reduction in the SGK total protein 
levels. 
 
Summarizing, the AKT-mTOR pathway seems to be deregulated in the striatum of 
R6/1 mouse models of Huntington’s disease. An increase in Rictor and phosphorylated 
mTOR levels could trigger enhanced activity of the complex mTORC2 to 
phosphorylate, specifically, AKT. Importantly AKT is a key protein in the regulation of 
cell survival. An increase in AKT phosphorylation and activity is known to induce cell 
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survival upon mutant huntingtin expression (Humbert et al., 2002), with the implication 
of a broad branch of substrates. An early increase in pAKT, described in distinct 
Huntington’s disease models, has been suggested to counteract the toxic effect 
triggered by mutant huntingtin, by phosphorylating and inactivating different pro-
apoptotic substrates, such as FoxO and GSK3β (Gines et al., 2003; Saavedra et al., 
2010). Furthermore, AKT is also known to phosphorylate mutant huntingtin at Ser421, 
reducing the caspase-mediated mutant huntingtin cleavage and its toxicity (Humbert et 
al., 2002; Warby et al., 2009). However, further experiments are needed in order to 
demonstrate that over-expression of Rictor together with increased pSer2481 mTOR, 
account for the already published increase in pSer473 AKT protein levels. One such 
experiment would be to examine by co-immunoprecipitation whether the increase in 
Rictor protein levels, observed in the striatum of R6/1 mice, entails in an increase in 
Rictor-mTOR interaction, and to analyze whether this results in enhanced AKT 
phosphorylation, using an in vitro activity kinase assay.  
 
 
7 - REGULATION OF PKC ISOZYMES IN HUNTINGTON’S DISEASE PATHOLOGY 
 
Decreased PHLPP1 protein levels in brains of R6/1 mice (Saavedra et al., 2010) 
could also result in changes in the protein levels of PKCs (Gao et al., 2008). Therefore, 
we have analyzed the protein levels of two cPKCs, PKCα and PKCβII, and one nPKC, 
PKCδ. Although different isozymes can trigger overlapping functions or even opposite 
effects depending on the cell type analyzed (Mischak et al., 1993), PKCα and PKCβII 
are generally considered to induce cell survival, whereas PKCδ is classically involved 
in apoptosis (Reyland, 2007). We have shown a decrease of the three isoforms protein 
levels in three different R6/1 mouse brain areas. PKCδ is the isoform whose protein 
levels start to get reduced earlier in the pathology, and whose protein levels present a 
greater reduction when compared to control littermates. Moreover, PKCδ protein levels 
are also reduced in the putamen of Huntington’s disease patients. Interestingly, this 
decrease gets accentuated along the progression of the disease and is not dependent 
on the brain region, since striatum, cortex and hippocampus present a similar PKCδ 
protein reduction. Many mechanisms, such as gene expression or PKC degradation 
could lead to the protein down-regulation that occurs for the three PKC isoforms along 
the progression of the disease in R6/1 mice brains. On one hand, mutant huntingtin 
has been related to affect several transcription activities by sequestering and rendering 
inactive many important transcriptional factors (Steffan et al., 2000; Nucifora et al., 
2001). Consistent with our protein results, decreased PKCβII gene expression levels 
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have been described in R6/2 mouse brains (Harris et al., 2001), which could result in 
less PKCβII protein levels. In the same direction, we analyzed PKCα and PKCδ mRNA 
levels, but failed to find alterations at any time-point of the disease, suggesting that the 
down-regulation of these isoforms could take place by another mechanism than gene 
expression. On the other hand, PKC stability is dependent on factors, such as 
phosphorylation and binding to scaffold proteins (Newton, 2010). Phosphorylation 
represents a key event that is required for PKC maturation, which primes PKC for 
second messenger-activation and protects it from degradation, since most 
unphosphorylated PKC isoforms are rapidly degraded (Newton, 2010). Interestingly, 
PKCs that have been activated by second messengers have an increased sensitivity to 
phosphatases (Dutil et al., 1994), and prolonged PKC activation, as occurs with 
phorbol esters (functional analogues of diacylglycerol), results in the dephosphorylation 
and degradation of PKCs (Hansra et al., 1999). PHLPP is known to dephosphorylate 
PKC specifically at the hydrophobic motif and shunt it for further dephosphorylation, 
ubiquitination and proteasomal degradation (Gao et al., 2008; Newton, 2010). 
However, since PHLPP1 is already down-regulated in the R6/1 mouse model of 
Huntington’s disease (Saavedra et al., 2010), other mechanisms should account for the 
down-regulation of PKCs. Lack of enzyme activation could also lead to PKC 
degradation (Battaini & Pascale, 2005), and thus, it would be interesting to measure 
the levels of membrane-bound PKCα, PKCβII and PKCδ. Moreover, PKC binding to 
scaffold proteins, such as RACKs, AKAPs and 14-3-3 proteins helps in stabilizing the 
enzyme (Klauck et al., 1996; Ron et al., 1994; Van Der Hoeven et al., 2000), so that 
alterations in those anchoring proteins could plausible lead to less sustained activation 
of PKCs and faster dephosphorylation and degradation. 
 
 
8 - PUTATIVE MECHANISMS LEADING TO INCREASED PKCδ DEGRADATION IN 
HUNTINGTON’S DISEASE 
 
It is noteworthy to mention that some PKC isoform-specific mechanism for 
signalling termination may exist (Melnikov & Sagi-Eisenberg, 2009; Srivastava et al., 
2002). Since the greatest reduction at a protein level was found for PKCδ, and this 
reduction could represent an early pro-survival compensatory mechanism activated in 
the R6/1 model of Huntington’s disease, further experiments were performed in order 
to find the mechanism that would lead to PKCδ down-regulation. Interestingly, while 
dephosphorylation commonly triggers PKC degradation, experiments in which 
phosphatases were specifically inhibited revealed an increase in PKCδ degradation 
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(Srivastava et al., 2002). A specific phosphorylation of PKCδ at Thr505 was found to 
prime PKCδ for degradation (Srivastava et al., 2002). This phosphorylation site is 
located at the activation loop of PKCδ but, differing from other PKC isozymes, is not 
necessary for protein activation (Stempka et al., 1997). PKCε has been suggested to 
trigger this phosphorylation on PKCδ (Garczarczyk et al., 2009). We further analyzed 
this phosphorylation event in brains of R6/1 mice at two different ages, at 8 weeks of 
age, when PKCδ protein levels started to decrease, and at 30 weeks of age. We 
observed that the pThr505 PKCδ/PKCδ ratio was increased only at later stages of the 
disease in the striatum, cortex and hippocampus, correlating with decreased PKCδ 
protein levels. The absence of alterations in pThr505 PKCδ at 8 weeks of age, 
suggests that in the presence of mutant huntingtin other mechanisms would contribute 
to PKCδ degradation. These findings suggest that phosphorylation at Thr505 is 
enhanced at later stages of the disease and that this is an event that could participate 
in PKCδ down-regulation. However, there must be another mechanism that accounts 
for PKCδ down-regulation earlier in the pathology, such as ubiquitination. Thus, it 
would be interesting to also analyze the levels of ubiquitinated PKCδ. 
 
 
9 - EFFECTS OF PKC DOWN-REGULATION UPON MUTANT HUNTINGTIN 
EXPRESSION 
 
Down-regulation of PKCα, PKCβII and PKCδ could lead to different effects due to 
their functional disparity.  
 
Loss of PKCα and PKCβII could trigger dysfunction and also account for the 
synaptic loss that has been observed in R6/1 mice (Spires et al., 2004), as they have 
been implicated in the regulation of survival and also in changes of pre- and post-
synaptic ultra-structure (Hongpaisan & Alkon, 2007). Furthermore, they could account 
for memory deficits in Huntington’s disease, as their function has been tightly linked to 
memory storage (Nelson et al., 2008), and its deficiency has been widely associated 
with memory-loss diseases such as Alzheimer’s disease (Alkon et al., 2007; Cole et al., 
1988; Masliah et al., 1990). In particular, PKCα has a neuroprotective effect in an 
Alzheimer’s disease mouse model upon its forced activation with bryostatin-1, which 
has been shown to restore synaptic loss, cognitive deficits and also reduce soluble β-
amyloid levels (Hongpaisan et al., 2011). Mice deficient in PKCβ showed normal brain 
anatomy and normal hippocampal synaptic transmission, normal long-term potentiation 
and normal sensory and motor responses, but exhibited a loss of learning (Weeber et 
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al., 2000). Interestingly, no motor alterations have been observed in PKCα and PKCβ-
deficient mice, since they exhibit indistinguishable motor performance on the rota-rod 
when compared to control mice (Weeber et al., 2000; Zhao et al., 2011), thus 
suggesting that loss of PKCα and PKCβII could account for the cognitive deficits in 
Huntington’s disease, but probably not for motor disturbances. 
 
In contrast, PKCδ has emerged as a general pro-apoptotic intermediate in a broad 
number of cells, mainly in non-proliferating cells, including neurons (Fujii et al., 2000; 
Maher 2001). Thus, PKCδ down-regulation could be beneficial for cells to avoid 
apoptosis upon mutant huntingtin expression. Many different cell types from PKCδ-null 
mice have a suppressed response to apoptotic agents in vitro (Humphries et al., 2006; 
Leitges et al., 2001; Allen-Petersen et al., 2010). Most notably, parotid salivary glands 
from PKCδ-null mice lack efficient in vivo apoptotic response (Humphries et al., 2006). 
Furthermore, PKCδ is up-regulated after transient global brain ischemia, and its 
induction precedes neuronal death (Koponen et al., 2000). Upon apoptotic stimuli, 
PKCδ is phosphorylated at tyrosines 64 and 155 and translocates to the nucleus, 
where it is cleaved by caspase-3 at the hinge region generating the constitutive 
catalytic fragment δCF that is able to induce apoptosis (Humphries et al., 2008). 
However, although this δCF is sufficient to induce apoptosis, it seems not to be that 
essential, and PKCδ-mediated apoptosis can still occur in the absence of proteolytic 
cleavage by caspase-3 (Fujii et al., 2000; Maher 2001). Our results show a similar 
decrease of PKCδ in both cytoplasmic and nuclear compartments in R6/1 brains when 
compared to control littermates. In addition, we do not detect any difference in the 
protein levels of δCF, suggesting that PKCδ is not mediating cell death in response to 
mutant huntingtin expression. In contrast to our results, others have shown an 
association of three PKC isozymes, including PKCδ, with mutant huntingtin and 
ubiquitinated aggregates in cerebellar sections of R6/2 mice (Zemskov et al., 2003). 
We failed to observe colocalization of ubiquitin-positive inclusions with PKCδ in R6/1 
mice striatum. Since the mouse model that we have used for our study is very similar to 
the R6/2, this difference could be mainly due to the fact that in this study the authors 
analyzed cerebellar sections, whereas we have analyzed the striatum. We cannot 
discard that PKCδ protein dynamics behave distinctly in the cerebellum than in the 
striatum. In any case, association of PKCδ with ubiquitinated aggregates could also 
result in PKCδ inhibition. Finally, PKCδ not only regulates different apoptotic events, 
including caspase activation and DNA fragmentation, as well as loss of mitochondrial 
membrane potential (Matassa et al., 2001), but also it has been suggested to play an 
important role in inducing mitochondrial fission in neurons upon oxidative stress (Qi et 
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al., 2011). Thus, early reduction of PKCδ protein levels in striatal, cortical and 
hippocampal cells could represent a pro-survival mechanism to avoid, or at least delay, 
neurodegeneration induced by mutant huntingtin. In accordance to this hypothesis, 
PKCδ-deficient mice do not present motor abnormalities, as examined with the rota-rod 
test, but loss PKCδ is protective and partially restores the motor deficits triggered by 
methamphetamine-induced dopaminergic toxicity (Shin et al., 2011). This is consistent 
with our results showing that over-expression of PKCδ together with mutant huntingtin, 
but not with wild-type huntingtin, increases cell death in an immortalized striatal cell 
line. 
 
 
10 - SELECTIVE AUTOPHAGY AND mTOR AND PKCδ SIGNALLING PATHWAYS, 
AS COMPENSATORY PRO-SURVIVAL MECHANISMS ACTIVATED IN 
HUNTINGTON’S DISEASE  
 
Compensatory pro-survival mechanisms are essential to counteract mutant 
huntingtin-induced toxicity and delay the progression of Huntington’s disease. We have 
studied here three different mechanisms along the progression of the disease in R6/1 
mice brains that could enhance cell survival and delay cell dysfunction (Fig. 45).  
 
We found an early activation in selective autophagy that was maintained in the 
cortex at late stages of the disease (Fig. 45), but returned to normal or even decreased 
levels in the striatum and hippocampus of R6/1 mice, respectively. Moreover, we have 
detected increased pmTOR and Rictor protein levels that could account for the over-
activation of AKT and consequently for AKT-mediated cell survival. We failed to find 
differences in pSer757 ULK1 protein levels in the striatum of R6/1 mice, suggesting 
that early selective autophagy over-activation could be induced through an mTOR-
independent pathway. Pharmacological induction of autophagy could be a good 
therapeutic approach to reduce the amount of the toxic protein. In fact, activation of 
mTOR-dependent autophagy with rapamycin attenuated the toxic effects of mutant 
huntingtin in fly and mouse models of Huntington's disease (Ravikumar et al., 2004). 
However, rapamycin treatment has side-effects, and it is noteworthy to mention that 
prolonged inhibition of mTOR with rapamycin can also impair mTORC2 activity, by 
sequestering the cellular pool of mTOR in a complex with rapamycin linked to FKBP12, 
making it unavailable for assembly into mTORC2 (Sarbassov et al., 2006). Inhibition of 
mTORC2 could impair the over-activation of the pro-survival kinase AKT in 
Huntington’s disease. Moreover, mTOR inhibition could also lead to deficits in learning 
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and memory processes, since mTOR, at least at basal levels, regulates those 
processes (Garelick & Kennedy, 2011; Swiech et al., 2008). Furthermore, rapamycin 
might modulate the levels of misfolded mutant huntingtin via other pathways than 
autophagy, since it decreases mutant huntingtin also in autophagy-deficient cells (King 
et al., 2008). For all these reasons, we suggest that rather than inducing autophagy by 
inhibiting mTOR, a better approach might be the use of mTOR-independent autophagy 
enhancers, which, in fact, have already been suggested for treatment in Huntington’s 
disease (Sarkar & Rubinsztein, 2008). Furthermore, from our point of view, the best 
time-point of the disease to administer and autophagy enhancer, would be at early 
stages of the disease, when both autophagy cargo receptors, p62 and NBR1, are 
available. We have shown that at later stages of the disease p62 gets sequestered into 
the nuclear mutant huntingtin aggregates, which could impair the efficiency of 
autophagy inducers in degrading cytoplasmic mutant huntingtin. 
 
Finally, we have detected very low levels of the pro-apoptotic PKCδ in R6/1 brains 
when compared to their control littermates (Fig. 45). We have also found reduced 
levels of two other PKC isoforms, PKCα and PKCβII (Fig. 45). These results do not 
correlate with the decrease in PHLPP1 levels. Thus, other mechanisms must account 
for the reduction in PKC protein levels, such as low gene expression, low protein levels 
of anchoring proteins or low PKC activation. Since we have observed that mutant 
huntingtin expressing cells present enhanced susceptibility to PKCδ over-expression, 
decreased PKCδ protein levels could be added to the list of kinases that are 
deregulated in Huntington’s disease to induce pro-survival signalling (Anglada-Huguet 
et al., 2012; Gines et al., 2003; Humbert et al., 2002; Lievens et al., 2002; Saavedra et 
al., 2010, 2011; Xifro et al., 2011).  
 
Huntington’s disease is a progressive neurodegenerative disease with the most 
common onset in adulthood, although mutant huntingtin is expressed from early in 
development. Interestingly, while cell death does not occur in almost any mouse model 
of the disease, mice develop motor and cognitive deficits (Table 1). The lack of cell 
death in these models lets hypothesize that these deficits are more related to cell 
dysfunction. Interestingly, in the conditional HD94 model of the disease, mutant 
huntingtin gene silencing in mice with already 20% cell death, protected not only from 
additional loss but also recovered mice from their motor deficits (Diaz-Hernandez et al., 
2005). 
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Figure 45. Scheme summarizing results obtained in this Thesis. (1) In an early stage of the disease, selective 
autophagy is increased by an mTOR-independent mechanism, suggesting an enhanced degradation of mutant 
huntingtin that could compensate for its toxicity. (2) Rictor levels could contribute to enhance mTORC2 activity, which, in 
turn, could lead to increased cell survival through AKT signalling. (3) Distinct PKCs protein levels are down-regulated in 
cells expressing mutant huntingtin. While decreases in PKCα and PKCβII could lead to cell dysfunction, down-regulation 
of PKCδ could trigger cell survival and counteract mutant huntingtin toxicity. 
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Thus, pro-survival mechanisms are highly important in Huntington’s disease, and if 
in a therapeutical approach pro-survival mechanisms were potentiated while neurons 
are still alive, neuronal function might be improved and Huntington’s disease 
progression might be delayed. 
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1. Selective autophagic activity is deregulated in R6/1 mice brains in a region- 
and age-dependent manner, as monitored by the analyzis of NBR1 protein 
levels. 
 
2. NBR1 might be a better marker than p62 to study selective autophagy flux at 
late stages of Huntington’s disease, since p62 gets sequestered into the 
mutant huntingtin nuclear aggregates but NBR1 remains in the cytoplasm. 
 
3. Age-dependent Xpo-1 protein levels decrease could contribute for the 
observed macroautophagy block at late stages of the disease. 
 
4. Macroautophagy deregulation in the R6/1 mouse model of Huntington’s 
disease does not seem related to mTOR activity, at least not in an ULK1-
dependent manner in the striatum of R6/1 mice.  
 
5. Striatal increased levels of Rictor and phosphorylated mTOR could contribute 
to enhance mTORC2 activity in striatal cells expressing mutant huntingtin. 
 
6. Increased levels of striatal AKT phosphorylation, and the consequent pro-
survival signalling, might be triggered not only by a decrease in PHLPP1 
levels, but also by an increase in mTORC2 activity. 
 
7. The pro-apoptotic protein PKCδ is down-regulated in Huntington’s disease 
probably by an increase in its targeting for degradation.  
 
8. Decreased levels of PKCδ could represent a common pro-survival 
compensatory mechanism in different cell types to delay neurodegeneration 
induced by mutant huntingtin. 
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